Summer 8-12-2015

Investigation in to the Effect of Spin Locking on Contrast Agent Relaxivity

Julian Saunders Haigh
Portland State University

Follow this and additional works at: https://pdxscholar.library.pdx.edu/open_access_etds

Part of the [Diagnosis Commons](#)

Let us know how access to this document benefits you.

Recommended Citation

Haigh, Julian Saunders, "Investigation in to the Effect of Spin Locking on Contrast Agent Relaxivity" (2015). *Dissertations and Theses*. Paper 2496.
<https://doi.org/10.15760/etd.2493>

This Dissertation is brought to you for free and open access. It has been accepted for inclusion in Dissertations and Theses by an authorized administrator of PDXScholar. Please contact us if we can make this document more accessible: pdxscholar@pdx.edu.

Investigation in to the Effect of Spin Locking on Contrast Agent Relaxivity

by

Julian Saunders Haigh

A dissertation submitted in partial fulfillment of the
requirements for the degree of

Doctor of Philosophy
in
Chemistry

Dissertation Committee:
Mark Woods, Chair
Andrea Goforth
David Peyton
Andrew Rice
William Rooney

Portland State University
2015

© 2015 Julian Saunders Haigh

Abstract

The current trend in magnetic resonance imaging (MRI) is towards higher external magnetic field strengths (B_0) to take advantage of increased sensitivity and signal to noise ratio (SNR). Unfortunately, as B_0 increases the effectiveness (relaxivity) of clinical gadolinium (Gd^{3+})-based contrast agents (CAs) administered to enhance image contrast is significantly reduced. Excellent soft tissue contrast can be generated with current agents despite their non-optimum relaxivities but necessitates large doses. The limits of detection of a CA at high B_0 fields can be lowered by recovering the lost relaxivity and is a pre-requisite to the goal of molecular imaging in which CAs are bound to biomarkers of pathology that exist at very low concentrations. Traditional methods for increasing the detectability of CAs have focused on optimizing critical parameters identified from the Solomon-Bloembergen-Morgan (SBM) theory that affect relaxivity. Gains in relaxivity with these methods to date have been modest and are far from the theoretical maximum possible. Although researchers continue to investigate novel complexes that provide improved relaxivities, any such complex would require a lengthy and costly approval process with the U.S. Food and Drug Administration (FDA). Therefore, a method that affords improved relaxivities of current clinically approved CAs, particularly at high B_0 fields, that could be adopted into clinical practice rapidly, is of great interest.

Spin locking is a nuclear magnetic resonance (NMR) technique that was introduced for imaging in 1985, but has received very little attention in combination with Gd^{3+} -based CAs. The technique employs a low power long duration radiofrequency (RF) pulse (B_1)

parallel to the net magnetization in the x,y-plane. This locks the magnetization into lower precessional frequencies around an “effective” field (B_{eff}) that is reduced with respect to B_0 but maintains the high field advantages required for imaging. When considered in the rotating frame, longitudinal relaxation of the magnetization against B_{eff} exhibits shorter time constants ($T_{1\rho}$) expected at these lower precessional frequencies. This leads to higher relaxivities, which has implications for increasing CA detectability.

The experiments described herein show that rotating frame longitudinal relaxivities ($r_{1\rho}$) for current clinical Gd^{3+} -based CAs are essentially independent of the strength of the spin lock pulse (γB_1) as predicted by theory. This result is important because it allows the value of γB_1 to be neglected when comparing $r_{1\rho}$ of Gd^{3+} -based CAs across several B_0 fields. The magnetic field dependence of $r_{1\rho}$ for all clinical agents showed that relaxivity, lost by moving to higher fields, could be “recovered” and that $r_{1\rho}$ was sensitive to the rotational correlation time constant (τ_R) of the agent. Using high molecular weight Nanoassembled capsules (NACs) containing a Gd^{3+} -based CA to probe this finding further, we were able to generate relaxivities at high field up to an order of magnitude greater than clinical agents at current imaging fields. These are beyond anything previously reported, or likely to be, with current techniques. Finally, we demonstrated that by spin locking Mn^{2+} agents, relaxivities at high field increased by a factor of ~ 30 than without spin locking, due to their larger dependence on scalar coupling. These findings show the potential of spin locking to increase detection limits dramatically at high field and are an exciting development towards the goal of molecular imaging.

I dedicate this thesis to the memory of my father-in-law who passed away suddenly towards the end of writing of this thesis. He will be sorely missed.

Professor Selwyn Wright
(1934 – 2015)

Acknowledgements

I would like to take this opportunity to thank the following:

Prof. Mark Woods for all his support, encouragement and assistance throughout the course of this research.

Annah Farashishiko for the provision of NACs that contributed to the success of this work.

Dr Benjamin Webber, Katherine Payne, Jacqueline Slack, Guadalupe Camacho and Lauren Rust for their contributions to the development of this work through feedback from listening to much iteration of my research presentations in group meetings.

Prof. Mauro Botta for the provision of several NMRD profiles modeling rotating frame relaxivities in particular.

Robert Jensen for his swift response to scheduling requests for access to the high field NMR spectrometers and for providing his expertise when required.

Dr Thomas Barbara for his discussions on power attenuation calculations.

My wife, Justine, and son, Daniel for all their support and patience throughout my graduate education.

Professors Andrea Goforth, David Peyton, Andrew Rice and William Rooney for their time and feedback as members of the dissertation committee.

Portland State University, Oregon Health & Sciences University and Oregon Nanoscience and Microtechnology Institute for financial support.

Table of Contents

Abstract	i
Dedication	iii
Acknowledgements	iv
List of Tables	xii
List of Figures	xiv
List of Equations	xvii
List of Terms and Abbreviations	xx
Chapter 1. Introduction	1
1.1. Magnetic resonance imaging: a critical imaging mode of the past, present and future	1
1.1.1. The rise to popularity of MRI	1
1.1.2. Modern day MRI and its comparison with other imaging modalities	2
1.1.3. The future of clinical MRI	3
1.2. Nuclear magnetic resonance (NMR) theory	3
1.2.1. The Zeeman effect	4
1.2.2. Signal detection	8
1.2.3. Longitudinal relaxation	9
1.2.4. Transverse relaxation	15
1.2.5. Fourier transformation, T_1 and T_2 determination	17
1.3. Inherent soft tissue contrast and image weighting	19
1.4. Gd^{3+} -based contrast agents for soft tissue contrast enhancement	24

1.4.1.	Classification of clinically approved Gd^{3+} -based CA	24
1.4.2.	Stabilization of Gd^{3+} -based CAs	28
1.4.3.	Mechanism of action of Gd^{3+} -based CAs	29
1.4.4.	Contributions to the PRE effect	30
1.5.	Traditional methods for optimization of relaxivity: A discussion of SBM theory	32
1.5.1.	Motives for increasing relaxivity	32
1.5.2.	SBM parameters for optimizing relaxivity	34
1.5.3.	Hydration state (q)	34
1.5.4.	Inner sphere water proton relaxation time constant (T_{1M})	35
1.5.5.	Rotational correlation time constant (τ_R)	36
1.5.6.	Water residence lifetime (τ_M)	37
1.5.7.	Electron relaxation time constants (τ_{S1} and τ_{S2})	38
1.6.	Spin locking for recovering lost relaxivity	38
1.6.1.	Theory of spin locking	39
1.6.2.	Determination of rotating frame longitudinal relaxation time constants ($T_{1\rho}$)	39
1.7.	Scope of this work: Determining the effect of a spin locking pulse on relaxivity	42
1.7.1.	Effect of pulse sequence parameters on T_1 and $T_{1\rho}$ time constants	42
1.7.2.	Effect of spin lock pulse strength (γB_1) on longitudinal relaxation rate constants ($R_{1\rho}$)	42

1.7.3.	A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame longitudinal relaxivities for $q = 1$ clinical Gd^{3+} -based CAs	43
1.7.4.	Effect of rotational correlation time (τ_R) on rotating frame longitudinal relaxivity ($r_{1\rho}$)	43
1.7.5.	Effect of hydration number (q) on rotating frame longitudinal relaxivity ($r_{1\rho}$)	44
Chapter 2.	Effect of pulse sequence parameters on longitudinal (T_1) and rotating ($T_{1\rho}$) frame time constants	45
2.1.	Establishing pertinent pulse sequence parameters with potential to effect reliability of fit of relaxation data	45
2.1.1.	Relaxation delay (RD) time	46
2.1.2.	Pulse delay (τ) times	46
2.1.3.	Number of data points	46
2.2.	Establishment of ideal pulse sequence parameter values	47
2.3.	Other parameters and general considerations	47
2.3.1.	Sample temperature, volume and position	48
2.3.2.	Pulse angles	48
2.3.3.	Offset frequency	48
2.3.4.	Number of scans	49
2.3.5.	Receiver gain, detection mode and fitting equations	49
2.4.	Determination of natural variance (standard deviation) from replicate analysis	49
2.5.	Effect of pulse sequence parameters on the reliability of fit of relaxation data	51

2.5.1.	Relaxation delay (RD) time	52
2.5.2.	Pulse delay (τ) times	54
2.5.3.	Number of data points	57
2.6.	Recommendations	57
2.6.1.	Relaxation delay (RD) times	59
2.6.2.	Pulse delay times	61
2.6.3.	Number of data points	62
2.7.	Conclusions	62
Chapter 3.	Effect of spin lock field strength (γB_1) on the rotating frame longitudinal relaxation rate constant ($r_{1\rho}$)	64
3.1.	Establishing the γB_1 independency of $R_{1\rho}$	64
3.2.	Modulation of the strength of the spin lock field (γB_1)	66
3.3.	Effect of γB_1 on $R_{1\rho}$ at low B_0 field strengths	68
3.4.	Effect of γB_1 on $R_{1\rho}$ at high B_0 field strengths	70
3.5.	A comparison between spin locking and CPMG with short pulse delay times	73
3.6.	Conclusions	77
Chapter 4.	A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame longitudinal relaxivities for $q = 1$ clinical Gd^{3+} -based CAs	78
4.1.	Establishing the potential benefits of spin locking on relaxivity	78
4.2.	Comparison of r_1 and $r_{1\rho}$ for linear and macrocyclic $q = 1$ clinical Gd^{3+} -based CAs	80

4.3.	A comparison of $r_{1\rho}$ for linear and macrocyclic chelates to simulated theory	86
4.4.	A comparison of r_1 and $r_{1\rho}$ for bulky $q = 1$ clinical Gd^{3+} -based CAs	90
4.5.	Summary of relaxivity changes	94
4.6.	Conclusions	95
Chapter 5.	Effect of rotational correlation time (τ_R) on rotating frame longitudinal relaxivity ($r_{1\rho}$)	98
5.1.	Establishing the potential for increasing relaxivity by spin locking slow tumbling nano-encapsulated Gd^{3+} chelates.	98
5.2.	Nanoassembled capsules as a model system for investigating the effect of τ_R on $r_{1\rho}$	100
5.3.	Mechanism of action of nanoassembled capsules (NACs) incorporating $GdDOTP^{5-}$	100
5.4.	Effect of NAC design parameters on relaxivity	102
5.5.	Effect of γB_1 on $R_{1\rho}$ for NACs at high B_0 field strengths	103
5.6.	A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame NMRD for NACs	105
5.6.1.	Effect of τ_R on r_1 as a function of B_0	105
5.6.2.	Effect of τ_R on $r_{1\rho}$ as a function of B_0	108
5.7.	Summary of relaxivity changes	109
5.8.	Conclusions	110
Chapter 6.	Effect of hydration number (q) on rotating frame longitudinal relaxivity ($r_{1\rho}$)	113
6.1.	Potential applications of spin locking with hydration numbers (q) $\neq 1$	113

6.2.	Low molecular weight chelates of Gd^{3+} and Mn^{2+} as systems for investigating the effect of q on $r_{1\rho}$	114
6.3.	Effect of γB_1 on $R_{1\rho}$ for MnCl_2 at low B_0 field strengths	115
6.4.	A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame NMRD for low molecular weight Gd^{3+} and Mn^{2+} agents as a function of hydration number (q)	118
6.4.1.	A comparison of r_1 and $r_{1\rho}$ for low molecular weight non-bulky Gd^{3+} complexes	118
6.4.2.	A comparison of r_1 and $r_{1\rho}$ for low molecular weight Mn^{2+} complexes	119
6.5.	Conclusions	126
Chapter 7.	Experimental section	127
7.1.	Reagents and solvents	127
7.2.	Instrumentation	127
7.3.	Pulse sequences	128
7.3.1.	Inversion recovery pulse sequence	128
7.3.2.	Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence	128
7.3.3.	Spin locking pulse sequence	128
7.4.	Fitting	128
7.5.	Contrast media stock solution preparations	129
7.5.1.	Clinical Gd^{3+} -based contrast agents	129
7.5.2.	GdCl_3	129
7.5.3.	MnCl_2	130
7.5.4.	GdTTTHA^{3-}	130

7.5.5.	MnEDTA	131
7.6.	Working solution preparations and experimental parameters	131
7.6.1.	Chapter 2. Effect of pulse sequence parameters on longitudinal (T_1) and rotating ($T_{1\rho}$) frame time constants	131
7.6.2.	Chapter 3. Effect of spin lock field strength (γB_1) on the rotating frame longitudinal relaxation rate constant ($R_{1\rho}$)	132
7.6.3.	Chapter 4. A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame longitudinal relaxivities for $q = 1$ clinical Gd^{3+} -based CAs	132
7.6.4.	Chapter 5. Effect of rotational correlation time (τ_R) on rotating frame longitudinal relaxivity ($r_{1\rho}$)	134
7.6.5.	Chapter 6. Effect of hydration state (q) on rotating frame longitudinal relaxivity ($r_{1\rho}$)	136
	COMPLETE LIST OF REFERENCES	138
	APPENDIX: T_1 and $T_{1\rho}$ time curves at 1.41 T (60 MHz) and 37 °C (appendix to chapter 2)	149

List of Tables

Table 1.1: Physical properties of Gd ³⁺ -based CAs studied	28
Table 2.1: Suggested “ideal” pulse sequence parameter values	47
Table 2.2: T_1 and $T_{1\rho}$ measurement repeatability data	51
Table 2.3: Effect of relaxation delay times on T_1 and $T_{1\rho}$ values	54
Table 2.4: Effect of pulse delay times on T_1 and $T_{1\rho}$ values	58
Table 2.5: Effect of number of data points on T_1 and $T_{1\rho}$ values	59
Table 2.6: Recommended pulse sequence parameter values	61
Table 3.1: Effect of pulse delay time on T_2	76
Table 4.1: r_1 and $r_{1\rho}$ NMRD data for clinical linear and macrocyclic q = 1 CAs (low field, 25 °C)	82
Table 4.2: r_1 and $r_{1\rho}$ NMRD data for clinical linear and macrocyclic q = 1 CAs (low field, 37 °C)	83
Table 4.3: r_1 and $r_{1\rho}$ NMRD data for clinical linear and macrocyclic q = 1 CAs (high field, 25 °C)	84
Table 4.4: r_1 and $r_{1\rho}$ NMRD data for clinical linear and macrocyclic q = 1 CAs (high field, 37 °C)	85
Table 4.5: r_1 and $r_{1\rho}$ NMRD data for clinical bulky q = 1 CAs (low field)	92
Table 4.6: r_1 and $r_{1\rho}$ NMRD data for clinical bulky q = 1 CAs (high field)	93

Table 5.1: Size and relaxivity data for GdDOTP ⁵⁻ NACs	103
Table 6.1: r_1 and $r_{1\rho}$ NMRD data for low molecular weight complexes of Gd ³⁺	121
Table 6.2: r_1 and $r_{1\rho}$ NMRD data for low molecular weight complexes of Mn ²⁺	124

List of Figures

Figure 1.1: Influence of B_0 on a collection of proton nuclei	8
Figure 1.2: Influence of a 90° RF B_1 pulse on net longitudinal magnetization	10
Figure 1.3: Inversion recovery pulse timing diagram and course of magnetization	14
Figure 1.4: CPMG pulse timing diagram and course of magnetization	16
Figure 1.5: Summary of T_1 relaxation time constant determination	18
Figure 1.6: Summary of T_2 relaxation time constant determination	19
Figure 1.7: Spin echo pulse timing diagram for weighted imaging	20
Figure 1.8: Effect of image weighting on contrast	23
Figure 1.9: Distribution and excretion pathways of clinical Gd^{3+} -based CAs	25
Figure 1.10: Structures of class 1 (ECF) agents	26
Figure 1.11: Structure of class 2 (ECF/liver) agents	27
Figure 1.12: Structure of class 3 (blood pool) agent	27
Figure 1.13: Macrocyclic and linear parent ligands for clinical Gd^{3+} -based CAs	29
Figure 1.14: Schematic of the spheres of water that contribute to relaxivity	31
Figure 1.15: Laboratory frame NMRD profiles of Dotarem and an optimized gadoterate chelate	33
Figure 1.16: Simulated effect of τ_R and τ_M on relaxivity for a generic Gd^{3+} chelate	36
Figure 1.17: Spin Locking pulse timing diagram and course of magnetization	40

Figure 1.18: Summary of $T_{1\rho}$ relaxation time constant determination	41
Figure 2.1: T_1 and $T_{1\rho}$ measurement repeatability data	50
Figure 2.2: Effect of relaxation delay times on T_1 time curves (25 °C)	52
Figure 2.3: Effect of relaxation delay times on $T_{1\rho}$ time curves (25 °C)	53
Figure 2.4: Effect of first pulse delay times on T_1 and $T_{1\rho}$ time curves (25 °C)	55
Figure 2.5: Effect of last pulse delay times on T_1 and $T_{1\rho}$ time curves (25 °C)	56
Figure 2.6: Effect of number of data points on T_1 and $T_{1\rho}$ time curves (25 °C)	60
Figure 3.1: Dependence of $R_{1\rho}$ on γB_1 (low field)	69
Figure 3.2: Dependence of $R_{1\rho}$ on γB_1 (high field)	72
Figure 3.3: Sample raw data for the high field γB_1 dependence figure	74
Figure 3.4: Dependence of T_2 on pulse delay time	76
Figure 4.1: r_1 and $r_{1\rho}$ NMRD profiles for linear and macrocyclic q = 1 clinical Gd^{3+} -based CAs	81
Figure 4.2: Sample relaxivity (r_1) plots for the macrocyclic class of clinical agents	87
Figure 4.3: Simulated versus observed $r_{1\rho}$ NMRD data for Magnevist and Dotarem	89
Figure 4.4: r_1 and $r_{1\rho}$ NMRD profiles for bulky q = 1 clinical Gd^{3+} -based CAs	90
Figure 4.5: Summary of the % change in relaxivity by spin locking clinical agents	96
Figure 5.1: Simulated inner sphere contribution to r_1 and $r_{1\rho}$ NMRD of a theoretically “optimized” gadoterate chelate versus r_1 NMRD of non-optimized gadoterate	99

Figure 5.2: Cartoon of the spheres of water contributing to relaxivity for GdDOTP ⁵⁻	101
Figure 5.3: Cartoon of a GdDOTP ⁵⁻ NAC	102
Figure 5.4: SEM of GdDOTP ⁵⁻ NACs	103
Figure 5.5: Dependence of R_{1p} on γB_1 of NACs (high field)	105
Figure 5.6: r_1 and $r_{1\rho}$ NMRD profiles of GdDOTP ⁵⁻ NACs versus free chelate	106
Figure 5.7: Summary of the % change in relaxivity by spin locking NACs	111
Figure 6.1: Ligands for the preparation of low molecular weight Gd ³⁺ and Mn ²⁺ chelates with a variety of hydration states	115
Figure 6.2: Dependence of R_{1p} on γB_1 for MnCl ₂ (low field)	118
Figure 6.3: NMRD profiles of several low molecular weight chelates of Gd ³⁺ with varying hydration states	120
Figure 6.4: NMRD profiles of several low molecular weight chelates of Mn ²⁺ with varying hydration states	123
Figure 6.5: NMRD profiles of aqueous transition metal ions from literature	125

List of Equations

Equation 1.1: Relationship between spin angular momentum and spin quantum number	4
Equation 1.2: Projection of the spin angular momentum vector along the z-axis	5
Equation 1.3: Proportionality between magnetic moment and spin angular momentum	5
Equation 1.4: Energy of spin states generated by Zeeman splitting	6
Equation 1.5: Redefined energy of spin states for a magnetic field along the z-axis	6
Equation 1.6: Difference in energy between two spin states	6
Equation 1.7: Linear frequency of EM radiation corresponding to energy gap	6
Equation 1.8: The Boltzmann distribution of spins	7
Equation 1.9: The Larmor frequency	7
Equation 1.10: Derivation of the general solution to the integrated first order rate law	12
Equation 1.11: Exponential recovery equation that describes the return of the z component of net magnetization towards equilibrium along the z axis after a 90° pulse	13
Equation 1.12: Exponential recovery equation that describes the return of the z component of net magnetization towards equilibrium along the z axis after a 180° pulse	13
Equation 1.13: Exponential decay equation that describes the loss of transverse relaxation from the x,y-plane and return to its equilibrium value after a 90° pulse	15
Equation 1.14: Macroscopic transverse magnetization components of the FID in the x,y-plane as a function of time	17

Equation 1.15: Fourier transformation equation for mathematical transformation of signal from the time domain to frequency domain	17
Equation 1.16: Signal intensity equation for the spin echo weighting pulse sequence	21
Equation 1.17: Laboratory frame longitudinal relaxivity	30
Equation 1.18: Observed laboratory frame longitudinal relaxation rate constant	30
Equation 1.19: Inner sphere contribution to the observed laboratory frame longitudinal relaxation rate constant	31
Equation 1.20: Dependence of the inner sphere laboratory frame longitudinal relaxation rate constant	35
Equation 1.21: Dependence of the laboratory frame longitudinal and transverse correlation time constant	35
Equation 1.22: Dependence of the laboratory frame longitudinal electron spin relaxation time constant	38
Equation 1.23: Dependence of the laboratory frame transverse electron spin relaxation time constant	38
Equation 1.24: Exponential decay equation that describes the loss of transverse relaxation from the x,y-plane in the presence of a spin lock pulse and return to its equilibrium value after a 90° excitation pulse	41
Equation 3.1: Dependence of the rotating frame longitudinal relaxation rate constant	64
Equation 3.2: The Rabi frequency	64
Equation 3.3: Condition for which R_{1r} should be independent of γB_1 in the presence of Gd^{3+} ions	65

Equation 3.4: Dependence of $R_{1\rho}$ in the presence of Gd^{3+} ions	65
Equation 3.5: Dependence of $r_{1\rho}$ in the presence of Gd^{3+} ions	65
Equation 3.6: Dependence of a RF flip angle	66
Equation 3.7: Power attenuation for a power quantity	67
Equation 3.8: Relationship between power and current	67
Equation 3.9: Power attenuation for a field quantity	67
Equation 4.1: Dependence of the inner sphere laboratory frame longitudinal relaxation rate constant	88
Equation 6.1: Low power limit dependence of the rotating frame longitudinal relaxation rate constant	116

List of Terms and Abbreviations

BBB	Blood brain barrier
B_{eff}	Effective external magnetic field
BSA	Bovine serum albumin
CAs	Contrast agents
CNR	Contrast to noise ratio
CSF	Cerebrospinal fluid
CT	Computed tomography
DLS	Dynamic light scattering
DOTA	2,2',2'',2'''-(1,4,7,10-tetraazacyclododecane-1,4,7,10-tetrayl)tetraacetate
DOTP	1, 4, 7, 10-tetra-azacyclododecane- N,N',N'',N''' -tetrakis(methylenephosphonic acetate)
DTPA	2,2',2'',2'''-(1,2-ethanediyl)nitrito)pentaacetate
ECF	Extracellular fluid
EDTA	2,2',2'',2'''-(1,2-ethanediyl)dinitrito)tetraacetate
EU	European union
FDA	Food and Drug Administration
FID	Free induction decay
Gd ³⁺ -based CAs	Trivalent Gadolinium based contrast agent
γB_1	Spin lock pulse strength

HSA	Human serum albumin
ICF	Intracellular fluid
ICP-AES	Inductively coupled plasma-atomic emission spectroscopy
M	Net magnetization
MeCN	Methyl cyanide (Acetonitrile)
M_0	Equilibrium magnetization
M_L	Net longitudinal magnetization
M_T	Net transverse magnetization
MR	Magnetic resonance
MRI	Magnetic resonance imaging
MW	Molecular weight
NACs	Nanoassembled capsules
NMR	Nuclear magnetic resonance
NMRD	Nuclear magnetic relaxation dispersion
NPs	Nanoparticles
PAH	Polyallylamine hydrochloride
PBS	Phosphate buffered saline
PD	Proton density
PET	Positron emission tomography
ppm	Parts per million
PRE	Paramagnetic relaxation enhancement
r_1	Laboratory frame relaxivity

r_{1p}	Rotating frame relaxivity
R	Charge ratio
$R_1^{\text{Inner-sphere}}$	Inner sphere bound water proton laboratory frame longitudinal relaxation rate constant
R_1^{obs}	Observed laboratory frame longitudinal relaxation rate constant (solvent).
$R_1^{\text{Outer-sphere}}$	Outer sphere bound water proton laboratory frame longitudinal relaxation rate constant
$R_1^{\text{Second-sphere}}$	Second sphere bound water proton laboratory frame longitudinal relaxation rate constant
R_1	Laboratory frame longitudinal relaxation rate constant
R_2	Laboratory frame transverse relaxation rate constant
R_{1p}	Rotating frame longitudinal relaxation rate constant
R_{1M}	Bound water proton laboratory frame longitudinal relaxation rate constant
R_{2M}	Bound water proton laboratory frame transverse relaxation rate constant
R_{1W}	Bulk water proton laboratory frame longitudinal relaxation rate constant
R_{2W}	Bulk water proton laboratory frame transverse relaxation rate constant
RD	Relaxation delay

RF	Radiofrequency
SBM	Solomon-Bloembergen-Morgan
SE	Spin echo
SD	Standard deviation
SEM	Scanning electron microscopy
SNR	Signal to noise ratio
T_1	Laboratory frame longitudinal relaxation time constant
T_2	Laboratory frame transverse relaxation time constant
$T_{1\rho}$	Rotating frame longitudinal relaxation time constant
T_{1M}	Bound water proton longitudinal relaxation time constant
TL	Locking time
TTHA	3,6,9,12-tetrakis(carboxymethyl)-3,6,9,12-tetraazatetradecanedioic acetate
τ	Delay time
τ_{c1}	Longitudinal correlation time constant
τ_{c2}	Transverse correlation time constant
τ_M	Inner-sphere water residence time constant
τ_R	Rotational correlation time constant
τ_{S1}	Longitudinal electron relaxation time constant
τ_{S2}	Transverse electron relaxation time constant
τ_b	Correlation time of the ZFS

US	Ultrasound
VDU	Visual display unit
Voxel	3D pixel
ZFS	Zero-field splitting

CHAPTER 1. INTRODUCTION

1.1. Magnetic resonance imaging: a critical imaging mode of the past, present and future

1.1.1. The rise to popularity of MRI

In 1938 Isidor Rabi conducted the first nuclear magnetic resonance (NMR) experiments on Lithium chloride in his laboratory at Columbia University.¹ In 1946, and within a month of each other, teams at Harvard, lead by Purcell,² and Stanford, lead by Bloch,³ had refined the technique and independently made observations of weak magnetism of protons in condensed matter. Awarded the Nobel Prize in physics for their work these were the founding fathers of NMR, which has since found many applications. One such application is magnetic resonance imaging (MRI). In 1973 Paul Lauterbur demonstrated the imaging potential of MR by differentiating heavy and normal water *in-vitro*.⁴ The utility of such a technique was quickly recognized and the push towards the ultimate goal of imaging a living human began. In the late 1970's, shortly after Lauterbur's discovery, *in-vivo* images of the human finger⁵ and whole body imaging⁶ were published. Since, many technological advances including: cryogenic magnets, Gadolinium contrast agents, actively shielded magnets and the emergence of stronger magnetic fields for routine imaging to name just a few, have led to the current state of development of clinical MRI.⁷

1.1.2. Modern day MRI and its comparison with other imaging modalities

During this time, MRI has steadily become established amongst other imaging modalities available to radiologists including: X-ray, computed tomography (CT), ultrasound (US) and positron emission tomography (PET). Since the first commercial system in 1983 ~20,000 MRI systems have been installed worldwide⁷ with ~27 million scans (half the number of X-ray scans) being performed in the US alone in 2007.⁸ The popularity of MRI can largely be attributed to the technique being relatively non-invasive, employing non-ionizing radiation and having the ability to measure whole tissue samples with exceptional soft tissue spatial resolution and contrast, albeit at the expense of imaging time. However, the real power of MRI is in its flexibility. MRI has the ability to characterize several tissue parameters that can vary from tissue to tissue, allowing it to distinguish between healthy and diseased tissue and identify key markers of many diseases and disorders including those most prevalent in human kind.⁹⁻¹³ Moreover, this can be achieved whilst keeping the hardware required relatively constant and presenting clinically relevant information as easy-to-interpret 3D digital contrast images based on signal intensity. The signal in an MR image is typically generated from the water proton nuclei, the most abundant nuclei *in vivo*, maximizing the technique's sensitivity. Despite this, the sensitivity of MRI remains poor in comparison to X-ray-based methods, PET and US. However, MRI offers the advantage of fewer safety concerns. Although US is also considered very safe and the sound waves employed afford excellent temporal resolution, its drawback comes from poor spatial resolution. As can be imagined, for

accurate diagnosis and optimal treatment of disease a combination of these complimentary imaging modalities is often required.

1.1.3. The future of clinical MRI

The major drawback for MRI is the technique's lack of sensitivity which is related to the field strength (B) of the magnet, measured in flux density (tesla, T). Since the introduction of NMR in the 1960's, and later MRI, the operating magnetic field strength for both has increased linearly over time, leading to small incremental gains in sensitivity.¹⁴ The vast majority of clinical scanners today operate at 1.5 and 3 T, however, many 4.7 T scanners are in preclinical use and human imaging is permitted up to 8 T.⁷ There is no evidence to suggest that the current trend is about to change and as such larger magnets will dot the landscape in the not so distant future. At these high fields, scientists seek to further lower detection limits and increase spatial resolution as a result of the improved signal-to-noise ratio (SNR).¹⁵ For as long as there is both a clinical and commercial requirement for larger magnets, any technological challenge imposed shall be met. Such challenges to large magnets include, but are not limited to: instrument siting within current radiology departments, B_0 field homogeneity across large bore instruments and economics of the setup and running costs.

1.2. Nuclear magnetic resonance (NMR) theory

Although much of what follows is in the context of MR imaging, the theories are entirely grounded in those of NMR. Thus, it is important to be reminded of the underlying

physics, the origin of the signal as it pertains to MRI and its detection for contrast generation.

1.2.1. The Zeeman effect

Atoms comprise of electrons and a positively charged nucleus containing protons and neutrons. Interactions between the nuclei of many isotopes and the magnetic fields that surround them, allows NMR to provide detailed molecular information. Fundamental to NMR is spin, a physical property of all nuclei. Spin is a purely quantum mechanical concept that can be represented by the classical vector model of angular momentum. However, unlike classical angular momentum, induced by rotation, spin angular momentum is an intrinsic property. The total spin angular momentum, $\mathbf{I}$, a vector quantity, is given by Equation 1.1 where $\hbar$ is the reduced Planck's constant (Planck's constant divided by 2π) and I is the specific spin quantum number of the nuclei of interest, a positive multiple of $\frac{1}{2}$.

$$|\mathbf{I}| = \hbar[I(I + 1)]^{\frac{1}{2}} \quad (1.1)$$

Isotopes with even mass numbers and even numbers of both protons and neutrons (*e.g.* $^{12}\text{C}_6$) possess a spin quantum number (I) of zero and therefore no angular momentum and are NMR inactive. However, if the proton and neutron numbers are both odd (*e.g.* $^2\text{H}_1$ and $^{14}\text{N}_7$) I takes non-zero integer values. Isotopes with odd mass numbers and either odd or even numbers of protons and neutrons, such as the main isotope of hydrogen ($^1\text{H}_1$)

and the minor stable isotope of carbon ($^{13}\text{C}_6$), possess half-integer spin values. Isotopes with non-zero spin values possess angular momentum and are NMR active.

With respect to an arbitrarily chosen axis, shown projected with respect to the z-axis in Equation 1.2, the spin vector of the angular momentum can have several possible directions, a result of the quantized nature of the spin projection magnetic quantum number, m_I , for which quantum mechanics dictates there are $2I+1$ possible values which range from $-I$ to $+I$ with integer steps.

$$I_z = m_I \hbar \quad (1.2)$$

The angular momentum of the nuclei gives rise to a nuclear magnetic moment (μ) proportional to the total spin angular momentum (I) and the gyromagnetic ratio (γ), a constant specific to the nuclei of interest (Equation 1.3).

$$\mu = \gamma I \quad (1.3)$$

The magnetic moment of the proton creates a weak magnetic field that interacts with local magnetic fields. In MRI, the nucleus of interest is that of the abundant water proton ($^1\text{H}_1$) which has a spin quantum number (I) of a $\frac{1}{2}$ and therefore two possible spin projection quantum numbers (m_I) of $-\frac{1}{2}$ and $+\frac{1}{2}$. In the absence of an external magnetic field these two spin states have equal probability and therefore equal spin populations and are considered energetically degenerate. As a consequence of this degeneracy the total magnetic moment is zero. When a subject is immersed in the strong homogenous magnetic field (B_0) of an MRI instrument two interesting processes occur simultaneously.

One, the degeneracy of the two spin states is broken and the proton nuclei can either align parallel to B_0 , denoted as $+\frac{1}{2}$ (low energy, α), or anti parallel to B_0 , denoted $-\frac{1}{2}$ (high energy, β). This is known as the Zeeman effect, where the energy is the product of the magnetic moment and B_0 (Equation 1.4).

$$E = -\mu B_0 \quad (1.4)$$

For a magnetic field along the z-axis and from Equation 1.2 and 1.3, this can be stated as;

$$E = -\mu_z B_0 = -m_I \hbar \gamma B_0 \quad (1.5)$$

Where the difference in energy between the equally spaced spin states is;

$$\Delta E = \hbar \gamma B_0 \quad (1.6)$$

This corresponds to a frequency (ν_0) of electromagnetic radiation that can be found as follows;

$$\text{Given; } \Delta E = h\nu_0 = \hbar \gamma B_0$$

$$\nu_0 = \frac{\gamma B_0}{2\pi} \quad (1.7)$$

For magnetic field strengths typical in MRI and NMR, these frequencies correspond to the RF region of the electromagnetic spectrum.

The extent to which each state is populated is governed by the Boltzmann distribution law (Equation 1.8) where N_α and N_β are the number of protons in the low (anti parallel)

and high (parallel) energy states respectively, k_B is the Boltzmann distribution constant, T is the absolute temperature and ΔE is the difference in energy between the two states.

$$\frac{N_\alpha}{N_\beta} = e^{\frac{\Delta E}{k_B T}} = e^{\frac{\hbar \gamma B_0}{k_B T}} \quad (1.8)$$

Due to energy considerations a slight excess of spins reside in the lower energy spin state. From Equation 1.8 it can be seen that the spin populations are influenced by the strength of B_0 and temperature. For a typical magnetic field strength used in clinical MRI of 1.41 T and at a temperature of 37 °C, this population difference is approximately 1 spin per 100000 spins, *i.e.* ~ 10 ppm.

Two, B_0 exerts torque on the individual magnetic moments of the proton nuclei and they begin to precess out of phase with the angular momentum, $\mathbf{I}$, at some constant angle around the axis of B_0 . The angular frequency of this precession, which corresponds to the energy difference between the two spin states as described above, is termed the Larmor frequency (ω_0) and is dependent on γ and the strength of B_0 (Equation 1.9). Equation 1.9 describes the Larmor frequency for a proton with respect to the direction of precession about B_0 , where the negative sign indicates a negative sense of precession (clockwise) when viewed from a position above the direction of B_0 .

$$\omega_0 = -\gamma B_0 \quad (1.9)$$

The end result of these two processes is that a net macroscopic magnetization (M), a vector sum of all the individual spin magnetic moments, is induced. When viewed from the rotating frame of reference (*i.e.* the x,y -axis is rotating at the Larmor frequency), M lies directly along the z -axis, longitudinal to the direction of B_0 . Figure 1.1 summarizes the influence of B_0 on a collection of proton nuclei.

Figure 1.1: Summary of the influence of B_0 on a collection of proton nuclei. a) Degenerate nuclear spin orientations in the absence of B_0 . b) Non-degenerate nuclear spin orientations in the presence of B_0 . c) Excess spins randomly precessing around B_0 . d) Net magnetization longitudinal to the direction of B_0 viewed from the rotating frame of reference.

1.2.2. Signal detection

In the above section a net magnetization vector (M) was established. This represents a vector sum of the entire ensemble of spins, whose magnitude is determined by the population difference (spin excess) between spin states. This difference in population, on the order of parts per million (ppm), is the origin of the MRI signal. But, it is also the source of the relatively poor sensitivity of MRI. Unfortunately the nuclear longitudinal magnetization is practically undetectable as its signal is swamped by three orders of magnitude of diamagnetism derived from the electrons (diamagnetic shielding).¹⁶

In order to detect the net magnetization it must be rotated in to the x,y-plane, transverse to the direction of B_0 . This is achieved by perturbation of the magnetization with a second magnetic field (B_1) that is weak, relative to B_0 , and generated by the application of a RF pulse, typically along the x-axis. The result is that the magnetization is effectively rotated away from B_0 and the diamagnetism of electrons where it can be detected. In order for this to occur, the frequency of B_1 must match the Larmor frequency of the magnetic moments causing the spins to resonate. Under these conditions, the spins in the lower energy state absorb the RF energy and are promoted to the higher energy state, resulting in equalization of the spin populations. In addition, the B_1 pulse causes the individual magnetic moments to begin to precess together, *i.e.* in phase (phase coherent), and for magnetization to grow in the x,y-plane (transverse magnetization). The extent of the rotation of the magnetization is dependent on the strength and duration of the B_1 field, with maximum signal intensity being observed when the magnetization is rotated 90° . The net magnetization precesses at the Larmor frequency (ω_0) in the x,y-plane, generating a rotating magnetic field and an associated electric field. This electric field drives an oscillating electric current (the signal) in a wire coil near the sample in the x,y-plane. Figure 1.2 summarizes the influence of a 90° B_1 pulse on the net magnetization.

1.2.3. Longitudinal relaxation

After the pulse is turned off the gate to the RF receiver opens and a free induction decay (FID) signal is detected and the spins relax back to thermal equilibrium. The thermal equilibrium state is that in which the spin populations of the energy levels are those

predicted by the Boltzmann distribution and one in which no coherences exist, *i.e.* no component of the net magnetization is in the x,y -plane. The return of the spin populations back to those predicted by the Boltzmann distribution, where an excess of spins are in the low energy spin state, requires dissipation of energy from the high energy spin states. This occurs as a result of field fluctuations that arise primarily from magnetic dipole-dipole interactions. This regenerates magnetization longitudinal to B_0 along the z axis and is termed longitudinal relaxation. Longitudinal relaxation is characterized by the time constant T_1 , and the rate of the change of magnetization follows first order kinetics.

Figure 1.2: A summary of the influence of a 90° RF B_1 pulse on the net magnetization. a) A 90° RF pulse promotes spins from the low energy state to the high energy state. b) When the RF pulse is complete the spin populations are equalized and precess in phase. The net magnetization has rotated into the x,y -plane generating transverse magnetization.

Derivation of the general solution to the integrated first order rate law demonstrates that the return of the magnetization to equilibrium from its position immediately after a RF pulse is turned off, is exponential in form, Equation 1.10, where $M_z(\tau)$ is the magnetization at a given delay time (τ), $M_{z(\text{eq})}$ is the equilibrium magnetization after

complete recovery, $M_z(0)$ is the magnetization at the time, $\tau = 0$, directly after a RF pulse,

T_1 is the longitudinal relaxation time constant and $e^{-\frac{\tau}{T_1}}$ is the exponential decay function.

$$rate = k(M_z(\tau) - M_{z(eq)})$$

Where the rate constant, $k = \frac{1}{T_1}$

$$rate = -\frac{dM_z(\tau)}{d\tau} = \frac{1}{T_1}(M_z(\tau) - M_{z(eq)})$$

$$\frac{dM_z(\tau)}{(M_z(\tau) - M_{z(eq)})} = -\frac{1}{T_1}d\tau$$

$$\int \frac{dM_z(\tau)}{(M_z(\tau) - M_{z(eq)})} = -\frac{1}{T_1} \int d\tau$$

$$\ln(M_z(\tau) - M_{z(eq)}) = -\frac{1}{T_1}\tau + C$$

If, at time $\tau = 0$, the magnetization is $M_z(0)$, then the constant of integration, C , is;

$$\ln(M_z(0) - M_{z(eq)}) = C$$

$$\therefore \ln(M_z(\tau) - M_{z(eq)}) = -\frac{\tau}{T_1} + \ln(M_z(0) - M_{z(eq)})$$

$$\ln(M_z(\tau) - M_{z(eq)}) - \ln(M_z(0) - M_{z(eq)}) = -\frac{\tau}{T_1}$$

$$\ln \frac{(M_z(\tau) - M_{z(eq)})}{(M_z(0) - M_{z(eq)})} = -\frac{\tau}{T_1}$$

$$e^{\ln \left(\frac{M_z(\tau) - M_{z(eq)}}{M_z(0) - M_{z(eq)}} \right)} = e^{-\frac{\tau}{T_1}}$$

$$\frac{M_z(\tau) - M_{z(eq)}}{M_z(0) - M_{z(eq)}} = e^{-\frac{\tau}{T_1}}$$

$$M_z(\tau) - M_{z(eq)} = (M_z(0) - M_{z(eq)})e^{-\frac{\tau}{T_1}}$$

$$M_z(\tau) = M_{z(eq)} + (M_z(0) - M_{z(eq)})e^{-\frac{\tau}{T_1}}$$

$$M_z(\tau) = M_{z(eq)} + (-1)(M_{z(eq)} - M_z(0))e^{-\frac{\tau}{T_1}}$$

$$M_z(\tau) = M_{z(eq)} - (M_{z(eq)} - M_z(0))e^{-\frac{\tau}{T_1}} \quad (1.10)$$

Exponential recovery of the z component of the net magnetization towards equilibrium along the z axis after a 90° RF pulse (Equation 1.11) can be derived by expressing Equation 1.10 as:

$$M_z(\tau) = M_{z(eq)} - M_{z(eq)} \left(1 - \frac{M_z(0)}{M_{z(eq)}} \right) e^{-\frac{\tau}{T_1}}$$

This simplifies to;

$$M_z(\tau) = M_{z(eq)} \left(1 - \left(1 - \frac{M_z(0)}{M_{z(eq)}} \right) e^{-\frac{\tau}{T_1}} \right)$$

For a 90° pulse $M_z(0)$ is 0, and if we let $M_{z(eq)}$ be 1, then this simplifies further to;

$$\begin{aligned}
 M_z(\tau) &= 1 \left(1 - \left(1 - \frac{0}{M_{z(eq)}} \right) e^{-\frac{\tau}{T_1}} \right) \\
 M_z(\tau) &= M_{z(eq)} \left(1 - (1 - 0) e^{-\frac{\tau}{T_1}} \right) \\
 M_z(\tau) &= M_{z(eq)} \left(1 - (1) e^{-\frac{\tau}{T_1}} \right) \\
 M_z(\tau) &= M_{z(eq)} \left(1 - e^{-\frac{\tau}{T_1}} \right) \tag{1.11}
 \end{aligned}$$

For a delay time (τ) equal to one time constant (T_1) it can be shown that the magnetization recovers 63% towards equilibrium (1) on the z axis.

$$M_z(\tau = T_1) = 1 \left(1 - e^{-\frac{T_1}{T_1}} \right) = 1 \left(1 - \frac{1}{e} \right) = 1 \left(1 - \frac{1}{2.718} \right) = 0.63 = 63\%$$

T_1 values are often determined using an inversion recovery pulse sequence. This pulse sequence employs an initial 180° RF pulse that inverts the net magnetization to the $-z$ axis such that $M_z(0)$ is equal to $-M_{z(eq)}$, *i.e.* -1. Equation 1.11 can therefore be re-written to describe the recovery of the net magnetization after a 180° RF pulse as;

$$M_z(\tau) = 1 \left(1 - 2e^{-\frac{\tau}{T_1}} \right) \tag{1.12}$$

After one T_1 , 63% of the magnetization will recover towards equilibrium on the +z axis (+1). Since the initial magnetization is on the -z axis (-1), the magnetization after one T_1 is 63% of 2 plus the initial magnetization (-1), *i.e.* $2 \times (0.63) + -1 = 0.26$, as shown;

$$M_z(\tau = T_1) = 1 \left(1 - 2e^{-\frac{T_1}{T_1}} \right) = 1 \left(1 - 2\frac{1}{e} \right) = 1 \left(1 - 2\frac{1}{2.718} \right) = 0.26$$

The inversion recovery pulse sequence consists of a series of radiofrequency (RF) pulses and time delays¹⁷ (Figure 1.3). An initial 180° RF pulse along the +x axis ($B_{1(180)x}$) ① inverts the net magnetization from its equilibrium position along the +z axis parallel to B_0 to the -z axis ②. During the pulse delay (τ) the magnetization is allowed to relax back towards equilibrium, after which a 90° RF pulse is employed along the +x axis ($B_{1(90)x}$) ③ and converts the remaining magnetization into the x,y-plane where the FID signal is detected ④. A relaxation delay time (RD) allows full relaxation of the magnetization back to equilibrium to occur prior to the next iteration of the pulse sequence ① with a longer pulse delay time (τ).

Figure 1.3: IR timing diagram (top), course and position of the net magnetization (bottom).

1.2.4. Transverse relaxation

The loss of phase coherence of spins, transverse relaxation, occurs via fluctuating magnetic fields caused by molecular motions and B_0 field inhomogeneities. Transverse relaxation is characterized by the time constant T_2 , the decay time constant for the loss of magnetization in the x,y-plane and the return to its equilibrium value (0), and also follows first order kinetics. Derivation of the solution to the integrated first order rate law demonstrates that the loss of transverse magnetization is also exponential in form, Equation 1.13, $M_{xy}(\tau)$ is the magnetization at a given delay time (τ), $M_{xy}(0)$ is the magnetization at time 0 directly after a RF pulse, T_2 is the transverse relaxation time constant and $e^{-\frac{\tau}{T_2}}$ is the exponential function of the decay.

$$M_{xy}(\tau) = M_{xy}(0)e^{-\frac{\tau}{T_2}} \quad (1.13)$$

After a 90° pulse $M_{xy}(0)$ is 1. From Equation 1.13 it can be determined that for a delay time (τ) equal to one time constant (T_2), magnetization in the x,y-plane decays to 37% of its original value (1);

$$M_{xy}(\tau = T_2) = 1e^{-\frac{T_2}{T_2}} = 1\left(\frac{1}{e}\right) = 1\left(\frac{1}{2.718}\right) = 0.37 = 37\%$$

T_2 can be determined from a CPMG (Carr-Purcell-Meiboom-Gill) pulse sequence named after the contributing scientists responsible for its development. The CPMG pulse sequence consists of a 90° excitation pulse followed by a 180° (π) pulse that refocuses

de-phasing spins in the x,y-plane to produce an echo signal. However, to ensure time constants more closely reflect the true T_2 value rather than T_2^* which includes contributions due to de-phasing that arises from the inhomogeneity of B_0 , a train of phase encoded 180° pulses are employed. The alternating phase of each 180° pulse of the train reduces the inherent errors associated with each pulse through averaging, thereby improving the accuracy of T_2 values.¹⁸ With respect to Figure 1.4, the CPMG pulse sequence employs a 90° RF pulse (B_1) ① that converts the net magnetization into the x,y-plane ②. The FID here is ignored. Instead, during a pulse delay time (τ) the spins begin to dephase, after which a 180° pulse is applied ③. The 180° pulse inverts the ensemble of spins ④ and they begin to re-phase such that after another pulse delay time (τ) the coherences are restored and an echo signal is detected for which the FID signal is recorded ⑤. This is repeated for a train of 180° pulses of alternating phase along the y-axis where the exponential decrease of the echo signal intensity is due to the effective T_2 . After the final echo of the train a relaxation delay time (RD) allows full relaxation back to equilibrium prior to the next iteration of the pulse sequence ①.

Figure 1.4: CPMG timing diagram (top), course and position of the net magnetization (bottom).

1.2.5. Fourier transformation, T_1 and T_2 determination

The macroscopic transverse magnetization components of the FID in the x,y-plane as a function of time t, take the following forms;

$$\begin{aligned} M_x &= (M_{eq} - M_z(t)) \sin(\omega t) e^{-\frac{t}{T_2}} \\ M_y &= -(M_{eq} - M_z(t)) \cos(\omega t) e^{-\frac{t}{T_2}} \end{aligned} \quad (1.14)$$

The analogue FID signal picked up by a receiver coil in the x,y-plane is digitized for computer processing. Digitizing the FID produces a time domain function, $s(t)$, where each time point corresponds to signal amplitude. The digitized signal is complex, *i.e.* comprises values from both the x and y components of the magnetization and is known as quadrature detection. The FIDs recorded for all iterations of the pulse sequence with varying pulse delay times (τ) are mathematically transformed to the frequency domain $S(\omega)$, a function of the initial signal amplitude in the time domain, $s(t)$. This is accomplished by a Fourier transformation (Equation 1.15) taking as the input both components of the net transverse magnetization, M_x and M_y from Equation 1.14.

$$S(\omega) = \sum_0^\infty s(t) [\cos(\omega t) - i \sin(\omega t)] \quad (1.15)$$

T_1 is determined by plotting the signal intensity (S) of the peak maximum in the frequency domain at ④ (Figure 1.5, top) as a function of τ , the pulse delay time (Figure 1.5, bottom) and fitting to Equation 1.12

Figure 1.5: Summary of T_1 determination. IR pulse sequence and generation of spectra (top) and the evolution of magnetization (M_z) as a function of the variable pulse delay time (τ) (bottom).

T_2 is determined by plotting the signal intensity (S) of the peak maximum in the frequency domain at ⑤ (Figure 1.6, top) as a function of τ , the pulse delay time (Figure 1.6, bottom) and fitting to Equation 1.13.

Figure 1.6: Summary of T_2 determination. CPMG pulse sequence and generation of spectra (top) and the decay of magnetization (M_{xy}) as a function of the variable total pulse delay time (τ) (bottom).

1.3. Inherent soft tissue contrast and image weighting

The molecular composition of human soft tissue can be broadly divided into either water or macromolecules (lipids, carbohydrates, proteins etc). These molecules contain a vast number of hydrogen atoms (about 67% of all atoms in tissue), the source of signal in most MRI. By applying a gradient magnetic field on top of the static B_0 field, each hydrogen nuclei experiences a slightly different total magnetic field and resonate at slightly different Larmor frequencies. This introduces spatial encoding allowing a three-

dimensional image to be generated. The signal intensity within an imaging voxel (1 mm^3) is reported as relative brightness thus producing contrast in the image. The signal intensity is, in part, related to the number of hydrogen atoms in the voxel, proton density, a biologically variable parameter, and, to tissue T_1 and T_2 time constants discussed above, which also vary from tissue to tissue.

A spin echo (SE) pulse sequence¹⁹ is capable of extracting inherent proton density $[H^+]$, T_1 or T_2 contrast. A traditional SE pulse sequence has the same features as a CPMG pulse sequence but with a single echo generated by a single 180° refocusing pulse (Figure 1.7). With appropriate selection of the echo time (TE), the time between the initial 90° RF pulse and the echo signal, and the repetition time (TR), the time between consecutive 90° RF pulses of subsequent scans, image contrast can be biased, or “weighted”, towards any of the three contrast mechanisms discussed.

Figure 1.7: Spin echo pulse timing diagram for weighted imaging.

This can be seen from the signal intensity equation for this pulse sequence (Equation 1.16) where; S is the amplitude of the signal in the frequency domain, k is a constant that depends on the signal detection sensitivity of the instrument being used, $[H^+]$ is the

proton concentration and T_1 and T_2 are the longitudinal and transverse relaxation time constants respectively. It is apparent from this equation that TR is related to T_1 and TE to T_2 , and that $[H^+]$ is unrelated to either T_1 or T_2 but is always present to some extent.

$$S = k[H^+] \left(1 - e^{-\frac{TR}{T_1}} \cdot e^{-\frac{TE}{T_2}} \right) \quad (1.16)$$

If TR is set to be longer than T_1 then the term e^{-TR/T_1} tends to 0 and T_1 effects on image contrast will be suppressed. This is a result of negligible differences in signal intensity between two tissues with different T_1 values as magnetization recovers towards equilibrium. Likewise, if TE is set to be shorter than T_2 then the term e^{-TE/T_2} tends to 1 and T_2 effects on image contrast will be suppressed. In this situation, little decay of the signal has occurred and again there is a negligible difference in signal intensity between two tissues with different T_2 values. If a SE pulse sequence is employed in which both T_1 and T_2 effects are suppressed (short TE and long TR) then image contrast will be weighted towards the remaining contribution, proton density, where greater numbers of protons in a voxel generates increased signal intensity. In practice, all images generated with the SE pulse sequence contain a mix of each contrast mechanism. Experimentation and experience is required to optimize the desired contrast between tissues of interest. A summary of the effects of different types of image weighting on brain tissue contrast between ventricles, that contains CSF (cerebrospinal fluid), an aqueous fluid, and white matter, that consists of a large amount of lipid containing myelin, is shown in Figure 1.8. T_1 and T_2 time constants for CSF and white matter were obtained from literature at 1.5

T.^{14, 20} Images were generated with the specified parameters using a web-based simulation²¹ with consent from the creator.

CSF contains mostly water, a fast tumbling small molecule for which the frequency of the oscillations of the proton magnetic dipole is typically greater than the Larmor frequency. This results in inefficient dipole-dipole interactions due to short correlation times (τ_c), the time two dipoles spend interacting, and thus long time constants. Water molecules associated with macromolecules in soft tissue such as white matter and protons that are part of the macromolecular structure are less free to rotate. As such, the oscillation of the proton magnetic dipole is closer to the Larmor frequency leading to longer correlation times and shorter time constants. If TR is long, $\gg T_1$, and TE is short, $\ll T_2$, then the resultant image is proton density-weighted as both T_1 and T_2 effects are suppressed (Figure 1.8, top row). In this case the proton density-weighted image is essentially isointense with little contrast between the bright internal volume of the ventricles and white matter. This is a result of high proton densities in the two tissues, the ventricles, which contains CSF (cerebrospinal fluid), a water based fluid, and white matter which consists of large amounts lipid containing myelin. If TR is long, $\gg T_1$, and TE is approximately the average of the expected T_2 values of the tissues for which contrast is desired, then the image is T_2 -weighted, with T_1 effects being suppressed (Figure 1.8, middle row). In a T_2 -weighted image the CSF in the ventricles is hyperintense as a result of its longer T_2 value compared to white matter, which appears hypointense. Conversely, If TE is appropriately selected in order to suppress T_2 contrast,

typically $< T_2$, and TR is approximately the average of the expected T_1 values of the tissues for which contrast is desired, then the image is T_1 -weighted (Figure 1.8, bottom row). In a T_1 -weighted image the CSF in the ventricles is hypointense as a result of its longer T_1 value compared to white matter, which appears hyperintense.

Figure 1.8: Effect of image weighting on contrast between CSF in the ventricles and white matter. Proton density-weighted (top), T_2 -weighted (middle) and T_1 -weighted (bottom).

1.4. Gd³⁺-based contrast agents for soft tissue contrast enhancement

Contrast generated by T_1 -weighting can be enhanced by the intravenous administration of an extracellular Gd³⁺-based contrast agent (CAs). In 2007, 43% of the 27 million scans performed in the US required contrast enhancement from such agents.⁸ Their ability to increase contrast between tissue in which they are taken up (typically diseased) and neighboring tissue (typically healthy) has been the subject of much research²²⁻²⁹ by chemists since the early 1980's when they were first introduced.³⁰ This has led to unparalleled improvements in tissue discrimination by increasing water proton relaxation rate constants of tissue in which they are taken up relative to surrounding tissue that would otherwise be in a similar magnetic environment and generate little contrast. Contrast agents are particularly useful for the imaging of brain pathology. In healthy brain tissue an intact blood brain barrier (BBB) prevents a contrast agent from entering cells. However, in diseased tissue the BBB can become damaged allowing a contrast agent to enter. In this case, contrast agents can be thought of as a means of identify the disruption of the BBB, particularly useful for pathologies such as multiple sclerosis.

1.4.1. Classification of clinically approved Gd³⁺-based CA

Over the last 25 years or so several Gd³⁺-based CAs have been approved for clinical use in the US and EU and fall into one of three classes based on their biodistribution (Figure 1.9). All are extra cellular agents, with those that are excreted exclusively through the kidneys belonging to one class and those that exhibit some biliary clearance belonging to

another. Those restricted to the intravascular compartment due to binding and their increased size make up a third class.

Figure 1.9: Distribution and excretion pathways for clinically approved Gd^{3+} -based CAs.

Six of the nine FDA approved agents are very hydrophilic do not exhibit any specific binding properties (Figure 1.10). After intravenous injection they circulate in the extracellular fluid compartment (ECF) prior to elimination through the kidneys. Chelates of Gd^{3+} in which the diethylenetriaminepentacetate (DTPA) ligand scaffold is modified to contain a benzyl substituent (Figure 1.11) are taken up by hepatocytes³¹ and cleared, to a degree (2 – 4%), via the hepatobiliary system making them useful for liver imaging application. The relaxivity of these agents are elevated compared to the ECF agents due to a slight binding function (~10%) between the benzyl group and plasma proteins.³² The third class of clinically approved Gd^{3+} -based CAs contains just one agent, Ablavar, (Figure 1.12). Expanding on the success of Multihance and Eovist/Primovist, Ablavar allows for an even greater increase in relaxivity to be observed via a reversible binding

function with serum albumin that lengthens the rotational correlation time due to the large effective molecular weight. Ablavar contains a lipophilic biphenylcyclohexyl group for binding and restricts access to the interstitial compartment making it particularly useful for the imaging of the blood pool. The binding moiety is attached to a pendant arm of the DTPA ligand via a phosphodiester linker that results in Ablavar being eliminated renally.

Figure 1.10: Class 1: Extracellular fluid (ECF) agents.

Figure 1.11: Class 2: Extracellular fluid (ECF) and liver agents.

Figure 1.12: Class 3: Blood pool agent with serum albumin binding moiety.

These agents can be further categorized as being derived from macrocyclic (category A) or linear (category B) parent ligands (Figure 1.13) or bulky chelates (category C) (Table 1.1).

Figure 1.13: Macrocyclic and linear parent ligands for clinical Gd³⁺-based CAs.

Table 1.1: Physical properties of the three categories of Gd³⁺-based CAs studied.

^a Obtained from Weinmann *et al.*³³ ^b Observed equilibrium relaxivity with human serum albumin

Trade name	Plasma relaxivity 1.5 T 37 °C (mM ⁻¹ s ⁻¹) ^a	Standard dose (mmol/kg)	Formulation concentration (M)	Osmolality (Osm/kg H ₂ O)	Formal charge
	<i>r</i> ₁	<i>r</i> ₂			
Category A: Cyclic					
Dotarem	3.6	4.3	0.1	0.5	1-
ProHance	4.1	5.0	0.1	0.5	0
Gadovist	5.2	6.1	0.1	1.0	0
Category B: Linear					
Magnevist	4.1	4.6	0.1	0.5	2-
Omniscan	4.3	5.2	0.1	0.5	0
Category C: Bulky					
MultiHance	6.3	8.7	0.1	0.5	2-
Ablavar	19 ^b	34 ^b	0.03	0.25	3-

(HSA) bound and free contributions. All other data readily obtainable from supplier information.

1.4.2. Stabilization of Gd³⁺-based CAs

Free Gd³⁺ is both insoluble at physiological pH and is known to be toxic.³⁴ Toxicity arises due to the ability of Gd³⁺ to take part in transmetallation with other important biological cations such as Ca²⁺, Cu²⁺ and Zn²⁺, thus disrupting important cellular mechanisms,³⁵ a factor worsened by its long residence time in the body and evidence

showing deposits in skin and bone.³⁶⁻⁴¹ Therefore, Gd^{3+} -based CAs must be formulated with the metal ion bound extremely tightly to an organic ligand. This affords thermodynamically and kinetically stable nontoxic chelates which are cleared more rapidly than they dissociate, such as those in clinical use shown above in Figures 1.10 – 1.12.

1.4.3. Mechanism of action of Gd^{3+} -based CAs

Gd^{3+} -based CAs can be rationally designed for optimum per molar effectiveness (relaxivity) and for targeting specific tissue type to allow for more localized contrast improvement and improved clinical relevance and has been extensively published and reviewed²²⁻²⁹ The basic pre-requisite of a CA for MRI is that it should increase the relaxation rate constant of bulk water protons. To that end, almost any paramagnetic solute could be used since relaxation processes occur as a consequence of the interactions between magnetic moments of unpaired electrons and those of interacting nuclei. However, the trivalent paramagnetic gadolinium ion (Gd^{3+}) has garnered most attention. This is due to its seven unpaired f electrons (maximum available) and long electron relaxation times (τ_s) that allow for increased efficacy of relaxation of the interacting water proton nuclei.²² In the presence of a Gd^{3+} ‘bound’ water molecule, these properties lead to shorter longitudinal relaxation time constants for the bound water protons (T_{1M}) which, when in fast exchange with bulk water, are able to transmit the paramagnetic relaxation enhancement (PRE) effect more effectively and thus increasing their relaxivity (r_1), described as the paramagnetic relaxation enhancement ($R_1^{\text{observed}} - R_1^w$) normalized to

the Gadolinium concentration (Equation 1.17). Where; R_1^{observed} is the observed tissue water proton longitudinal relaxation rate constant (the inverse time constant) and R_1^w is the longitudinal relaxation rate constant of pure water (or other solvent).

$$r_1 = \frac{R_1^{\text{observed}} - R_1^w}{[Gd]} \quad (1.17)$$

1.4.4. Contributions to the PRE effect

The observed longitudinal relaxation rate constant (R_1^{obs}) of water protons in the presence of a Gd^{3+} -based CA has several contributions as a consequence of various spheres of water molecules surrounding the metal ion, each of which are in a constant and rapid exchange with the bulk water protons and contribute to the paramagnetic relaxation enhancement to different extents (Equation 1.18). $R_1^{\text{Inner-sphere}}$ is the inner sphere relaxation rate constant, $R_1^{\text{Second-sphere}}$ is the second sphere relaxation rate constant, $R_1^{\text{Outer-sphere}}$ is the outer sphere relaxation rate constant and R_1^w is the solvent relaxation rate constant. Figure 1.14 shows a cartoon representation of the several spheres of water surrounding a typical Gd^{3+} -based CA.

$$R_1^{\text{Observed}} = R_1^{\text{Inner-sphere}} + R_1^{\text{Second-sphere}} + R_1^{\text{Outer-sphere}} + R_1^w \quad (1.18)$$

The coordination number of the Gd^{3+} ion ranges from eight to ten; however, it is typically nine as in the case of each of the chelates approved for clinical use. Eight are occupied by the organic chelating ligand and one by a single water molecule, the inner sphere water, which defines the hydration number (q) of the complex.

Figure 1.14: Schematic of the spheres of water that contribute to relaxivity of Gd^{3+} -based CA.

A chelates inner sphere contribution (R_1^{IS}) to R_1^{obs} is well described by Solomon-Bloembergen-Morgan (SBM) theory⁴²⁻⁴⁵ and has been shown to be dependent on the hydration number, the inner sphere water proton relaxation time constant (T_{1M}), the water proton residence life time (τ_M) and the molar concentration of Gd^{3+} (c) (Equation 1.19).

$$R_1^{\text{IS}} = \frac{c \times q}{55.6} \left(\frac{1}{T_{1M}^H + \tau_M} \right) \quad (1.19)$$

Second sphere contributions (R_1^{SS}) to R_1^{obs} occur due to an ordered sphere of water molecules beyond the inner sphere water molecules. Second sphere water molecules are in close proximity to the metal ion and are also well described by SBM theory and the parameters outline above for R_1^{IS} . Second sphere contributions have been shown to arise as a result of hydrogen bonding between the second sphere water molecules and lone pairs on the ligand groups.²⁸ Outer sphere contributions (R_1^{OS}) to R_1^{obs} occur due to

diffusion of the complex through the water and can be described by modified Freed's equations.⁴⁶

1.5. Traditional methods for optimization of relaxivity: A discussion of SBM theory

1.5.1. Motives for increasing relaxivity

Relaxivity has long since been established by SBM theory to be magnetic field dependant.⁴²⁻⁴⁵ This dependence can be determined using a field cycling relaxometer developed from the technical concepts of Anderson and Redfield.⁴⁷ The instrument is able to rapidly measure relaxivity as a function of a large range of magnetic field strengths. A plot of such measurements is known as a nuclear magnetic relaxation dispersion (NMRD) profile. The NMRD profile for Dotarem, the original cyclic Gd^{3+} -based CA approved for clinical use, is shown in Figure 1.15 (dashed line). As can be seen the relaxivities are significantly reduced at current clinical imaging fields of 1.41 – 3 T (60 – 128 MHz) and continue to decrease as field strength increases further, a considerable concern given the current trend towards greater magnetic field strengths¹⁴ that afford improved signal to noise.¹⁵

Since inherent tissue T_1 increases with increasing B_0 ,⁴⁸ agent detectability is improved. However, these gains are not fully realized due to the decrease in relaxivity at higher B_0 fields. This results in Gd^{3+} -based CAs having high detection limits, a problem faced by chemists since their introduction into diagnostic radiology in the early 1980s,⁴⁹ and necessitates high doses be administered. High doses cause a significant reduction of the

tissue T_1 and leads to an observable change in image contrast, determined from the change in T_1 in the presence of the agent with respect to the inherent T_1 of the tissue.

Figure 1.15: The nuclear magnetic relaxation dispersion (NMRD) profile of Dotarem (dashed line⁵⁰) plotting laboratory frame relaxivity as a function of B_0 field, the outer-sphere contribution is shown by the dotted line. Also plotted is the NMRD profile of a theoretically “optimized” gadoterate chelate (solid line).

Despite of these significant shortcomings, tissue contrast in MRI is remarkable and spatial resolution unsurpassed. The driving force behind the quest for higher relaxivities comes from the desire to perform molecular imaging which entails selectively targeting CAs to biomarkers of disease pathology that exist in very low concentrations. Assuming 1:1 binding stoichiometry between target and agent it can be calculated that for current agents that have a relaxivity between 4 and 5 $\text{mM}^{-1} \text{ s}^{-1}$, the target molecule must be present at $\sim 125 \text{ } \mu\text{M}$ or greater⁵¹, a value that limits the number of target candidates. Contrast agents with lower detection limits as a result of their high relaxivity will make this more feasible and shows the importance of optimizing agent relaxivities.

1.5.2. SBM parameters for optimizing relaxivity

Researchers have given most attention to optimizing agent relaxivity through modifications to the inner sphere contribution (R_1^{IS}) to the observed longitudinal relaxation rate constant; the outer sphere contributions are fixed by limitations of realistic contrast agent design. From Equation 1.19 it can be seen that a limited number of parameters are available to affect R_1^{IS} . These are; the hydration number of the Gd^{3+} ion, the inner sphere water proton relaxation time constant (T_{1M}) and the lifetime of an inner sphere coordinated water molecule, τ_M .

1.5.3. Hydration state (q)

All clinical Gd^{3+} -based CAs have one metal bound water molecule and therefore are $q = 1$ agents. Opening up additional coordination sites to water by reducing the denticity of the ligand can lead to increases in relaxivity. However, this is often at the expense of increased agent toxicity, a result of decreased selectivity of the ligand for Gd^{3+} versus endogenous metals rather than directly related to stability.⁵² In addition to their decreased stability, agents with reduced ligand denticity are more prone to binding endogenous anions, such as phosphate, that displaces the inner sphere water leading to decreased relaxivities.⁵³ Reports have recently been made of chelates in which $q = 2$.⁵⁴⁻⁵⁵ However, it is unclear that these chelates would be sufficiently stable for human use. Therefore, the hydration state is essentially fixed at one.

1.5.4. Inner sphere water proton relaxation time constant (T_{1M})

To understand the factors that influence the inner sphere water proton relaxation time constant (T_{1M}) further analysis of SBM theory is required. T_{1M} has been found to be highly dependent on the longitudinal (τ_{c1}) and transverse (τ_{c2}) correlation time constants, and on r_{Gd-H}^{-6} , the distance between the metal ion and the coordinated water proton (Equation 1.20). The latter is comparable for all clinical $q = 1$ agents and has historically been considered to be fixed. All other components in Equation 1.20 are constants where; μ_0 is the permeability of free space, $\hbar$ is the reduced Plancks constant equal to $h/2\pi$, γ_H and γ_S are the gyromagnetic ratios of a proton and electron respectively, S is the electron spin quantum number, ω_H and ω_S are the proton and electronic Larmor frequencies respectively.

$$\frac{1}{T_{1M}} = R_{1M} = \frac{2}{15} \left(\frac{\mu_0}{4\pi} \right)^2 \frac{\hbar^2 \gamma_H^2 \gamma_S^2}{r_{GdH}^6} S(S+1) \left[\frac{3\tau_{c1}}{1+\omega_H^2 \tau_{c1}^2} + \frac{7\tau_{c2}}{1+\omega_S^2 \tau_{c2}^2} \right] \quad (1.20)$$

τ_{c1} and τ_{c2} are themselves dependent on the rotational correlation time constant (τ_R), the water residence life time (τ_M) and the longitudinal and transverse electron relaxation time constants (τ_{S1} and τ_{S2} respectively) as shown in Equation 1.21. Control of the later is less well understood and values for a given chelate have to be accepted.

$$\frac{1}{\tau_{ci}} = \frac{1}{\tau_R} + \frac{1}{\tau_M} + \frac{1}{\tau_{Si}} \quad i = 1,2 \quad (1.21)$$

Using these equations and fixing values for c , q , r_{Gd-H} and τ_S , the effect of τ_R and τ_M on relaxivity can be modeled. Such models show τ_R and τ_M values are key parameters for

relaxivity enhancement. A relaxivity plot as a function of these two critical parameters at a fixed field strengths is often published. Figure 1.16 is typical of such plots and demonstrates the effect of τ_R and τ_M for a generic Gd^{3+} chelate at 0.47 T (20 MHz).

Figure 1.16: 3D simulation illustrating the effect of the rotational correlation time (τ_R) and the residence lifetime of the water molecule (τ_M) coordinated to a metal ion for a generic Gd^{3+} chelate at 0.47 T (20 MHz).

1.5.5. Rotational correlation time constant (τ_R)

Bulky agents restrict the ability of the molecule to tumble in space resulting in lengthened τ_R values. This has a favorable outcome in terms of relaxivity gains but their increased size also restricts movement from the vasculature to the interstitial space. τ_R is optimized when the rotational frequency is comparable to the proton larmor frequency at the imaging field strength. Most clinical imaging is performed at 1.41 – 3 T (60 – 128 MHz) therefore the GHz τ_R values for clinically available $q = 1$ low molecular weight agents⁵⁶

are too fast, requiring their rotation to be slowed to become more optimum, such as in the case of Ablavar (Figure 1.12).

Ablavar consists of a stable gadopentate core, with a phosphodiester linkage to a lipophilic albumin binding group. On binding (non-covalently) to human serum albumin (HSA) the effective molecular weight increases substantially and thus τ_R increases resulting in an increase in relaxivity. Several derivatives of this type of CA have been investigated including variants covalently bound to large macro and supramolecular carriers.⁵⁷

1.5.6. Water residence life time (τ_M)

The time a water molecule spends associated with the Gd^{3+} ion is its water residence lifetime (τ_M). The inverse of which describes the exchange kinetics of the inner sphere water molecules. If the water molecule is coordinated for too short a time before being exchanged with a bulk water molecule, and catalyze the PRE effect, then the water proton will not be fully relaxed and optimum relaxivity will take longer to reach. Conversely, if the water molecule remains associated fully relaxed for too long before being transferred to the bulk (as is the case for clinical Gd^{3+} -based CA) then the efficiency of the relaxation is poor and relaxivity is not optimum. Investigations reveal that the optimum value of τ_M for clinical agents is approximately 6 ns at the clinically relevant field strength of 1.41 T (60 MHz)⁵⁸ compared to about 20 – 40 ns at 0.47 T (20 MHz).

1.5.7. Electron relaxation time constants (τ_{S1} and τ_{S2})

Although the effect of electron spin relaxation time constants, τ_{S1} and τ_{S2} , on relaxivity is known⁵⁹⁻⁶⁰ and can be predicted by SBM theory, methods to accurately control their values are less well understood. According to experimental observations, increased rigidity and symmetry within a chelate, such as those based on the cyclic ligand DOTA, gives rise to better electron relaxation than with chelates based on the linear ligand DTPA, particularly for complexes that tumble slowly.^{22, 61} This latter point makes them field dependent parameters as a result of the dependence of τ_{S1} and τ_{S2} on the zero-field splitting (ZFS) and is characterized by the correlation time (τ_v) expressed by the square of the trace of the ZFS tensor, Δ , as shown in Equations 1.22 and 1.23 respectively. All other terms are constants as described previously.

$$\frac{1}{\tau_{S1}}^{ZFS} = \frac{12}{5} \Delta^2 \tau_v \left[\frac{1}{1+\omega_S^2 \tau_v^2} + \frac{4}{1+4\omega_S^2 \tau_v^2} \right] \quad (1.22)$$

$$\frac{1}{\tau_{S2}}^{ZFS} = \frac{12}{10} \Delta^2 \tau_v \left[3 + \frac{5}{1+\omega_S^2 \tau_v^2} + \frac{2}{1+4\omega_S^2 \tau_v^2} \right] \quad (1.23)$$

1.6. Spin locking for recovering lost relaxivity

In spite of the relatively sound understanding of all that has been discussed above, relaxivities of Gd^{3+} -based CAs at clinical imaging fields are significantly lower than predicted by theory (Figure 1.15). Moreover, these values are much reduced from those obtainable at lower fields and continue to decrease as field strength increases. Therefore,

a method to “recover” lost relaxivity from current clinically approved agents at high field strengths that retain SNR advantages could be adopted into clinical practice rapidly and would be of tremendous importance.

1.6.1. Theory of spin locking

The technique was initially investigated as an NMR technique in the 1950's,⁶² but developed for imaging 30 years later⁶³ where it has been used extensively in non-enhancing tissue since.⁶⁴⁻⁶⁹ Spin locking refers to the application of a lower power, longer duration RF pulse (B_1) in the x,y-plane phase shifted from a 90° B_1 excitation pulse such that it is parallel to the net magnetization. The purpose of which is to “lock” the magnetization into lower precessional frequencies around an “effective” field (B_{eff}) that is reduced with respect to B_0 but maintains the high field advantages required for imaging. When considered in the rotating frame of reference, longitudinal relaxation of the magnetization against B_{eff} exhibits time constants ($T_{1\rho}$) representative of those at the lower precessional frequencies induced by the spin locking pulse and this has implications for increasing CA detectability.

1.6.2. Determination of rotating frame longitudinal relaxation time constants ($T_{1\rho}$)

$T_{1\rho}$ values are determined using a spin lock pulse sequence (Figure 1.17). An initial 90° RF excitation pulse along the +x axis ($B_{1(90)x}$) ① converts the net magnetization into the x,y-plane ②. Directly after which, the $B_{1(90)x}$ is turned off and a lower power, long duration 90° spin lock RF pulse phase shifted by 90° ($B_{1(90)y}$) is turned on for a period of

time (τ) known as the locking time (TL) and generates an effective field (B_{eff}). Throughout the duration of the spin lock pulse the net magnetization is locked in the x,y-plane and undergoes longitudinal relaxation in the absence of transverse relaxation. When the spin locking pulse is turned off the signal from transverse magnetization in the x,y-plane is detected ③. A relaxation delay time (RD) allows full relaxation of the magnetization back to equilibrium to occur prior to the next iteration of the pulse sequence ① with a longer locking time (τ).

Figure 1.17: Spin lock pulse timing diagram (top), course and position of the net magnetization (bottom).

$T_{1\rho}$, the longitudinal relaxation time constant in the rotating frame measured as the decay of transverse magnetization, is determined by plotting the signal intensity (S) of the peak maximum in the frequency domain at ③ (Figure 1.18, top) as a function of τ , the spin locking time (Figure 1.18, bottom). As for T_2 , $T_{1\rho}$ is the time required for magnetization

in the x,y-plane to decay to 37% of its original value (1) and is calculated by fitting the acquired data to Equation 1.24 that describes the decay of magnetization from the x,y-plane after a 90° phase shifted SL pulse and $e^{-\frac{\tau}{T_{1\rho}}}$ is the exponential decay function.

$$M_{xy}(\tau) = M_{xy}(0)e^{-\frac{\tau}{T_{1\rho}}} \quad (1.24)$$

Figure 1.18: Summary of $T_{1\rho}$ determination. Spin locking pulse sequence and generation of spectra (top) and the decay of magnetization (M_{xy}) as a function of the variable spin lock duration (τ) (bottom).

1.7. Scope of this work: Determining the effect of a spin locking pulse on relaxivity

The scope of this work is to determine the extent to which a spin locking pulse can “recover” lost relaxivity over a range of relatively high B_0 fields for a range of MRI contrast agents.

1.7.1. Effect of pulse sequence parameters on T_1 and $T_{1\rho}$ time constants

To compare relaxivities across several B_0 field strengths it is essential that relaxation time constants be obtained with parameters that offer the best possible fit of the data in order to generate reliable NMRD profiles. A number of pulse sequence parameters are available that potentially alter the reliability of a fit to observed relaxation data. Therefore, it was prudent to investigate the impact of deliberate variations to several pulse sequence parameters on the fitting of laboratory and rotating frames relaxation data and the subsequent time constants generated.

1.7.2. Effect of spin lock pulse strength (γB_1) on longitudinal relaxation rate constants ($R_{1\rho}$)

Of the few reports relating to the rotating frame relaxation mechanism in the presence of paramagnetic ions, the work by Jordan and co-workers⁷⁰ stands out. In it they describe the effect a hydrated paramagnetic ion would have on $R_{1\rho}$ of bulk solvent nuclei. However, this paper did not investigate the effect of combining spin locking with paramagnetic Gd^{3+} -based CAs. Unique to Gd^{3+} of the lanthanide metal ion series, Gd^{3+}

does not induce a hyperfine shift ($\Delta\omega_m^2$). This invokes a condition identified by the authors that suggests there should be no significant change in $R_{1\rho}$ as a function of the strength of the spin locking pulse (γB_1). A study to investigate this hypothesis is critical in order to generate accurate $r_{1\rho}$ NMRD profiles for Gd^{3+} -based CAs in which reliable comparison of data across several fields and instrument types can be made.

1.7.3. A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame longitudinal relaxivities for $q = 1$ clinical Gd^{3+} -based CAs

The use of a low field spin locking pulse in the presence of a large B_0 field may allow for the generation of relaxivities in the rotating frame for current clinically available Gd^{3+} -based CAs higher than is presently obtainable in the laboratory frame. This has potential implications in any imaging applications that may require the administration of one of several Gd^{3+} -based CAs clinically approved for MRI. Therefore a study to determine the extent of any increase in relaxivity by employing a spin locking pulse is critical to provide greater detail of the potential to improve agent detectability.

1.7.4. Effect of rotational correlation time (τ_R) on rotating frame longitudinal relaxivity ($r_{1\rho}$)

It is also possible from the theory derived by Jordan *et al.* to hypothesize that $r_{1\rho}$ should be more sensitive to the rotational correlation time (τ_R) than r_1 . This is due to the introduction of the laboratory frame transverse relaxation rate constant (R_{2M}) into the

description of $r_{1\rho}$ and its dominance over the laboratory frame longitudinal relaxation rate constant (R_{1M}). Nanoassembled capsules (NACs) prepared by Annah Farashishiko in our group that contain a $q = 0$ chelate (GdDOTP^{5-}) bound to polymer and encapsulated in SiO_2 are a useful model for studying the effect slowly tumbling agents with long τ_R values have on rotating frame relaxivities. A study to investigate the effect of spin locking on the rotating frame relaxivities of NACs was performed and results compared to the laboratory frame relaxivities over a range of B_0 fields.

1.7.5. Effect of hydration number (q) on rotating frame longitudinal relaxivity ($r_{1\rho}$)

It is well established that the laboratory frame longitudinal relaxivity (r_1) of Gd^{3+} -based CAs scales with hydration number (q) at the expense of the thermodynamic stability of the chelate. On opening up an extra coordination site to water, stability reduces by up to as much as three orders of magnitude limiting the choice of agents for practical in vivo use to those with a hydration number of just one.⁷¹ However, for *ex vivo* and post mortem investigations stability of the CA is not a concern. Applications such as these were just the reason we needed, other than for fundamental purposes, to study the effect hydration number has on the rotating frame longitudinal relaxivity ($r_{1\rho}$).

CHAPTER 2. EFFECT OF PULSE SEQUENCE PARAMETERS ON LONGITUDINAL (T_1) AND ROTATING ($T_{1\rho}$) FRAME TIME CONSTANTS

2.1. Establishing pertinent pulse sequence parameters with potential to effect reliability of fit of relaxation data

To compare relaxivities across several B_0 field strengths it is essential that relaxation time constants be obtained with parameters that offer the best possible fit of the data in order to generate reliable NMRD profiles. A number of pulse sequence parameters are available that potentially alter the reliability of a fit to observed relaxation data. Herein, we investigate the effect deliberate variations to pertinent pulse sequence parameters have on the fitting of observed time curve data and the T_1 and $T_{1\rho}$ values generated. For this experiment, a PBS solution of Dotarem with a Gd^{3+} concentration of 25 mM was used and single point ($n = 1$) measurements taken. For each parameter and temperature investigated, the observed variance (standard deviation) in the time constants generated over the range of deliberate variations were compared to the natural variance (standard deviation) for a sample prepared in the same manner. The natural standard deviation was determined from replicate analysis ($n = 20$) on the same sample using a fixed set of parameter values. We limited the investigation to our 60 MHz (1.41 T) fixed low field relaxometer to reflect current clinical imaging field strengths. Measurements were made at historically and physiologically relevant temperatures, 25 and 37 °C respectively. Time constants generated from time curves at 25 and 37 °C are presented and discussed below. For clarity, a discussion of time curve fitting was restrained to time curves

generated at 25 °C, however, comparable fitting and trends were observed for time curves generated at 37 °C and can be found in appendix 1.

The pulse sequence parameters investigated were:

2.1.1. Relaxation delay (RD) time

The relaxation delay (RD) time defines the time between the detection of a signal and the subsequent RF pulse of the next scan or iteration of the pulse sequence and should allow sufficient time for full relaxation of the magnetization back to equilibrium to occur.

2.1.2. Pulse delay (τ) times

The pulse delay time defines the time magnetization is allowed to recover back to thermal equilibrium against B_0 and B_{eff} for T_1 and $T_{1\rho}$ measurements respectively prior to signal being detected. For $T_{1\rho}$ measurements, this occurs in the presence of a spin lock pulse and is called the spin lock time (TL). The pulse delays should allow for a full range of signal intensities to be detected.

2.1.3. Number of data points

The number of data points (or pulse delays) dispersed across the range of pulse delays sampled determines how closely spaced in time the pulse delays are. The number should be appropriate for the type of exponential behavior expected and reduce instrument and operator time.

2.2. Establishment of ideal pulse sequence parameter values

The following table identifies the suggested “ideal” values for the pulse sequence parameters to be investigated obtained from either the user manual⁷² or reported in literature.⁷³

Table 2.1: Suggested “ideal” pulse sequence parameter values for determinations of T_1 and $T_{1\rho}$.

Pulse sequence parameter	Inversion recovery	Spin locking
Relaxation delay time (s)	$= 10 \times T_1$	$= 10 \times T_1$ or minimum allowable $\geq 10 \times T_1$
Pulse delays times (ms)		
First pulse delay	$< 1/10\text{th} \times T_1$	$< 1/10\text{th} \times T_1$
Last pulse delay	$> 5 \times T_1$	$> 5 \times T_1$ or maximum allowed (40 ms)
Number of pulse delays for mono-exponential behavior	16	16

2.3. Other parameters and general considerations

Several other parameters that a user would not typically alter but do affect the reliability of fit of relaxation data if not controlled are discussed below for completeness. These parameters were held constant for all experiments herein with the values stated where applicable.

2.3.1. Sample temperature, volume and position

Relaxation time constants are temperature dependent, therefore, the sample was inserted into the coil of the probe head and equilibrated to the desired temperature for at least five minutes prior to any measurements being made. To maximize the signal-to-noise a sample volume sufficient to fill the RF receiver coil is recommended by the instrument manufacturer. A volume of 0.5 mL was employed. The sample was positioned safely within the built-in sample holder and the minispec operated on a benchtop that minimizes vibrations and reduces pulse angle errors.

2.3.2. Pulse angles

The angle by which the net magnetization is flipped is determined by the power and duration of the pulse. Pulse angles can be calibrated to ensure accurate flip angles are achieved. For these experiments, 90° and 180° pulse angles were achieved with pulse durations of 2.54 and 4.78 μs for 0 decibels attenuation. These values are provided by the minispec software. however, at the time of writing are thought to be wrong.

2.3.3. Offset frequency

The offset resonance frequency should be equal to the resonance (Larmor) frequency of the water protons determined by the spectrometer, *i.e.* on-resonance.

2.3.4. Number of scans

The number of scans for all experiments was 4, 1 scan per phase, the minimum required when the phase cycling option is selected.

2.3.5. Receiver gain, detection mode and fitting equations

Receiver gain was set to the factory installed setting (-66 dB). For T_1 determinations the “Real” detection mode was used. For $T_{1\rho}$ determination the “Magnitude” detection mode was used to allow the full range of signal to be observed. A mono-exponential behavior was expected, therefore, fitting to the relevant exponential equation (Equation 1.12 and 1.24) was satisfactory.

2.4. Determination of natural variance (standard deviation) from replicate analysis

Using the suggested “ideal” pulse sequence parameter values in Table 2.1 replicate ($n = 20$) determinations of T_1 and $T_{1\rho}$ were made on a single sample preparation of Dotarem in PBS pH 7.4 at a Gd^{3+} concentration of 25 mM. The time constants and the natural variance in the data (measured as standard deviation) for each time constant at both 25 and 37 °C are presented (Table 2.2). Figure 2.1 shows more clearly the measurement repeatability of the data. The difference due to temperature is a consequence of Dotarem, a small molecule, being in the fast exchange regime and having a short correlation time (τ_c). In this case, a decrease in temperature results in a decrease in the time constant due to a lengthening of the correlation time and more efficient dipole-dipole interactions.

Figure 2.1: Determination of natural variance in T_1 and $T_{1\rho}$ at 1.41 T (60 MHz) for a single sample preparation of Dotarem in PBS pH 7.4 with a Gd^{3+} concentration of 25 mM. The “ideal” pulse sequence parameters identified in Table 2.1 were used.

It can be seen from the data presented in Figure 2.1 and Table 2.2 that the natural variance in the repeatability data of T_1 and $T_{1\rho}$ at both 25 and 37 °C is very low with standard deviations of 0.10 and 0.067 ms for T_1 measurements at 25 and 37 °C respectively and 0.042 and 0.047 ms for $T_{1\rho}$ measurements at 25 and 37 °C respectively.

The standard deviations for time constants obtained by changing pulse sequence parameter values shall be determined and compared to the standard deviations reported above, where the above represents the natural variance from replicate analysis. If the standard deviation for a series of time constants is greater than the standard deviation due to natural variation in the data then the variation in the time constant values will be considered significant and a result of the change to the parameter value. From this it will be possible to make recommendations to ensure reliable time constants.

Table 2.2: Determination of natural variance in T_1 and $T_{1\rho}$ at 1.41 T (60 MHz) for a single sample preparation of Dotarem in PBS pH 7.4 with a Gd^{3+} concentration of 25 mM. The “ideal” pulse sequence parameters identified in Table 2.1 were used. SD is the standard deviation.

Repetition #	T_1 (ms)		$T_{1\rho}$ (ms)	
	25 °C	37 °C	25 °C	37 °C
1	9.67	12.2	8.10	10.4
2	9.65	12.2	8.12	10.5
3	9.71	12.0	8.15	10.5
4	9.72	12.1	8.15	10.4
5	9.7	12.1	8.16	10.5
6	9.7	12.2	8.16	10.4
7	9.82	12.1	8.2	10.5
8	9.8	12.2	8.2	10.4
9	9.75	12.0	8.2	10.5
10	9.7	12.1	8.2	10.4
11	9.82	12.1	8.2	10.5
12	9.8	12.0	8.2	10.4
13	9.9	12.2	8.3	10.4
14	9.87	12.2	8.20	10.4
15	9.9	12.1	8.24	10.4
16	9.9	12.1	8.24	10.4
17	9.9	12.1	8.20	10.4
18	10.0	12.1	8.20	10.4
19	9.9	12.1	8.20	10.4
20	9.90	12.1	8.20	10.4
<i>Natural variance (SD)</i>	0.10	0.067	0.042	0.047

2.5. Effect of pulse sequence parameters on the reliability of fit of relaxation data

2.5.1. Relaxation delay (RD) time

With the inversion recovery pulse sequence it was noticed that with a relaxation delay time $< 10 \times T_1$ the measured signal for short pulse delay times (τ) are offset by $\sim 20\%$ (Figure 2.2, squares) compared to when the relaxation delay is $= 10 \times T_1$ (diamonds), $> 10 \times T_1$ (triangles) or $\gg 10 \times T_1$ (crosses). This demonstrates that a relaxation delay time that is too short does not allow full relaxation back to equilibrium thus reducing the signal of the subsequent scan.

Figure 2.2: Effect of deliberate variations to the relaxation delay (RD) time on T_1 time curves (inset shows deviation (squares) when relaxation delay is $< 10 \times T_1$). Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25$ mM. $n = 1$.

With the spin locking pulse sequence almost identical time curves were generated (Figure 2.3) for all four RD times studied. This is due to the RD times employed all being $\gg 10 \times T_1$ due to a 4 s minimum imposed by the instrument to preserve hardware during the use of long pulse delays required to observe full signal decay.

Figure 2.3: Effect of deliberate variations to the relaxation delay (RD) time on $T_{1\rho}$ time curves.

Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25 \text{ mM}$. $n = 1$.

The measured standard deviation for time constants generated here ($n = 1$) from mono-exponential fitting of the time curves are 0.015 and 0.00 ms for T_1 measurements at 25 and 37 °C respectively and 0.031 and 0.050 ms for $T_{1\rho}$ measurements at 25 and 37 °C respectively (Table 2.3). All standard deviations are approximately equal or less than the natural variance (standard deviation) of the data. It can therefore be said that there was no significant effect on time constants by varying the relaxation delay time.

Table 2.3: Effect of deliberate variations to the relaxation delay (RD) time on T_1 and $T_{1\rho}$ values at 1.41 T (60 MHz). Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25 \text{ mM}$. ($n = 1$).

	T_1 (ms)			$T_{1\rho}$ (ms)	
RD time (s)	25 °C	37 °C	RD time (s)	25 °C	37 °C
0.01 ($<10 \times T_1$)	9.35	11.4	4 ($>>10 \times T_1$)	8.05	10.4
0.1 ($=10 \times T_1$)	9.32	11.4	8 ($>>10 \times T_1$)	8.09	10.3
1 ($>10 \times T_1$)	9.32	11.4	12 ($>>10 \times T_1$)	8.11	10.3
4 ($>>10 \times T_1$)	9.32	11.4	16 ($>>10 \times T_1$)	8.12	10.3
RD variance (SD)	0.015	0.00		0.031	0.050
Natural variance (SD)	0.10	0.067		0.042	0.047

2.5.2. Pulse delay (τ) times

By increasing the duration of the first pulse delay time (Figure 2.4) in the inversion recovery and spin lock pulse sequences a smaller proportion of the relaxation time curve is observed. This is due to relaxation occurring at a rate relatively fast compared to the timing of the first pulse delay time. With a first pulse delay time of 0.01 ms ($<< 1/10^{\text{th}} \times T_1$) and 0.2 ms ($< 1/10^{\text{th}} \times T_1$) for the determination of $T_{1\rho}$ the measured signal for short pulse delay times (τ) are scattered (Figure 2.4d and 2.4e). This is the result of small coherences that remain in the transverse plane that are unable to relax during very short delay times resulting in errors of the time constant estimation. On increasing the duration of the first pulse delay time to 1 ms ($= 1/10^{\text{th}} \times T_1$) and 2 ms ($> 1/10^{\text{th}} \times T_1$) this scatter is avoided at the cost of at most $\sim 10\%$ of the time curve (Figure 2.4f and 2.4g).

Figure 2.4: Effect of deliberate variations to the first pulse delay time (τ) on T_1 (a – c) and $T_{1\rho}$ (d – g) time curves. Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25 \text{ mM}$. $n = 1$.

Similarly, by decreasing the duration of the last pulse delay time (Figure 2.5) in the inversion recovery and spin lock pulse sequences a smaller proportion of the relaxation

time curve is observed. This is due to not employing sufficiently long pulse delay times to observe the full return of signal to equilibrium.

Figure 2.5: Effect of deliberate variations to the last pulse delay time (τ) on T_1 (a – c) and $T_{1\rho}$ (d – e) time curves. Sample: PBS pH 7.4 solution of Dotarem, $[Gd^{3+}] = 25$ mM. $n = 1$.

The measured standard deviation for time constants generated here ($n = 1$) from mono-exponential fitting of the time curves for first pulse delay times are 0.082 and 0.16 ms for T_1 measurements at 25 and 37 °C respectively and 0.13 and 0.32 ms for $T_{1\rho}$ measurements at 25 and 37 °C respectively. For last pulse delay times the range

differences are 0.21 and 0.53 ms for T_1 measurements at 25 and 37 °C respectively and 0.27 and 0.16 ms for $T_{1\rho}$ measurements at 25 and 37 °C, respectively (Table 2.4).

All standard deviations are larger than the natural variance (standard deviation) in the data with the exception of T_1 values at 25 °C when varying the duration of the first pulse delay time. It can therefore be said that, generally, there was a significant effect on time constants by varying the relaxation delay time.

2.5.3. Number of data points

An increased number of data points decreases the time between sampling of the magnetization and allows for more data points around the inflection of the time curve (Figure 2.6).

The measured standard deviation for time constants generated here ($n = 1$) from mono-exponential fitting of the time curves are 0.047 and 0.00 ms for T_1 measurements at 25 and 37 °C respectively and 0.026 and 0.024 ms for $T_{1\rho}$ measurements at 25 and 37 °C respectively (Table 2.5). All standard deviations are less than the natural variance (standard deviation) in the data. It can therefore be said that there was no significant effect on time constants by varying the number of data points.

2.6. Recommendations

Often the expected T_1 or $T_{1\rho}$ is unknown and pulse sequence parameters have to be chosen based on a best estimate of the time constants and subsequently refined. The

following recommendations provide a starting point for initial experiments and should allow for reliable time constants to be generated. These are summarized in Table 2.6.

Table 2.4: Effect of deliberate variations to the first and last pulse delay (τ) times on T_1 and $T_{1\rho}$ values at 1.41 T (60 MHz). Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25 \text{ mM}$. ($n = 1$).

	T_1 (ms)			$T_{1\rho}$ (ms)	
First delay time (τ) (ms)	25 °C	37 °C	First delay time (τ) (ms)	25 °C	37 °C
0.2 ($<1/10^{\text{th}} \times T_1$)	9.81	11.1	0.01 ($<<1/10^{\text{th}} \times T_1$)	7.90	9.20
1 ($=1/10^{\text{th}} \times T_1$)	9.78	11.2	0.2 ($<1/10^{\text{th}} \times T_1$)	8.20	9.70
10 ($>1/10^{\text{th}} \times T_1$)	9.67	10.9	1 ($=1/10^{\text{th}} \times T_1$)	8.07	9.83
-	-	-	2 ($>1/10^{\text{th}} \times T_1$)	8.00	9.91
First delay variance (SD)	0.082	0.16		0.13	0.32
Natural variance (SD)	0.10	0.067		0.042	0.047

	T_1 (ms)			$T_{1\rho}$ (ms)	
Last delay time (τ) (ms)	25 °C	37 °C	Last delay time (τ) (ms)	25 °C	37 °C
10 ($<5 \times T_1$)	9.70	10.0	21 ($<5 \times T_1$)	8.28	10.3
30 ($\cong 5 \times T_1$)	9.46	10.8	40 ($\cong 5 \times T_1$)	7.90	10.1
100 ($>5 \times T_1$)	9.28	11.0	-	-	-
Last delay variance (SD)	0.21	0.53		0.27	0.16
Natural variance (SD)	0.10	0.067		0.042	0.047

Table 2.5: Effect of deliberate variations to the number of data points on T_1 and $T_{1\rho}$ values at 1.41 T (60 MHz). Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25 \text{ mM}$. ($n = 1$).

# data points	T_1 (ms)		$T_{1\rho}$ (ms)	
	25 °C	37 °C	25 °C	37 °C
8	9.80	11.4	8.10	9.80
16	9.75	11.4	8.10	9.85
32	9.69	11.4	8.15	9.80
64	9.77	11.4	8.14	9.81
# data point (SD)	0.047	0.00	0.026	0.024
Natural variance (SD)	0.10	0.067	0.042	0.047

2.6.1. Relaxation delay (RD) times

It has been demonstrated that time constants were not affected significantly (standard deviation was less than the standard deviation due to natural variation in the data) by the relaxation delay times examined including those less than the suggested ideal value of $10 \times T_1$ where the magnetization range covered becomes narrower. However, a relaxation delay time of $10 \times T_1$ is more conventional to ensure full relaxation before subsequent scans and is therefore recommended. It should be noted that when using the spin locking pulse sequence long pulse delay times are sometimes necessary to observe the full relaxation time curve. This necessitates long relaxation delay times which are automatically imposed by the instrument and are typically much greater than $10 \times T_1$. In these cases, the minimum allowable relaxation delay time should be used to avoid excessively long experiment times.

Figure 2.6: Effect of deliberate variations to the number of data points on T_1 (a – d) and $T_{1\rho}$ (e – h) time curves. Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25$ mM. $n = 1$.

Table 2.6: Recommended pulse sequence parameter values for determinations of T_1 and $T_{1\rho}$.

Pulse sequence parameter	Inversion recovery	Spin locking
Relaxation delay time (s)	$= 10 \times T_1$	$= 10 \times T_1$ or minimum allowable $\geq 10 \times T_1$
Time delays		
First pulse (ms)	$< 1/10^{\text{th}} \times T_1$	$> 1/10^{\text{th}} \times T_1$
Last pulse (ms)	$> 5 \times T_1$	$> 5 \times T_1$ or maximum allowed (40 ms)
Number of pulse delays for mono-exponential behavior	16	16

2.6.2. Pulse delay times

These results demonstrate that significant variation in time constant values (standard deviation greater than the standard deviation due to natural variation in the data) were observed when different proportions of the relaxation time curve are measured by varying the first and last pulse delay times. Additionally, scatter of data points is possible with pulse delay times that are too short. First and last pulse delay times are sample specific parameters and therefore exact values are not recommended. However, it is recommended that time constants be generated by measuring as much of the time curve as possible that allows scatter to be avoided. Therefore, first and last pulse delay times of $< 1/10^{\text{th}} \times T_1$ and $> 5 \times T_1$ respectively are recommended when determining T_1 values with the inversion recovery pulse sequence and $> 1/10^{\text{th}} \times T_1$ and $> 5 \times T_1$ respectively when determining $T_{1\rho}$ values with the spin lock pulse sequence. It should be noted that a

last pulse delay $> 5 \times T_1$ is not always possible due to instrument limitations to prevent hardware failure. In this case the maximum allowable should be employed. Reliable time constants may be generated with longer first pulse and shorter last pulse delay times, however, the recommended values allow for as much of the time curve as possible to be measured.

2.6.3. Number of data points

It has been demonstrated that time constants were not affected significantly (standard deviation was less than the standard deviation due to natural variation in the data) by the number of data points ranging from between 8 – 64. However, the recommended number is 16 as this provides more data around the inflection of the time curve whilst keeping instrument and operator time to a minimum.

2.7. Conclusions

When deliberate variations were made to the suggested “ideal” pulse sequence parameter values for the three parameters investigated good fittings were generally still observed and time constants within did not vary by more than the natural variation in the data. The exception was when an insufficient proportion of the time curve was measured by varying the first and last pulse delay times. This suggests that this parameter is most critical for obtaining reliable time constants, more so than the number of data points along the time curve and the relaxation delay time employed. By investigating the effect the parameter values have on time constants the values in Table 2.6 are recommended.

These should provide accurate time constants that do not vary by more than the natural variation in the data and ensure confidence in NMRD profiles generated from them.

CHAPTER 3. EFFECT OF SPIN LOCK FIELD STRENGTH (γB_1) ON THE ROTATING FRAME LONGITUDINAL RELAXATION RATE CONSTANT ($R_{1\rho}$)

3.1. Establishing the γB_1 independency of $R_{1\rho}$

Jordan and co-workers⁷⁰ wrote a comprehensive paper describing the effect of a hydrated paramagnetic ion, undergoing solvent exchange, would have on the rotating frame longitudinal relaxation rate constant ($R_{1\rho}$) of bulk solvent nuclei (Equation 3.1), in which R_{2W} is the laboratory frame transverse relaxation rate constant of the solvent water; q the number of water molecules bound to the paramagnetic ion; $[M]$ the concentration of the metal ion, τ_M the average water residence lifetime of a coordinated water molecule; R_{1M} and R_{2M} are the laboratory frame longitudinal and transverse relaxation rate constants of the coordinated water, respectively; $\Delta\omega_M$ is the difference in Larmor frequency between coordinated and solvent water protons; and ω_1 is the Rabi frequency of the spin lock pulse). The magnitude of the spin lock field (B_1) is given by Equation 3.2.

$$R_{1\rho} = R_{2W} + \frac{q[M]}{55.6} \times \frac{1}{\tau_M} \left(\frac{R_{2M}}{R_{2M} + 1/\tau_M} \right) \left\{ \frac{(R_{1M} + 1/\tau_M) \left(R_{2M} + 1/\tau_M + \frac{\Delta\omega_M^2}{R_{2M}} \right) + \omega_1^2}{(R_{1M} + 1/\tau_M) \left(R_{2M} + 1/\tau_M + \frac{\Delta\omega_M^2}{R_{2M} + 1/\tau_M} \right) + \omega_1^2} \right\} \quad (3.1)$$

$$\omega_1 = -\gamma B_1 \quad (3.2)$$

Due to the isotropic f shell electronic configuration of the Gd^{3+} ion it does not induce a hyperfine shift. This means that $\Delta\omega_M^2$ will be close to zero, at the same time the high

paramagnetism of Gd^{3+} means that R_{2M} will be very large. This invokes the following condition identified by Jordan and co-workers.

$$R_{2M} \gg \Delta\omega_M^2 \quad (3.3)$$

In the presence of Gd^{3+} ions this condition is met and Equation 3.1 simplifies to;

$$R_{1\rho} = R_{2W} + \frac{q[Gd]}{55.6} \left(\frac{R_{2M} \times 1/\tau_M}{R_{1M} + 1/\tau_M} \right) \quad (3.4)$$

If Equation 3.4 is correct then there should be no dependence of $R_{1\rho}$ on the spin lock field strength characterized in the above equations by the Rabi frequency (ω_1).

Expressed as rotating frame longitudinal relaxivity (r_{1r}), Equation 3.4 becomes Equation 3.5.

$$r_{1\rho} = \frac{q}{55.6} \left(\frac{R_{2M} \times 1/\tau_M}{R_{1M} + 1/\tau_M} \right) \quad (3.5)$$

To verify this theory, at low field (0.47 and 1.41 T, 20 and 60 MHz respectively) the rotating frame relaxation time constants were measured and plotted as the rate constant against the spin lock field strength (γB_1) for 100 mM solutions of ProHance (cyclic) and Magnevist (linear) in PBS at 25 and 37 °C. Due to longer SL pulses that can be played out by more powerful superconducting instruments, high field experiments (14.1 T, 600 MHz) were performed with a less concentrated (5 mM) solution of Dotarem (cyclic) in PBS at 25 °C.

3.2. Modulation of the strength of the spin lock field (γB_1)

The flip angle (θ) of a RF pulse, in this case the spin lock pulse, is proportional to its strength (γB_1) and duration (τ) as shown in Equation 3.6.

$$\theta = \gamma B_1 \tau \quad (3.6)$$

To achieve a pulse angle of 90° the Bruker minispec instrument requires a pulse of duration $2.26 \mu s$. From Equation 3.6 the strength of this pulse, expressed as frequency with units of kHz, can be determined as follows;

$$\frac{\pi}{2} \times \frac{1}{2\pi} = \frac{\gamma B_1}{2\pi} \times 2.26 (\mu s)$$

$$\text{Given that } \frac{\gamma B_1}{2\pi} = \nu_1 (\text{Hz})$$

$$\therefore \frac{1000}{4} = \nu_1 (\text{kHz}) \times 2.26 (\mu s)$$

$$\frac{250}{2.26 (\mu s)} = \nu_1 (\text{kHz}) = 110.6 \text{ kHz}$$

Although correctly calculated, this strength, 110.6 kHz, seems high. This value represents a large pulse power for the modest minispec instrument to generate. It is worth noting that the much more robust 600 MHz spectrometer is set up to prevent the use of pulse powers in excess of 35 kHz. A resolution with the minispec manufacturer is ongoing at the time of writing and for the present purposes this value shall be used.

The strength of the spin lock field was modulated by attenuating its power. Measured in decibels (-dB), power attenuation describes the relationship between two power quantity values where as shown in Equation 3.7 where; P_{in} is input power, P_{out} is attenuated power and the factor of 10 accounts for a dB being $1/10^{\text{th}}$ of a bel.

$$\text{Attenuation } (-dB) = 10 \log_{10} \left(\frac{P_{out}}{P_{in}} \right) \quad (3.7)$$

However, a modified attenuation equation must be used for field quantities, such as field strength, since the field is generated by current whose square is proportional to power as shown;

$$\begin{aligned} P &= V \times I \\ \text{from Ohm's law; } V &= I \times R \\ P &= (I \times R) \times I = I^2 \times R \\ P &\propto I^2 \end{aligned} \quad (3.8)$$

By substituting the power ratio for a field quantity such as γB_1 , the modified attenuation equation can be derived;

$$\begin{aligned} \text{Attenuation } (-dB) &= 10 \log_{10} \left(\frac{(\gamma B_1^{out})^2}{(\gamma B_1^{in})^2} \right) \\ \text{Attenuation } (-dB) &= 10 \log_{10} \left(\frac{\gamma B_1^{out}}{\gamma B_1^{in}} \right)^2 \\ \text{Attenuation } (-dB) &= 20 \log_{10} \left(\frac{\gamma B_1^{out}}{\gamma B_1^{in}} \right) \end{aligned} \quad (3.9)$$

Unless otherwise stated for our experiments we attenuated the power in 1 dB increments between -40 – -6 dB, the maximum attenuation permitted by the low fixed field relaxometer instruments. The Rabi frequencies that characterize the strength of the spin lock field over this attenuation range correspond to 1.1 – 55.4 kHz.

3.3. Effect of γB_1 on $R_{1\rho}$ at low B_0 field strengths

All profiles show the same basic features regardless of temperature, field or chelate structure. From Figure 3.1 it can clearly be seen for ProHance at 0.47 T (20 MHz), which represents agents based on the cyclic ligand DOTA, that when the strength of the spin lock field is < 10 kHz the mean $R_{1\rho}$ values are scattered and the standard deviations of the six measurements are large (Figure 3.1a). As the strength of the spin lock field increases ($\gamma B_1 > 10$ kHz) the mean $R_{1\rho}$ values are more reproducible with lower standard deviations and essentially independent of γB_1 . From the same plot, it is also apparent that by increasing the temperature from 25 °C (open circles) to 37 °C (closed circles) the rotating frame relaxation rates decrease slightly, a consequence of ProHance, like all other clinical agents studied herein, being in the fast exchange regime. An increase in temperature is expected to result in an increase in $T_{1\rho}$, as for T_1 , due to a shortening of the correlation time (τ_c) and less efficient dipole-dipole interactions. On moving to 1.41 T (60 MHz) comparable observations were made (Figure 3.1b). As was the case for Magnevist, an agent based on the linear ligand DTPA (Figure 3.1c and d at 0.47 and 1.41 T respectively).

Figure 3.1: The dependence of the water proton rotating frame longitudinal relaxation rate constant ($R_{1\rho}$) on the strength of the spin lock field (γB_1) for a single PBS pH 7.4 solution of each contrast agent with a $[Gd^{3+}]$ of 100 mM at 25 °C (open symbols) and 37 °C (closed symbols). ProHance, 0.47 T (a), 1.41 T (b). Magnevist, 0.47 T (c), 1.41 T (d). Data shown are the mean of six measurements; the error bars represent the SD of the data. Note: γB_1 values calculated from a 90° pulse duration reported from the minispec instrument. These values are surprisingly large and suggest the the pulse duration reported is incorrect.

It follows from these experiments that in order to generate accurate and precise $R_{1\rho}$ data, useful for creating NMRD profiles, effective spin locking must occur, rendering $R_{1\rho}$ independent of γB_1 . From this data this appears to occur with a minimum spin locking field strength (γB_1) of ~ 10 kHz, however, this value is unrealistic and we demonstrate in the next section that it is possible to spin lock with a pulse of a few hundred Hz.

A limitation of the experimental design was a lack of randomization. For each agent, temperature and B_0 field strength the time constants were measured sequentially, starting at high powers and working towards lower powers. Moreover, the software measures signal intensity as a function of increasing pulse delay times rather than sampling the pulse delay times randomly. Randomization to reduce bias from other experimental factors would add a higher degree of validity to the claims here that the rotating frame longitudinal relaxation rate constant is independent of the strength of the spin lock pulse. The raw time curve data is not routinely saved by the low field minispec instrument software used for these experiments and therefore could not be shown. As a result, it was not available for offline processing. This could have provided a means to rule out any biexponential or multiexponential behavior as a source of contribution to the observed independence of $R_{1\rho}$ on γB_1 .

3.4. Effect of γB_1 on $R_{1\rho}$ at high B_0 field strengths

Our high field (14.1 T, 600 MHz) γB_1 dependency plot (Figure 3.2) shows similar facets to those observed at low B_0 fields (Figure 3.1). Namely, the rotating frame longitudinal relaxation rate ($R_{1\rho}$) of a 5 mM solution of Dotarem (cyclic-type agent) studied shows greater scatter at low spin lock field strengths. This again is reduced, as is the error associated with the data, as the strength of the spin lock pulse is increased. It is, however, noteworthy to point out some differences from the equivalent low field experiments. The strength of the spin lock pulse required to effectively lock the spins at high B_0 field is far less, and much more realistic, than those determined from our low

field experiments, with $R_{1\rho}$ values stabilizing at about 500 Hz. Additionally, the $R_{1\rho}$ values, and their associated errors, are significantly reduced at 14.1 T (600 MHz). Lastly, as a result of the increased precision and reduced errors in our high field data a notable trend was observed in the high field data. From the point the $R_{1\rho}$ data becomes stable to the end of the range of field strengths studied ($\sim 500 - 20000$ Hz) the $R_{1\rho}$ values decrease by approximately 5%. Although this is not an expected trend we believe the observation is not due to any limitation in the theory and offer two possible explanations for which both may contribute to this observation. Firstly, with the relatively long spin lock pulses (relative to those required at low field with higher Gd^{3+} concentrations) required to observe full signal decay and the incremental decrease in attenuation, buildup of heat from many successive experiments could be responsible for the observation. In unrelated experiments (not reported) significant increases in sample temperature were observed when long spin lock pulses were being employed. Secondly, at high B_0 field strengths the reduction of the effective field by the application of a spin lock pulse may be limiting. As a result, as the spin lock field strength increases the Rabi frequency may approach the Larmor frequencies in which dispersion of R_1 occurs due to R_{1M} and R_{2M} dependencies giving rise to the observed decreases in $r_{1\rho}$.

The reduced spin lock field strength required to effectively lock the spins at high B_0 fields compared to low B_0 fields as a consequence of two factors. First, the magnetic field homogeneity of the low field instruments is less than that of the high field superconducting spectrometers used in this study since the low field instruments are

absent of shim stacks capable of tuning the field homogeneity. Accordingly, the line width of the water proton resonance will be greater at low B_0 field strength. Secondly, due to other limitations of the low field instruments the length of the maximum spin lock pulse duration capable of being employed is substantially shorter than that achievable with the high field instruments. As a result, higher agent concentration was necessary and this also contributes to the increased line width of the signal.

Figure 3.2: The dependence of the water proton rotating frame longitudinal relaxation rate constant (R_{1p}) on the spin lock field strength (γB_1) for a single PBS pH 7.4 solution of Dotarem with a $[Gd^{3+}]$ of 5 mM at 14.1 T (600 MHz) and 25 °C. Data shown are the mean of six measurements; the error bars represent the SD of the data.

As for our low B_0 field strength study, our high B_0 field strength study was conducted by measuring rotating frame relaxation time constants and plotting the rate constant as a

function of the spin lock field strength (γB_1). However, unlike the low field instruments, the high resolution instrument allows for a Fourier transformed spectrum to be obtained as described in section 1.6.2. Figure 3.3 shows raw data, sampled from the sixth repetition of the analysis of the Dotarem sample, for a select number of spin lock field strength values (γB_1) used to generate Figure 3.2. The frequency domain spectrum shown for each γB_1 , corresponds to the FID produced from the acquisition of the pulse sequence with the shortest time delay in the experiment. The complete time curve is shown as the overlay along with the respective time and rate constant. This figure demonstrates that the time curves, generated from the decay of the signal intensity of the spectrum with subsequent delay times, allow for full decay of the signal to be observed and that the observed data is well fitted by Equation 1.24 thus providing reliability of the data in Figure 3.2.

3.5. *A comparison between spin locking and CPMG with short pulse delay times*

The CPMG pulse sequence for determining laboratory frame transverse relaxation time constants (T_2) can be likened to a spin lock pulse sequence if the variable pulse delay (τ), the delay time between the 180° pulses of the echo train, is very short. In such a situation the 180° refocusing pulses can be considered to be permanently on. The difference, however, being that the 180° refocusing pulse of the CPMG sequence is a ‘hard’ pulse (high power and short duration) that undergoes many phase changes whereas the spin lock pulse is ‘soft’ (low power long duration) and does not change phase whilst employed.

Figure 3.3: Sample raw data for the $n=6$ determination of $R_{1\rho}$ for several pulse strengths used to prepare Figure 3.2. Spectra were obtained from the FT of the FID from the acquisition with shortest time delay (τ). Time ($T_{1\rho}$) and rate ($R_{1\rho}$) constants are also shown.

Given their similarity it was important to compare time constants generated from relaxation data obtained from both pulse sequences. The same PBS solution of Dotarem prepared at a Gd^{3+} concentration of 25 mM used for the experiments described in Chapter 2 was used. We limited investigations to our 20 MHz (0.47 T) fixed low field relaxometer and measurements were only made at the historically relevant temperature of 25 °C. For this experiment we measured T_2 with a series of different pulse delay times keeping the total experiment time constant by varying the number of data points. It was only possible to investigate a limited range of τ values for the CPMG pulse sequence, due to a minimum limit of 40 ms. The time constants were plotted as a function of the variable pulse delay time (τ) and compared to the rotating frame longitudinal relaxation time constant for the same sample (Figure 3.4). Pulse powers for all measurements were set to 6 dB for continuity.

We have demonstrated (Figure 3.4) that over the range of pulse delay times investigated T_2 did not tend to $T_{1\rho}$ as τ varied. In fact, there was no significant change in the T_2 value at all. The standard deviation of mean T_2 values (0.05 ms) was less than the natural variation of the data for the similar time constant, $T_{1\rho}$, at 25 °C on the same instrument determined in chapter 2 (Table 3.1). This suggests that a CPMG pulse sequence with short pulse delay times is not equivalent to a spin locking pulse sequence, a likely consequence of the CPMG pulse sequence employing 180 refocusing pulse with alternating phase which does not result in spin locking.

Figure 3.4: The dependence of the laboratory frame transverse relaxation time constant (T_2) on the variable pulse delay time (τ) for a single PBS pH 7.4 solution of Dotarem with a $[\text{Gd}^{3+}]$ of 25 mM at 0.47 T (20 MHz) and 25 °C. The filled circle is the respective rotating frame longitudinal relaxation time constant ($T_{1\rho}$). Data shown are the mean of three measurements. Error bars representing the SD of the data were omitted for clarity but all were smaller than the markers. The line through the T_2 data is to guide the eye only.

Table 3.1: Effect of the pulse delay time (τ) on mean T_2 values ($n = 3$) at 0.47 T (20 MHz).

	T_2 (ms)
Pulse delay time (μs)	25 °C
40	7.26
70	7.24
100	7.26
150	7.28
200	7.27
500	7.23
Pulse delay time SD	0.018
Natural variance SD ($T_{1\rho}$)	0.042

3.6. Conclusions

The rotating frame relaxivity of Gd^{3+} -based CAs have been shown to be essentially independent of the magnitude of the B_1 field used to effect spin locking. This is consistent with previously reported theory as predicted by Jordan and co-workers.⁷⁰ This result is important because it allows the value of γB_1 to be neglected when comparing rotating frame relaxivities of Gd^{3+} -based CAs across several B_0 fields. Moreover it seems that a CPMG pulse sequence with short variable pulse delay times and a spin locking pulse sequences do not measure the same relaxation mechanism.

CHAPTER 4. A COMPARISON OF LABORATORY (r_1) AND ROTATING ($r_{1\rho}$) FRAME LONGITUDINAL RELAXIVITIES FOR $q = 1$ CLINICAL Gd^{3+} -BASED CAs

4.1. Establishing the potential benefits of spin locking on relaxivity

Although well described by theory, the laboratory frame relaxivities of clinical Gd^{3+} -based CAs are low, typically $4 - 5 \text{ mM}^{-1}\text{s}^{-1}$ (Figure 1.15). The low relaxivities arise from the rapid molecular tumbling of these low molecular weight chelates (short τ_R) and practical restrictions on their hydration number (q). These low relaxivities result in high detection limits for these agents, necessitating high doses. Agents with bulky substituents have longer τ_R values, a result of slower tumbling, which increases relaxivity. However, relaxivity often continues to be limited by water exchange parameters and relaxivity invariably falls short of the theoretically calculated maximum. Slowly tumbling chelates with more rapid water exchange rates ($1/\tau_M$) afford the highest relaxivities, at current clinical imaging fields. However, clinical imaging is being performed at increasingly higher magnetic field strengths and the optimal τ_M value for r_1 relaxivity is found to decrease as B_0 increases.³⁰ Furthermore, we have recently shown that the relationship between water exchange, molecular tumbling and relaxivity in Gd^{3+} chelates is more complex than previously appreciated,⁷⁴ as a result the theoretical relaxivity potential may be somewhat lower than previously thought. Improvements in detectability could also be made by increasing the hydration number (q) of the complex. Through opening up additional coordination sites to water relaxivity increases, however, this is at the cost of

reduced chelate stability. Even if a new “gold standard” agent were to be designed that could afford high relaxivities at high fields a lengthy and costly approvals process would ensue.

It has been conceived elsewhere⁷⁵⁻⁸⁰ that more significant gains in agent detectability may be possible by imaging at lower effective B_0 fields where relaxivity is likely to be greater. One method to produce such an image is to generate contrast based on the rotating frame longitudinal relaxation time constant ($T_{1\rho}$). $T_{1\rho}$ contrast is generated by employing a weak spin locking pulse parallel to the net magnetization in the x,y-plane and measuring the decay of transverse magnetization in the rotating frame of reference as a function of the spin locking time. Time constants generated in this manner are expected to be characteristic of those measured at low fields. If proven successful this technique would have the added benefit of a relatively quick adoption in to clinical practice. Moreover, if performed in the presence of a large external static B_0 field this would allow the s/n advantages of these fields to be maintained.⁸¹

At the time of writing very few reports pertaining to this hypothesis exist.⁸²⁻⁸⁵ With the exception of one publication investigating spin locking with Ablavar,⁸² the focus has solely been on Magnevist and the study of imaging metrics such as contrast and contrast to noise ratio (CNR)⁸³⁻⁸⁵ rather than the specific effect on relaxivity, a key indicator of CA effectiveness and determinant of agent detectability.

Accordingly, we set out to conduct a thorough investigation into the effect of spin locking on the relaxivity of seven $q = 1$ clinical Gd^{3+} -based CAs by generating and

comparing, under identical conditions, r_1 and $r_{1\rho}$ relaxivities as a function of B_0 in the form of NMRD profiles. Due to structural similarities of OptiMARK and Eovist/Primovist to Ominscan and MultiHance respectively, these agents were not studied. NMRD profiles for the seven agents were grouped according to the three structural categories identified in Table 1.1; linear, macrocyclic and bulky. Samples of the agents were prepared in phosphate buffered saline pH 7.4 and relaxivities determined over a range of B_0 field strengths, 0.47 – 14.1 T (20 – 600 MHz respectively), at both 25 and 37 °C.

4.2. Comparison of r_1 and $r_{1\rho}$ for linear and macrocyclic $q = 1$ clinical Gd^{3+} -based CAs

With the exception of Gadavist, whose relaxivities are slightly elevated over the others, there is little observable difference between the NMRD profiles generated for linear and macrocyclic agents other than the specific relaxivities measured (Figure 4.1). This demonstrates that there is little effect on both r_1 and $r_{1\rho}$ at these fields as a result of the known differences in electron spin relaxation (T_{1e}/T_{2e}) for both macrocyclic and linear chelates.⁸⁶ However, for all chelates of these two classes, $r_{1\rho}$ values are higher than r_1 values across their entire NMRD profile and both decrease as B_0 increases. It is also noticed that $r_{1\rho}$ falls off slightly less rapidly than r_1 does. This shows that by spin locking it is possible to “recover” relaxivity lost by moving to higher fields for these agents. However, the gains are fairly modest showing an increase in relaxivity by a factor of just 1.22 at 0.47 T on average, rising to 1.33 at 14.1 T on average (Table 4.1 – 4.4).

Figure 4.1: NMRD profiles of the linear and macrocyclic clinical contrast agents studied herein at 25 °C (A & C) and 37 °C (B & D) in PBS: laboratory frame data (r_1) are presented in red (closed symbols); and rotating frame data (r_{1p}) are presented in blue (open symbols); $\omega_1 = 35$ kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). A & B: macrocyclic agents: Dotarem (squares); ProHance (diamonds); Gadovist (circles). C & D: linear agents: Magnevist (diamonds); Omniscan (circles). Lines through the data are to guide the eye. Data shown are the mean of six measurements; error bars representing the SD of the data were omitted for clarity, all were smaller than the markers.

At both clinical (0.47 – 1.41 T) and research (9.4 – 14.1 T) field strengths, if a linear or macrocyclic agent is desired with high relaxivity then it is clear from Figure 4.1a and b that the agent of choice would be Gadavist and that a spin locking pulse should be applied. However, from Tables 4.1 – 4.4 it is clear that although Gadavist has the highest relaxivity of all the linear and macrocyclic agents, with or without spin locking,

Table 4.1: Raw r_1 and $r_{1\rho}$ data at 25 °C used to generate the NMRD above for linear and macrocyclic clinical agents studied herein at low field and their calculated ratios. Mean represents the average difference for the specified category of agents.

			0.47 T		$r_{1\rho}/r_1$	1.41 T		$r_{1\rho}/r_1$
			r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)		r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)	
25 °C	Macrocyclic	Dotarem	4.60	5.72	1.24	3.96	5.07	1.28
		ProHance	4.53	5.79	1.28	4.01	5.01	1.25
		Gadovist	5.28	6.79	1.29	4.85	6.20	1.28
	Linear	Magnevist	5.06	6.07	1.20	4.33	5.59	1.29
		Omniscan	4.64	5.12	1.10	4.15	4.66	1.12
		Mean			1.22			1.24

Table 4.2: Raw r_1 and $r_{1\rho}$ data at 37 °C used to generate the NMRD above for linear and macrocyclic clinical agents studied herein at low field and their calculated ratios. Mean represents the average difference for the specified category of agents.

			0.47 T		$r_{1\rho}/r_1$	1.41 T		$r_{1\rho}/r_1$
			r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)		r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)	
37 °C	Macrocyclic	Dotarem	3.74	4.68	1.25	3.18	4.04	1.27
		ProHance	3.79	4.63	1.22	3.20	4.03	1.26
		Gadovist	4.50	5.67	1.26	4.06	4.96	1.22
	Linear	Magnevist	4.18	5.05	1.21	3.47	4.47	1.29
		Omniscan	4.20	4.60	1.10	3.62	4.12	1.14
		Mean			1.21			1.24

Table 4.3: Raw r_1 and $r_{1\rho}$ data at 25 °C used to generate the NMRD above for linear and macrocyclic clinical agents studied herein at high field and their calculated ratios. Mean represents the average difference for the specified category of agents

			9.4 T		$r_{1\rho}/r_1$	14.1 T		$r_{1\rho}/r_1$
			r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)		r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)	
25 °C	Macrocyclic	Dotarem	3.79	4.95	1.31	3.49	4.56	1.26
		ProHance	3.31	5.04	1.52	3.48	4.83	1.39
		Gadovist	4.42	6.35	1.44	4.23	6.05	1.43
	Linear	Magnevist	4.21	5.91	1.40	4.18	5.65	1.35
		Omniscan	3.58	4.74	1.32	3.54	4.43	1.25
		Mean			1.40			1.34

Table 4.4: Raw r_1 and $r_{1\rho}$ data at 37 °C used to generate the NMRD above for linear and macrocyclic clinical agents studied herein at high field and their calculated ratios. Mean represents the average difference for the specified category of agents.

			9.4 T		$r_{1\rho}/r_1$	14.1 T		$r_{1\rho}/r_1$
			r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)		r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)	
37 °C	Macrocyclic	Dotarem	2.73	3.70	1.36	2.61	3.48	1.33
		ProHance	2.64	3.84	1.45	2.73	3.70	1.36
		Gadovist	3.66	5.08	1.39	3.57	4.86	1.36
	Linear	Magnevist	3.36	4.46	1.33	3.24	4.33	1.34
		Omniscan	3.02	4.07	1.35	3.03	3.80	1.25
		Mean			1.37			1.33

the observed increase by applying a spin locking pulse is not necessarily proportional to the magnitude of the laboratory frame values. For example, at 25 °C and 9.4 T the relaxivity of ProHance increases from 3.31 $\text{mM}^{-1}\text{s}^{-1}$ to 5.04 $\text{mM}^{-1}\text{s}^{-1}$ (a factor of 1.52) whereas Magnevist increases from 4.21 $\text{mM}^{-1}\text{s}^{-1}$ to 5.91 $\text{mM}^{-1}\text{s}^{-1}$ (a factor of 1.40) and Gadovist increases from 4.42 $\text{mM}^{-1}\text{s}^{-1}$ to 6.35 $\text{mM}^{-1}\text{s}^{-1}$ (a factor of 1.44). From the values in Table 4.2, if Gadavist is selected for a high field imaging application, on average, the relaxivity using a spin locking pulse increases by a factor of 1.68 when compared to values obtained from other linear and macrocyclic agents without spin locking.

Values of r_1 and $r_{1\rho}$ used in Figure 4.1 were obtained by measuring the laboratory and rotating frame relaxation time constants (T_i), where $i = 1$ or 1ρ , provided by fitting the raw time curve data, comparable to those shown in chapter 3, to the relevant fitting equations. From these, relaxivity plots were generated by plotting the rate constant ($1/T_i$) as a function of $[Gd^{3+}]$. Linear regression analysis of these plots affords the relaxivity as the slope, according to the linear form of Equation 1.17. A sample of typical relaxivity plots generated to determine relaxivities for Figure 4.1 are provided in Figure 4.2 and demonstrate excellent correlation coefficients typically >0.999 .

4.3. A comparison of $r_{1\rho}$ for linear and macrocyclic chelates to simulated theory

To determine if the data observed is a true reflection of theory the relevant parameters required to simulate rotating frame NMRD profiles are required to be identified. For this, further analysis of the work set out by Jordan and co-workers is required.

Figure 4.2: Sample relaxivity (r_1) plots for the macrocyclic class of clinical agents. Data shown are the mean of six measurements with the mean relaxivity (slope) for each agent shown in the legend. R^2 for all agents are > 0.978 . Error bars representing the SD of the data were omitted for clarity, all were smaller than the markers.

The dependence of $r_{1\rho}$ in the presence of a Gd^{3+} ion was previously derived in Chapter 3 (Equation 3.5) and is re-stated below.

$$r_{1\rho} = \frac{q}{55.6} \left(\frac{R_{2M} \times 1/\tau_M}{R_{1M} + 1/\tau_M} \right)$$

It can be seen that by spin locking a component of laboratory frame transverse relaxation (R_{2M}) is introduced and dominates over the laboratory frame longitudinal relaxation component (R_{1M}). R_{2M} and R_{1M} , the transverse and longitudinal relaxation rate constants respectively, are defined in the theory of Solomon-Bloembergen-Morgan. R_{2M} is shown below (Equation 4.1) considering only dipolar contribution; the scalar contribution is considered negligible as it is so small.⁸⁷ Similarly, R_{1M} , previously described in Chapter 1 (Equation 1.20) is also shown for ease of reference. Terms in both R_{2M} and R_{1M} are the same as previously described.

$$R_{2M} = \frac{1}{15} \frac{\gamma_I^2 g^2 \mu_B^2 S(S+1)}{r_{GdH}^6} \left[\frac{3\tau_{c1}}{1 + \omega_I^2 \tau_{c1}^2} + \frac{13\tau_{c2}}{1 + \omega_S^2 \tau_{c2}^2} \right] + 4\tau_{c1} \quad (4.1)$$

$$R_{1M} = \frac{2}{15} \frac{\gamma_I^2 g^2 \mu_B^2 S(S+1)}{r_{GdH}^6} \left[\frac{3\tau_{c1}}{1 + \omega_I^2 \tau_{c1}^2} + \frac{7\tau_{c2}}{1 + \omega_S^2 \tau_{c2}^2} \right]$$

R_{2M} has a larger dependence on the longitudinal correlation time constant (τ_{c1}) than R_{1M} , suggesting $r_{1\rho}$ should be more dependent on τ_R and τ_M , according to Equation 1.19.

Equations 1.19, 1.20, 3.5 and 4.1 were used to simulate the rotating frame NMRD profiles of Magnevist and Dotarem, the “original” and “gold standard” agents, using well

established physiochemical parameters at 25 °C obtained from decades of studying their laboratory frame NMRD.⁵⁰ The observed data generated here was plotted against the theoretical simulation and is shown in Figure 4.3. It can be seen that the observed data (open symbols) agrees well with the simulations (lines), and that from approximately 20 MHz (0.47 T) to 600 MHz (14.1 T) the simulation are almost entirely independent of B_0 , a consequence of the dominance of R_{2M} in the $r_{1\rho}$ equation (Equation 3.5). In comparison to simulations for r_1 (Figure 1.15) over the same range of B_0 fields, the $r_{1\rho}$ simulations decrease much less rapidly, confirming our observations.

Figure 4.3: Rotating frame NMRD profiles of Magnevist and Dotarem in PBS at 25 °C. The lines through the data are simulations, using Eqns 1.20, 1.21, 3.5 and 4.1, of the rotating frame NMRD profile based on literature values of relevant parameters derived from laboratory frame NMRD analysis;⁵⁰ Dotarem: $q = 1$; $r_{GdH} = 3.1\text{Å}$; $\tau_M = 250\text{ ns}$, $\tau_R = 68.4\text{ ps}$, $\Delta^2 = 1 \times 10^{19}\text{ s}^{-2}$; $\tau_V = 10\text{ ps}$; Magnevist: $q = 1$, $r_{GdH} = 3.1\text{Å}$; $\tau_M = 303\text{ ns}$, $\tau_R = 67.9\text{ ps}$, $\Delta^2 = 4.4 \times 10^{19}\text{ s}^{-2}$; $\tau_V = 24.9\text{ ps}$; the outer sphere contribution was measured by analysis of $GdTTTHA^{3-}$.

4.4. A comparison of r_1 and $r_{1\rho}$ for bulky $q = 1$ clinical Gd^{3+} -based CAs

Comparable experiments and data processing as described above for macrocyclic and linear agents was performed for bulky agents to determine their relaxivities and NMRD profiles. Due to the incorporation of bulky substituents to affect their biodistribution, Ablavar and MultHance have slightly longer τ_R values and elevated relaxivities when compared to the more rapidly tumbling linear and macrocyclic counterparts (Figure 4.4a and b at 25 and 37 °C, respectively). For this reason the bulky agents fare better than the linear and macrocyclic agents, particularly at high field, with an increase in relaxivity by a factor of 1.22 at 0.47 T on average, rising to 1.46 at 14.1 T on average (Table 4.5 - 4.6).

Figure 4.4: NMRD profiles of the bulky clinical contrast agents studied herein at 25 °C (A) and 37 °C (B) in PBS: laboratory frame data (r_1) are presented in red (closed symbols); and rotating frame data ($r_{1\rho}$) are presented in blue (open symbols); $\omega_1 = 35$ kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). MultiHance (diamonds); Ablavar (circles), the green cross is the $r_{1\rho}$ value calculated for Ablavar from reference.⁸² Lines through the data are to guide the eye only. Data shown are the mean of six measurements; error bars representing the SD of the data were omitted for clarity, all were smaller than the markers.

As for linear and macrocyclic agents the $r_{1\rho}$ values of bulky agents are higher than r_1 values for all fields investigated and both decrease as a function of B_0 . However, their $r_{1\rho}$ NMRD profiles decrease significantly more slowly than r_1 than was observed for the linear and macrocyclic agents, especially at lower temperatures.

The observed dependence of $r_{1\rho}$ on the magnitude of the τ_R value can be rationalized by referring to the theory described above and equations 1.20, 3.5 and 4.1. These show that $r_{1\rho}$ is more dependent than r_1 on the characteristic correlation time constant (τ_{C1}) of the contrast agent. Of the parameters in Equation 1.21 τ_R is limiting for Gd^{3+} -based CAs such as those studied herein in which the fast water exchange regime criteria are met.

Comparable observations were made in the only other report of the use of spin locking with a Gd^{3+} -based CA at high fields.⁸² In that report, Buckley and co-workers investigated spin locking at 4.7 T with Ablavar, known to bind reversibly to serum albumin, and observed significantly higher $R_{1\rho}$ values when bound than when unbound. Although Buckley and co-workers do not quantify relaxivities in their study it is evident that $r_{1\rho}$ values were greater than r_1 values. However, from the data presented this increases both the laboratory and rotating frame relaxivities of the agent.

By applying an analytical model used in a related study,⁸⁸ we were able to estimate the bound and free rotating frame relaxivities for Ablavar with BSA, circumventing limitations of the method in which the data presented by Buckley and co-workers was generated.

Table 4.5: Raw r_1 and $r_{1\rho}$ data at 25 and 37 °C used to generate the NMRD above for bulky clinical agents studied herein at low field and their calculated ratios. Mean represents the average difference for the specified category of agents.

			0.47 T		$r_{1\rho}/r_1$	1.41 T		$r_{1\rho}/r_1$
			r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)		r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)	
25 °C	Bulky	MultiHance	6.04	7.46	1.24	5.42	6.95	1.28
		Ablavar	7.86	9.75	1.24	7.11	9.63	1.35
		Mean			1.23			1.29
37 °C	Bulky	MultiHance	5.01	5.95	1.19	4.32	5.57	1.29
		Ablavar ^a	6.44	7.89	1.23	5.70	8.47	1.49
		Mean			1.21			1.34

^a Free Ablavar

Table 4.6: Raw r_1 and $r_{1\rho}$ data at 25 and 37 °C used to generate the NMRD above for bulky clinical agents studied herein at high field and their calculated ratios. Mean represents the average difference for the specified category of agents.

			9.4 T		$r_{1\rho}/r_1$	14.1 T		$r_{1\rho}/r_1$
			r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)		r_1 (mM ⁻¹ s ⁻¹)	$r_{1\rho}$ (mM ⁻¹ s ⁻¹)	
25 °C	Bulky	MultiHance	4.72	7.36	1.56	4.45	6.89	1.55
		Ablavar	6.84	9.1	1.33	5.30	8.39	1.58
		<i>Mean</i>			1.43			1.49
37 °C	Bulky	MultiHance	3.76	5.59	1.49	3.52	5.34	1.52
		Ablavar ^a	5.64	6.97	1.24	4.53	6.44	1.42
		<i>Mean</i>			1.37			1.42

^a Free Ablavar

The model we used assumes a 1:1 binding interaction and uses a binding constant derived empirically ($K_a = 12 \text{ M}^{-1}$).⁸⁹ Fitting the Buckley data to this model gave values of $r_{1\rho}^{\text{bound}} = 84.8 \text{ mM}^{-1}\text{s}^{-1}$ and $r_{1\rho}^{\text{free}} = 20.8 \text{ mM}^{-1}\text{s}^{-1}$. The bound $r_{1\rho}$ value compares favorably with the bound r_1 value reported in literature ($16.2 \text{ mM}^{-1}\text{s}^{-1}$) for the same agent with human serum albumin (HSA) but at slightly lower field and temperature (3 T and 25 °C).

The substantial increase of both laboratory and rotating frame relaxivity on binding to HSA or BSA is a direct consequence of the increase in the effective molecular weight of the agent and a lengthening of τ_R . It is worthwhile commenting on the magnitude of the free $r_{1\rho}$ calculated in the presence of BSA. Since the original experiments were performed in the presence of 4.5% w/v of BSA, an increase in viscosity is likely which further lengthens τ_R resulting in elevated relaxivities, particularly in the rotating frame which we have shown to be more sensitive to τ_R .

4.5. Summary of relaxivity changes

Figure 4.5 shows that, in the laboratory frame (red), an approximate 20 and 30% decrease in relaxivity is observed for low molecular weight (solid) and bulky (diagonal lines) clinical agents respectively when the external field strength is increased from 0.47 T (~ 0.5 T) to 14.1 T. This is a consequence of these agents having comparable laboratory frame relaxivities at 14.1 T, whereas at 0.5 T bulky agents have higher laboratory frame relaxivities. Figure 4.5 allows for a better appreciation of the increases in relaxivity by spin locking clinical agents demonstrated in Figures 4.1 and 4.4. At 0.5 T (purple) the

increase is modest for both low molecular weight and bulky agents with an increase of approximately 20% for each. At 14.1 T (green) more substantial increases are observed, with low molecular weight agents increasing by approximately 35% and bulky agents increasing by approximately 65%. As discussed previously, the increased gains at higher fields are a result of a less rapid decrease in $r_{1\rho}$ as a function of B_0 than that observed for r_1 (Figure 4.1 and 4.4).

By comparing the change in relaxivity between low molecular weight agents (short τ_R) and bulky agents (long τ_R) Figure 4.10 clearly demonstrates our finding that $r_{1\rho}$ is more sensitivity than r_1 to the rotational correlation time (τ_R), particularly at high field. Figure 4.5 also demonstrates that by spin locking at the high field strengths of the future, the loss of relaxivity observed by remaining in the laboratory frame (red) can not only be recovered, but increased (blue). Additionally, this increase occurs to a greater extent for bulky agents (~10% increase in relaxivity) than for low molecular weight agents (~5%).

4.6. Conclusions

We were able to demonstrate in the presence of an optimized spin lock pulse that relaxivity lost on moving to higher B_0 field strengths was able to be “recovered” across all B_0 field strengths studied and for all Gd^{3+} -based CAs in current clinical use at both 25 and 37 °C. For now, it remains to be seen if these findings will afford increased detectability and reduced limits of detection of these agents.

Figure 4.5: Percent change in relaxivity at 25 °C by spin locking (rot. frame) at low field (Purple), high field (green) and over the entire range of field strengths studied (blue) for low molecular weight agents (solid) and bulky agents (diagonal lines). For reference the percent change in relaxivity without spin locking (lab. frame) over the entire range of field strengths studied (red) is also shown for the same agents.

However, it is known that the effect the spin locking pulse will have on inherent rotating frame relaxation rate constants ($R_{1\rho}$) of tissue at these fields will play a role in achieving this particular goal. It can be theorized that since spin locking has a large R_2 contribution, inherent tissue $R_{1\rho}$ values may be comparable. At field strengths up to 2.35 T (100 MHz) inherent tissue R_2 values have been reported to be fairly independent of B_0 in both normal and pathological tissue.⁹⁰⁻⁹¹ However, at higher B_0 field strengths, such as those

investigated herein, inherent tissue R_2 values have been shown to increase.⁹² This suggests that agent detectability could be increased at such fields as a result of the less rapid decrease in relaxivities observed at these high fields by spin locking.

Our finding that the rotating frame relaxivity ($r_{1\rho}$) is especially sensitive to the rotational correlation time (τ_R) is of particular interest. This effect is more pronounced at high B_0 fields, where substantial loss of relaxivity is observed and to which future clinical imaging is heading. Spin locking is therefore likely to be of interest to researchers in the field of molecular imaging. In such applications, agents are designed to target large molecular weight biomarkers thereby increasing their effective molecular weight substantially. By employing a spin locking pulse with such agents it may be possible, at high field, to “recover” relaxivity in remarkably larger amounts than any gains possible from similar agents in the laboratory frame. This hypothesis if proven to be true could potentially decrease the limits of detection of such agents to levels required for successful molecular imaging where biomarkers typically exist at very low concentrations.

CHAPTER 5. EFFECT OF ROTATIONAL CORRELATION TIME (τ_R) ON ROTATING FRAME LONGITUDINAL RELAXIVITY ($r_{1\rho}$)

5.1. Establishing the potential for increasing relaxivity by spin locking slow tumbling nano-encapsulated Gd^{3+} chelates.

The NMRD profiles for $q = 1$ clinical Gd^{3+} -based CAs (Figures 4.1 and 4.7) and summary (Figure 4.10), demonstrate that lost relaxivity on moving to higher B_0 fields could be “recovered” by using a spin locking pulse and measuring the rotating frame relaxivity ($r_{1\rho}$). Comparison of $r_{1\rho}$ and r_1 NMRD profiles for all three classes of clinical agents revealed that $r_{1\rho}$ is more sensitive to the rotational correlation time (τ_R) than r_1 . Evidence for this was shown by measuring greater gains in relaxivity on applying a spin locking pulse with low molecular weight bulky agents that tumble more slowly than were measured for low molecular weight non-bulky agents. This was particularly apparent at high B_0 fields where substantial loss of laboratory frame relaxivity is typically observed and towards which clinical imaging is heading. However, due to only a slight difference in τ_R between the low molecular weight non-bulky and bulky agents studied, the relaxivity gains from slowing tumbling were fairly modest.

Using the SBM equations it has been possible to model the inner sphere contribution to r_1 and $r_{1\rho}$ for a theoretically “optimized” gadoterate chelate for which τ_R has been increased from 68.4 ps to 68.4 ns and τ_M has been reduced from 250 ns to 25 ns (Figure 5.1).

Figure 5.1: Nuclear magnetic relaxation dispersion (NMRD) profile, generated by us, plotting the inner sphere contribution to the laboratory frame (solid line) and rotating frame (dashed-dot-dot line) longitudinal relaxivity for a theoretically “optimized” gadoterate chelate for which τ_R has been increased from 68.4 ps to 68.4 ns and τ_M reduced from 250 ns to 25 ns. Also shown is the NMRD profile of gadoterate (dashed line⁶¹) plotting the inner sphere contribution to the laboratory frame longitudinal relaxivity as a function of B_0 field.

At around 0.71 T (30 MHz), r_1 (solid line) for an optimized gadoterate chelate shows a steady and continual decrease as B_0 increases. This occurs to such an extent that r_1 converges at around 4.7 T (200 MHz), the upper limit of current clinical imaging fields, with the r_1 value of a nonoptimal chelate (dashed line) and all contrast agents are found to behave identically. However, $r_{1\rho}$ (dashed-dot-dot line) increase rapidly from 0.71 T (30 MHz) up to around 4.7 T (200 MHz) after which it increases more slowly up to 23.5 T (1000 MHz). This demonstrates the potential for $r_{1\rho}$ to become exceedingly high at very high B_0 field strengths if molecular tumbling can be substantially slowed and water exchange optimized. Spin locking may provide a method for significantly increasing the detectability of such Gd^{3+} -based CAs. This would be useful in applications such as molecular imaging where biomarkers exist at very low concentrations.

5.2. Nanoassembled capsules as a model system for investigating the effect of τ_R on $r_{1\rho}$

Novel high molecular weight nanoassembled capsules (NACs) containing a Gd^{3+} -based CA represent a convenient model for investigating the effect of making τ_R longer. Samples of Gd^{3+} containing NACs were kindly supplied by Annah Farashishiko. The particular advantage of these capsules are that they afford well-defined, slowly rotating systems that are uncomplicated by the presence of binding equilibria. We therefore investigated NACs of different size comparing their r_1 and $r_{1\rho}$ values at high B_0 field strengths, 9.4 and 14.1 T (400 and 600 MHz respectively), at 25 °C. Low field r_1 values were also determined; however, due to instrument and sample limitations (short spin lock pulse durations and low Gd^{3+} concentrations) it was not possible to determine low field relaxivity in the rotating frame.

5.3. Mechanism of action of nanoassembled capsules (NACs) incorporating GdDOTP^{5-}

GdDOTP^{5-} (DOTP = 1, 4, 7, 10-tetra-azacyclododecane- N,N',N'',N''' -tetrakis(methylenephosphonic acid)) is a highly charged $q = 0$ chelate with a relaxivity of $4.7 \text{ mM}^{-1} \text{ s}^{-1}$ (23 MHz, 25 °C),⁹³ remarkably high considering the contributions are solely from second and outer sphere water. This has largely been attributed to the ability of the phosphonate groups to tightly bind water⁹⁴ and form an ordered second sphere⁹⁵ with extensive hydrogen bonding that slows water exchange ($1/\tau_M$) (Figure 5.2). This negatively charged anionic chelate forms aggregates with high molecular weight cationic polymers which when encapsulated with SiO_2 form NACs (Figure 5.3).

Figure 5.2: $[\text{GdDOTP}]^{5-}$ a $q = 0$ complex.

By encapsulating GdDOTP^{5-} with a SiO_2 nano-particle the outer sphere contribution to relaxivity is essentially eliminated rendering the capsules as purely second sphere agents. Additionally, the second sphere water exchange rate is further reduced by aggregate formation. The encapsulating shell does not inhibit water exchange to such an extent that it limits relaxivity, *i.e.* water remains in the fast exchange regime.⁹³ Second sphere contributions can be described by SBM theory (used to quantify inner-sphere contributions) and the typical governing parameters, τ_M and τ_R , albeit with an elongated $r_{\text{Gd-H}}$ distance. It has been shown that at magnetic field strengths of 0.47 – 1.41 T the limiting effect of τ_R is lifted by the lengthening of τ_R on forming aggregates and NACs and that under these conditions the laboratory frame relaxivities are elevated.⁹³

Figure 5.3: Cartoon representation of a Gd^{3+} based NAC.

5.4. Effect of NAC design parameters on relaxivity

Relaxivity is dependent on the size of the NACs. Smaller NACs give rise to the greatest gains in relaxivity owing to the increased facility for proton transport between chelate and bulk water – the result of shorter distances required to travel by the water in order to cross the capsule shell and transmit the paramagnetic relaxation enhancement to the bulk. The size of NACs have been shown to be dependent on three critical design parameters: the charge ratio, the cationic polymer and the solvent system used in their synthesis.⁹³ We chose to study NACs prepared with polyallylamine hydrochloride (PAH) in 3:2 MeCN/H₂O at a charge ratio (R) of 0.3, 0.5 and 1 with the penta-anionic chelate ($GdDOTP^{5-}$). These design parameters were chosen in an effort to maximize their relaxivities by limiting their size. Representative SEM images of NACs at each charge ratio studied are shown in Figure 5.4 and their respective relaxivities in Table 5.1.

Figure 5.4: SEM of PAH-GdDOTP⁵⁻-based NACs prepared in MeCN/H₂O, 3:2 at three different charge ratios (R).

Table 5.1: Laboratory frame longitudinal relaxivity (r_1) data for the PAH-GdDOTP⁵⁻-based NACs shown in Figure 5.4 (25 °C at 20 MHz).

	R = 0.3	R = 0.5	R = 1
r_1 (mM ⁻¹ s ⁻¹)	44.39	22.36	7.88

5.5. Effect of γB_1 on $R_{1\rho}$ for NACs at high B_0 field strengths

According to our model (Figure 5.1 dashed-dot-dot line) the rotating frame longitudinal relaxivity for an optimized agent should be very high at high fields, therefore, we investigated the effect of γB_1 on $R_{1\rho}$ for NACs at 600 MHz (14.1 T) and 25 °C. For this a sample of NACs with charge ratio (R) of 0.5 encapsulating GdDOTP⁵⁻ at a Gd³⁺ concentration of 0.89 mM in water were used. The strength of the spin locking field (γB_1) was modulated by attenuating the power. For comparison a sample of the free chelate at a Gd³⁺ concentration of 5 mM was also investigated. The Rabi frequencies that

characterize γB_1 over the attenuation range sampled corresponded to $\sim 200 - 20000$ Hz (NACs) and $\sim 400 - 20000$ Hz (GdDOTP⁵⁻) the results are shown in Figure 5.5.

As expected for the free chelate, similar facets to those observed for Dotarem (Figure 3.2), also a low molecular weight Gd³⁺-chelate, at high B_0 fields can be identified. Namely, the rotating frame longitudinal relaxation rate ($R_{1\rho}$) of GdDOTP⁵⁻ showed very low errors associated with the data but the mean data point did start to show some scatter at the lower spin lock field strengths studied. Also, the strength of the spin lock pulse required to effectively lock the spins at high B_0 field was approximately the same, ~ 500 Hz. Again these values are much more realistic than those determined from our low field experiments. The reduced spin lock field strength required to effectively spin lock, compared to low field experiments, can again be attributed to the shim capabilities of the superconducting instrument and the low Gd³⁺ concentration employed that both contribute to narrow line-widths and low pulse strengths being required to spin lock.

For the GdDOTP⁵⁻ encapsulated NACs, the errors associated with the data are again very low, however the data is shown to be dependent on the strength of the spin lock pulse with an increasing trend in the rotating frame relaxation rate constant as the power is decreased up to ~ 1000 Hz where an inflection in the data occurs and $R_{1\rho}$ starts to decrease as powers continue to decrease to ~ 200 Hz. It is important to keep in mind that equation 3.1 derived from the theory of Jordan and co-workers⁷⁰ does not apply in the case of an encapsulated Gd³⁺ chelate, the chelate no longer being in simple exchange with water.

Figure 5.5: The dependence of the water proton rotating frame longitudinal relaxation rate constant ($R_{1\rho}$) on the spin lock field strength (γB_1) for a sample of $R = 0.5$ PAH-GdDOTP $^{5-}$ encapsulated NACs (filled circles) and the free chelate (open circles) in water 14.1 T (600 MHz) and 25 °C. Data shown are the mean of six measurements; error bars representing the SD of the data were omitted for clarity but were all less than the markers.

5.6. A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame NMRD for NACs

Laboratory (r_1) and rotating ($r_{1\rho}$) frame relaxivities for NACs prepared in this study at several charge ratios were determined over a range of B_0 field strengths and their NMRD profiles generated. For comparative purposes, free un-encapsulated GdDOTP $^{5-}$ was also measured (Figure 5.6).

5.6.1. Effect of τ_R on r_1 as a function of B_0

As predicted by our model for a theoretically “optimized” agent (Figure 5.1, solid line) r_1 values for NACs (Figure 5.6, red open symbols) decrease on increasing the field strength

from 0.47 T (20 MHz) to 1.41 T (60 MHz) after likely reaching a maximum around 0.7 T (30 MHz).

Figure 5.6: NMRD profiles of NACs at 25 °C in water: laboratory (r_1) and rotating ($r_{1\rho}$) frame data are presented in red and blue (open symbols) respectively. $\omega_1 = 35$ kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). Charge ratio (R): 1 (circles), 0.5 (diamonds) and 0.3 (triangles). Laboratory (r_1) and rotating ($r_{1\rho}$) frame data are also presented in red and blue (closed squares) respectively for un-encapsulated GdDOTP⁵⁻. Data shown are the mean of three measurements; error bars representing the SD of the data were omitted for clarity, all were smaller than the markers except $r_{1\rho}$ for R = 0.3 NACs which are slightly larger than the marker. *Note: $r_{1\rho}$ for R = 0.3 NACs is based on an estimated $[Gd^{3+}]$, at the time of writing ICP-AES data was not available.*

The r_1 values continue to decrease as the field strength is increased further to 9.4 T (400 MHz) and 14.1 T (600 MHz), again, consistent with the model and presumably due to sub-optimal water exchange at these fields in the laboratory frame.

The r_1 values for the free chelate (red closed squares) are consistent with the model for a “non-optimized” low molecular weight non-bulky chelate (Figure 5.1, dashed line) and previous observations for such chelates studied herein. Consistent with previous observations for similar systems by our group,⁹³ r_1 values for NACs (red open symbols) at low field, 0.47 T (20 MHz), are elevated over those of the free chelate (red closed squares) as is the case at 1.41 T (60 MHz), a consequence of the slowing of rotation. At high fields, it might have been expected that the r_1 values for NACs and free chelate would converge on approximately the same value. However, this is not the case as laboratory frame relaxivity values for NACs were found to be lower than the respective values for the free chelate. This may be the result of two factors. Firstly, by eliminating the outer sphere contribution by encapsulation, the theoretical relaxivity possible for NACs would be expected to be lowered by approximately half compared to the free chelate.²² Secondly, water exchange for the NACs is likely to be slower, due to the encapsulation that provides a boundary to exchange, and thus less optimum at these field strengths than for the free chelate.

Also consistent with our previous findings with similar systems⁹³, r_1 increases as the charge ratio, proportional to size, decreases from 1 (red open circles) to 0.5 (red open diamonds) and further to 0.3 (red open triangles) at low fields. This is a result of more effective rotational restriction and increased water exchange rates ($1/\tau_M$) in smaller NACs. This was not observable at the higher fields studied herein due to the non-

optimum water exchange rates limiting the relaxivity at these fields leading to negligible difference in the r_1 values between the NACs with different charge ratios.

5.6.2. Effect of τ_R on $r_{1\rho}$ as a function of B_0

With the low field relaxometers the maximum spin lock pulse duration is 40 ms. This rendered it impossible to determine $r_{1\rho}$ values of NACs at 0.47 and 1.41 T (20 and 60 MHz) with the low sample concentrations employed. The higher concentrations needed for these experiments were not possible due to material limitations.

From the high field portion of the NMRD profiles in Figure 5.6 (9.4 – 14.1 T, 400 – 600 MHz) it can be seen that $r_{1\rho}$ values for NACs (blue open symbols) are substantially elevated over the respective r_1 values (red open symbols) as observed for the clinical agents discussed previously. However, and more importantly, the $r_{1\rho}$ values increase on moving to higher B_0 fields rather than decrease as for r_1 . This finding is in agreement with predictions made by our model for a theoretically “optimized” gadoterate chelate in the rotating frame (Figure 5.1, dashed-dot-dot). These results demonstrate the potential benefits of applying spin locking pulses when imaging using slowly tumbling Gd^{3+} -based contrast media at high magnetic field strengths.

As observed for other low molecular weight non-bulky agents in this work the rotating frame relaxivity of the free chelate (blue closed squares) was elevated over the laboratory frame relaxivity (red closed squares) at all B_0 field strengths studied and decreased as B_0 increased.

At high fields $r_{1\rho}$ values for NACs (blue open symbols) are greater than that of the respective values for the fast tumbling free chelate (blue closed squares). This is again a consequence of the significantly longer τ_R for NACs over that of the free chelate.

High field $r_{1\rho}$ values for NACs (blue open symbols) also exhibit a substantial increase as the charge ratio (size) decreases from 1 (blue open circles) to 0.5 (blue open diamonds) and further to 0.3 (blue open triangles). Again, this is a consequence of smaller capsules providing more effective rotational restriction and increased water exchange rates.

5.7. Summary of relaxivity changes

Figure 5.7 shows that, in the laboratory frame (red), an approximate 75, 90 and 95% decrease in relaxivity is observed for NACs prepared with a charge ratio of $R = 1$ (checker board), 0.5 (diagonal brick) and 0.3 (confetti) respectively when the external field strength is increased from 0.47 T (0.5 T) to 14.1 T. For comparison, the change in relaxivity in the laboratory frame for clinical agents, ~25% (solid), and the GdDTPA⁵⁻ free chelate, ~20% (diagonal lines), are also shown. The greater decrease in relaxivity for NACs compared to the clinical agents and free chelate is a consequence of NACs having different, and substantially elevated, laboratory frame relaxivities at 0.5 T over the clinical agent and free chelate (Figure 5.6) but comparable laboratory frame relaxivities at 14.1 T. Figure 5.7 allows for a better appreciation of the increase in relaxivity by spin locking NACs at high field demonstrated in Figure 5.6. At 14.1 T (green) the increases are exceptionally large for all NACs, approximately 600, 1000 and 1800% for $R = 1$, 0.5

and 0.3 respectively, and much more significant than the respective increases observed for clinical agents (solid) and the free chelate (diagonal lines). The NAC values were calculated relative to the r_1 value for the free chelate since this is greater than the r_1 value for NACs at these fields (Figure 5.6) a consequence of NACs having less optimum water exchange. This clearly demonstrates the sensitivity of $r_{1\rho}$ to the rotational correlation time (τ_R) which is lengthened on decreasing the NAC size, proportional to charge ratio, due to more effective rotational restriction and increased water exchange rates. Due to instrument and sample limitations discussed previously, it was not possible to measure rotating frame relaxivities on our low field instruments, therefore a comparison to r_1 at 0.5 T could not be made. Figure 5.7 also demonstrates that by spin locking at the high field strengths of the future, lost relaxivity that is expected by remaining in the laboratory frame (red) for clinical agents, free chelate or NACs, can not only be recovered but increased (blue). Additionally, this increase occurs to a greater extent for NACs (~ 260, 90 and 60% for $R = 1, 0.5$ and 0.3 respectively) than for clinical agents (~8%) and free chelate (~ 6%). The decrease in the change in relaxivity for NACs as a function of the charge ratio (blue) is a consequence of larger increases in r_1 at 0.5 T than $r_{1\rho}$ at 14.1 T (Figure 5.6).

5.8. Conclusions

Rotating frame relaxivities at high fields were found not only to be exceptionally large compared to those obtained in the laboratory frame ($43 \text{ mM}^{-1}\text{s}^{-1}$ vs. $1.9 \text{ mM}^{-1}\text{s}^{-1}$ for NACs with a charge ratio of 0.5 at 14.1 T), but also increased as B_0 increased.

Figure 5.7: Percent change in relaxivity at 25 °C by spin locking (rot. frame) at high field (green) and over the entire range of field strengths studied (blue) for clinical agents (solid), GdDOTP⁵⁻ free chelate (diagonal lines) and GdDOTP⁵⁻ NACs $R = 1$ (checker board), $R = 0.5$ (diagonal brick) and $R = 0.3$ (confetti). For reference the percent change in relaxivity without spin locking (lab. frame) over the entire range of field strengths studied (red) is also shown for the same agents.

Note: the percent change by spin locking NACs at high field was calculated relative to the laboratory frame relaxivities of the free chelate which are larger than those for NACs.

They were also found to be substantially elevated over those measured for the free chelate for which the latter shows a decreasing trend with B_0 . The rotating frame relaxivities measured herein for NACs at high fields are larger anything previously reported at these fields and were found to be in agreement with our models for a theoretically “optimized” gadoterate chelate in the rotating frame.

Laboratory frame relaxivities for NACs were found to be in agreement with our model for a theoretically “optimized” gadoterate chelate in the laboratory frame. That is, r_1 values for NACs are elevated over the free chelate at low fields, 0.47 – 1.41 T (20 – 60 MHz) but drops off dramatically at higher field strengths. At high fields, however, the laboratory frame relaxivities for NACs were found to be lower than those achievable for the free chelate. At low fields, as the charge ratio of NACs (inversely proportional to their size) decreased, the laboratory frame relaxivity was found to increase. This was consistent with previous finding for similar systems.⁹³ However, little difference in their laboratory frame relaxivity was observed at high fields.

The use of spin locking, particularly at high fields, may prove beneficial in targeted molecular imaging applications. For such applications contrast agents are targeted to large molecular weight biomarkers giving rise to very large effective molecular weights and long τ_R values. This work shows that employing a spin locking pulse could potentially increase relaxivities beyond values currently obtainable at high fields in the laboratory frame with comparable agents and may decrease limits of detection to levels at which biomarkers for disease pathology exist.

CHAPTER 6. EFFECT OF HYDRATION NUMBER (q) ON ROTATING FRAME LONGITUDINAL RELAXIVITY ($r_{1\rho}$)

6.1. Potential applications of spin locking with hydration numbers (q) $\neq 1$

As can be seen from the SBM equation (Equation 1.19) one possible means of increasing the relaxivity of an agent is to increase its hydration number (q). The hydration number refers to the number of water molecules in the inner coordination sphere of the metal ion. It is well established that by opening up extra coordination sites to additional water molecules the laboratory frame longitudinal relaxivity (r_1) of Gd^{3+} -based CAs scales proportionally. However, it does so at the expense of the thermodynamic stability of the chelate which has been shown to reduce by up to three orders of magnitude⁷¹ and as such all current clinical Gd^{3+} -based CAs are restricted to just one inner sphere water molecule. However, many investigations are performed *in vitro*, *ex vivo* and/or *in vivo* using animal models for which the stability of the CA is a lesser concern. Moreover, for such investigations the paramagnetic metal ion is not limited to Gd^{3+} . When looking to the periodic table for other paramagnetic ions with properties similar to Gd^{3+} , Mn^{2+} stands out. Mn^{2+} has five unpaired electrons, a long electron relaxation time and can bind water molecules that undergo exchange. In fact, Lauterbur and co-workers used a salt of MnCl_2 in dogs to demonstrate the importance of paramagnetic materials for MRI.⁹⁶ Mn^{2+} is capable of replacing the biologically active cation Ca^{2+} and penetrate cells⁹⁷ and has found widespread use in preclinical imaging in manganese enhanced MRI (MEMRI). Mn^{2+} also formed the basis of two FDA approved contrast agents, Teslascan, and

Lumenhance.⁹⁶ Although Mn^{2+} is an important biological metal, exposure to elevated levels has been shown to have neurotoxic effects⁹⁸ attributed to Mn^{2+} being internalized into neuronal cells.⁹⁹⁻¹⁰⁰ These agents have since been discontinued for clinical practice. However, there still remains a large body of work in the literature pertaining to the use of complexes of Mn^{2+} with various hydration numbers *ex vivo* and this comprises the field of MEMRI. This provided us the motivation to study the effect spin locking has on the relaxivity of agents with a variety of hydration numbers for both Gd^{3+} and Mn^{2+} -based chelates.

6.2. Low molecular weight chelates of Gd^{3+} and Mn^{2+} as systems for investigating the effect of q on $r_{1\rho}$

We restricted our investigations to low molecular weight complexes of Gd^{3+} and Mn^{2+} that have approximately the same rotational correlation time (τ_R). This allowed the effect on relaxivity of the hydration numbers of the complexes to be studied independent of the influence of τ_R , particularly at high fields where τ_R is non-limiting. Gd^{3+} and Mn^{2+} have nine and six coordination sites respectively and the hydration number of their complexes is dependent on the number of chelating atoms on the ligand. Chelates of Gd^{3+} and Mn^{2+} were prepared with a variety of hydration numbers (Figure 6.1) and their laboratory and rotating frame relaxivities compared over a range of low and high B_0 field strengths, 0.47 (20 MHz) – 14.1 T (600 MHz), at 25 °C.

	Hydration state, q	
	Gd^{3+}	Mn^{2+}
H_6TTHA 3,6,9,12-tetrakis(carboxymethyl)-3,6,9,12-tetraazatetradecanedioic acid	0	n.a.
H_5DTPA 2,2',2'',2''',2''''-(1,2-ethanediyl)nitri]pentaacetic acid	1	n.a.
H_4EDTA 2,2',2'',2''''-(1,2-ethanediyl)dinitri]tetraacetic acid	n.a.	0
Cl^- Chloride	9	6

Figure 6.1: Ligands for the preparation of low molecular weight Gd^{3+} and Mn^{2+} chelates with a variety of hydration numbers.

6.3. Effect of γB_1 on $R_{1\rho}$ for MnCl_2 at low B_0 field strengths

Unlike the Gd^{3+} metal ion, the Mn^{2+} ion induces a chemical shift with characteristically broad line-widths.¹⁰¹ However, with no ligand field stabilization Mn^{2+} complexes are

extremely labile and water exchange is rapid, leading to very large laboratory frame transverse relaxation rate constant (R_{2M}). Therefore it is hypothesized that the condition invoked by the use of Gd^{3+} chelates, i.e. $R_{2M} \gg \Delta\omega_M^2$, (Equation 3.3) that renders the rotating frame longitudinal relaxation rate constant ($R_{1\rho}$) independent of the spin locking field strength (γB_1), will hold true for Mn^{2+} chelates. If true, it will again allow the value of γB_1 to be neglected when comparing rotating frame relaxivities of Mn^{2+} -based CAs across several B_0 fields. Therefore, we investigated the effect of γB_1 on $R_{1\rho}$ using a 5 mM solution of MnCl_2 in PBS pH 7.4 at 20 MHz (0.47 T) and 25 °C. The strength of the spin locking field (γB_1) was modulated by attenuating the power. The Rabi frequencies expressed in kHz (ω_1) that characterize γB_1 over the attenuation range sampled corresponded to 1.1 – 55.4 kHz and the results are shown in Figure 6.2.

It can clearly be seen that $R_{1\rho}$ is unaffected across almost the entire range of Rabi frequencies sampled. Only when the γB_1 is <1.5 kHz does the mean $R_{1\rho}$ value begin to change, decreasing as γB_1 tends to zero, which as shown by Equation 6.1, where; $R_{1\rho}^0$ defines the lower power limit ($\omega_1 \rightarrow 0$) effect on $R_{1\rho}$ – again from the work of Jordan and co-workers,⁶⁸ but also explained by others^{63, 102} – and should tend to R_2 values.

$$R_{1\rho}^0 = R_{2W} + \frac{q[M]}{55.6} \frac{1}{\tau_M} \left\{ \frac{R_{2m}(R_{2M} + 1/\tau_M) + \Delta\omega_m^2}{(R_{2M} + 1/\tau_M)^2 + \Delta\omega_m^2} \right\} = R_2 \quad (6.1)$$

It is noteworthy that in comparison to the data for the Gd^{3+} -based CAs at 20 MHz and 25 °C (Figure 3.1a and 3.1c for ProHance and Magnevist respectively) the data for MnCl_2

have much lower associated errors, and effective spin locking occurred at lower powers. The reduced spin lock field strength required to effectively lock the spins of MnCl_2 is a consequence of narrower line-widths for the signal, a result of a much lower sample concentration employed due to the potency of MnCl_2 at effecting relaxation rates.

It follows from these experiments that in order to generate accurate and precise $R_{1\rho}$ data, useful for creating NMRD profiles, effective spin locking must occur. From this data this appears to occur with a minimum spin locking field strength (γB_1) of ~ 5 kHz, again an unrealistic value as a consequence of the likely incorrect pulse duration obtained from the minispec instrument, *vide supra*.

Under conditions of effective spin locking, the rotating frame relaxivity of Mn^{2+} -based chelates is largely independent of the strength of the spin locking field, as was the case for Gd^{3+} -based CAs. This suggests that the Mn^{2+} -bound water laboratory frame transverse relaxation rate constant must therefore be significantly larger than the chemical shift difference between the metal bound and bulk water protons induced by Mn^{2+} (*i.e.* $R_{2M} \gg \Delta\omega_M^2$). As such, this allows for the comparison of rotating frame longitudinal relaxivities of Mn^{2+} -based chelates across several B_0 fields without consideration of the effect of the spin locking pulse strength.

Figure 6.2: The dependence of the water proton rotating frame longitudinal relaxation rate constant ($R_{1\rho}$) on the strength of the spin locking field (γB_1) for a 5 mM MnCl_2 solution in PBS at 25 °C and 20 MHz. Data shown are the mean of six measurements; the error bars represent the SD of the data. Note: γB_1 values calculated from a 90° pulse duration reported from the minispec instrument. These values are surprisingly large and suggest the the pulse duration reported is incorrect.

6.4. A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame NMRD for low molecular weight Gd^{3+} and Mn^{2+} agents as a function of hydration number (q)

Laboratory (r_1) and rotating ($r_{1\rho}$) frame relaxivities for low molecular weight chelates of Gd^{3+} and Mn^{2+} with a variety of hydration number prepared in this study were determined over a range of B_0 field strengths and their NMRD profiles generated.

6.4.1. A comparison of r_1 and $r_{1\rho}$ for low molecular weight non-bulky Gd^{3+} complexes

The laboratory frame relaxivities of GdTTHA^{3-} ($q = 0$), GdDTPA ($q = 1$) and GdCl_3 ($q = 9$) follow a similar trend to those observed for clinical Gd^{3+} -based CAs (Figure 6.3) in

that r_1 decreases as B_0 increases, and increases as the hydration number increases. By applying a spin lock pulse, rotating frame relaxivities were again larger than the laboratory frame relaxivities at all field strengths measured (0.47 – 14.1 T, 20 – 600 MHz), increased as a function of increasing hydration number and decreased as B_0 increased. It was observed for all three agents that, again, the rotating frame relaxivity decreased slightly less rapidly than in the laboratory frame. As with clinical agents, the gain in relaxivity for each chelate by employing a spin locking pulse is fairly modest, showing an increase in relaxivity by a factor of just 1.10 at 0.47 T for GdTTHA³⁻, a $q = 0$ complex, rising to 1.35 at 14.1 T for GdDTPA, a $q = 1$ complex (Table 6.1). The magnitude of the increase in relaxivity by applying a spin locking pulse is again not necessarily proportional to the magnitude of the laboratory frame relaxivity. This can be seen from the data for the $q = 9$ chelate GdCl₃ at 14.1 T which increases from 10.7 to 13.1 mM⁻¹ s⁻¹ a factor of only 1.22 compared to 1.35 for GdDTPA (Table 6.1). Moreover, as predicted by SBM theory (Equation 1.9), at all field strengths studied the laboratory frame relaxivity increases as the hydration number increases. This was also observed for the rotating frame relaxivities.

6.4.2. A comparison of r_1 and $r_{1\rho}$ for low molecular weight Mn^{2+} complexes

The laboratory frame relaxivities of MnEDTA ($q = 0$) and MnCl₂ ($q = 6$) follow a similar trend to those observed for Gd³⁺ complexes (Figure 6.4) in that r_1 decreases as B_0 increases, and increases as the hydration number increases. By applying a spin lock pulse, rotating frame relaxivities were again larger than the laboratory frame relaxivities

at all field strengths measured (0.47 – 14.1 T, 20 – 600 MHz) and also increased as a function of increasing hydration number. However, the relaxivities in the rotating frame for both Mn^{2+} complexes increase on moving to higher B_0 fields rather than decrease as for r_1 and the Gd^{3+} analogues. By applying a spin lock pulse the relaxivity of MnEDTA, a $q = 0$ complex, increases from $4.07 \text{ mM}^{-1} \text{ s}^{-1}$ to $13.60 \text{ mM}^{-1} \text{ s}^{-1}$ at 0.47 T and 25 °C (a factor of 3.34).

Figure 6.3: NMRD profiles of low molecular weight chelates of Gd^{3+} with varying hydration numbers studied herein at 25 °C in H_2O : laboratory frame data (r_1) are presented in red (closed symbols); and rotating frame data ($r_{1\rho}$) are presented in blue (open symbols); $\omega_1 = 35 \text{ kHz}$ (0.47 and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). GdTTTHA^{3-} , $q = 0$, (squares); GdDTPA , $q = 1$, (diamonds); GdCl_3 , $q = 9$, (circles). Lines through the data are to guide the eye only. Data shown are the mean of six measurements; error bars representing the SD of the data were omitted for clarity, all were smaller than the markers.

Table 6.1: Raw r_1 and $r_{1\rho}$ data at 25 °C used to generate the NMRD above for the low molecular weight non-bulky Gd^{3+} complexes studied herein at low and high field and their calculated ratios. Mean represents the average difference for the specified category of agents.

			0.47 T		$r_{1\rho}/r_1$	1.41 T		$r_{1\rho}/r_1$
			r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)		r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)	
25 °C	Low MW Gd^{3+} chelates	GdTTTHA³⁻ (q = 0)	2.45	2.70	1.10	2.13	2.40	1.13
		GdDTPA (q = 1)	5.06	6.07	1.20	4.33	5.59	1.29
		GdCl₃ (q = 9)	12.72	14.36	1.13	10.20	12.20	1.20
		Mean			1.14			1.21
			9.4 T		$r_{1\rho}/r_1$	14.1 T		$r_{1\rho}/r_1$
			r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)		r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)	
25 °C	Low MW Gd^{3+} chelates	GdTTTHA³⁻ (q = 0)	1.10	1.30	1.18	0.95	1.27	1.34
		GdDTPA (q = 1)	4.21	5.91	1.40	4.18	5.65	1.35
		GdCl₃ (q = 9)	10.6	13.1	1.24	10.7	13.1	1.22
		Mean			1.27			1.30

At 14.1 T and 25 °C the increase is from $3.04 \text{ mM}^{-1} \text{ s}^{-1}$ to $41.3 \text{ mM}^{-1} \text{ s}^{-1}$ (a factor of 13.6) (Table 6.2). More substantial gains in relaxivity were observed for the $q = 6 \text{ MnCl}_2$ complex. At 0.47 T and 25 °C the relaxivity increased from $6.85 \text{ mM}^{-1} \text{ s}^{-1}$ in the laboratory frame to $38.26 \text{ mM}^{-1} \text{ s}^{-1}$ in the rotating frame (a factor of 5.59). But, at 14.1 T and 25 °C the increases was a factor of 31.1 going from $4.99 \text{ mM}^{-1} \text{ s}^{-1}$ in the laboratory frame to $155 \text{ mM}^{-1} \text{ s}^{-1}$ in the rotating frame! This is by far the highest relaxivity ever observed for a discrete metal complex at such a high magnetic field. Like clinical Gd^{3+} -based CA, these complexes are in the fast exchange regime. As such the relaxivities of MnCl_2 , for example, decrease when the temperature is increased.

In 1984 Keonig and Brown reviewed the implications for NMR imaging (MRI) of solvent proton relaxation by paramagnetic solutes and its dependence on magnetic field and chemical environment.¹⁰³ In that paper the dependence on magnetic field of $1/T_1$ (R_1) and $1/T_2$ (R_2) of water protons for aqueous solutions of several transition metal ions, including Mn^{2+} , were determined (Figure 6.5). SBM theory that explains the field dependence of $1/T_1$ can also be applied to describe $1/T_2$. The normalized r_1 and r_2 NMRD profiles for Mn^{2+} were shown to be unique from each other and also amongst the other ions analyzed. At low fields ($< \sim 1 \text{ MHz}$) r_1 and r_2 values for all ions except Mn^{2+} are essentially independent of field strength and follow the same trend, however, for Mn^{2+} ions an inflection at this point is observed with the relaxivities increasing substantially as B_0 decreases towards 0.01 MHz.

Figure 6.4: NMRD profiles of low molecular weight Mn^{2+} chelates with varying hydration numbers, MnEDTA (triangles) = 0, MnCl_2 (circles) = 6, studied herein at 25 °C (open symbols) and 37 °C (closed symbols) in H_2O . Laboratory (r_1) and rotating frame ($r_{1\rho}$) frame data are presented in red and blue respectively. $\omega_1 = 35$ kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 Hz (9.4 and 14.1 T respectively). Lines through the data are to guide the eye only. Data shown are the mean of six measurements; error bars representing the SD of the data were omitted for clarity, all were smaller than the markers.

At high fields the trend in r_1 for all ions, including Mn^{2+} , are comparable and differ only by the ratio $T_1/T_2 = 3.5/3$. An inflection occurs at around 3 MHz and the relaxivities decrease as B_0 increases. As B_0 increases up to ~ 10 MHz, r_2 for Mn^{2+} follows the same trend as for r_1 , albeit with larger values. However, at higher B_0 values r_2 rapidly and substantially increases.

CHAPTER 6. Effect of q on $r_{1\rho}$ **Table 6.2:** Raw r_1 and $r_{1\rho}$ data at 25 and 37 °C used to generate the NMRD above for the low molecular weight Mn^{2+} complexes studied herein at low and high field and their calculated ratios.

			0.47 T		$r_{1\rho}/r_1$	1.41 T		$r_{1\rho}/r_1$
			r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)		r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)	
25 °C	Low MW Mn^{2+} chelates	MnEDTA ($q = 0$)	4.07	13.60	3.34	3.18	20.68	6.50
		MnCl₂ ($q = 6$)	6.85	38.26	5.59	5.40	58.89	10.91
37 °C	Low MW Mn^{2+} chelates	MnCl₂ ($q = 6$)	5.88	35.30	6.00	4.38	50.70	11.58
			9.4 T		$r_{1\rho}/r_1$	14.1 T		$r_{1\rho}/r_1$
			r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)		r_1 ($\text{mM}^{-1}\text{s}^{-1}$)	$r_{1\rho}$ ($\text{mM}^{-1}\text{s}^{-1}$)	
25 °C	Low MW Mn^{2+} chelates	MnEDTA ($q = 0$)	3.14	38.1	12.1	3.04	41.3	13.6
		MnCl₂ ($q = 6$)	5.05	143	28.3	4.99	155	31.1
37 °C	Low MW Mn^{2+} chelates	MnCl₂ ($q = 6$)	3.73	98.8	26.5	3.66	108	29.5

Unlike the other transition metal ions studied, and Gd^{3+} ions/chelates, Mn^{2+} has a large contribution to relaxation from scalar coupling.¹⁰⁴ This is a result of a widely delocalized electronic wave function for hydrated Mn^{2+} ions such that the electron spin momenta has a greater interaction with the bound water protons. Although the scalar interaction is small compared to the dipole-dipole interaction, the contribution to the NMRD profile is large due to a 100-fold difference in their correlation times. The characteristic r_1 and r_2 NMRD profiles for Mn^{2+} ions are a consequence of this same phenomena.

Figure 6.5: r_1 NMRD profiles of aqueous solutions of transition metal ions at 35 °C scaled by the value of $S(S + 1)$ where S is their spin quantum number. The solid lines through the data are a result of a least-squares fitting of the data with well established theory appropriate to the solutions. r_2 profiles are not shown for any other ion except Mn^{2+} since they would be similar to r_1 . Mn^{2+} r_2 values (dotted line) were derived from theory and supported by experiment.

Since a spin locking pulse incorporates a component of laboratory frame transverse relaxation (R_{2M}) that is especially sensitive to the scalar contribution as described above this explains the exceptionally high rotating frame relaxivities obtained herein for our Mn^{2+} chelates.

6.5. *Conclusions*

Only modest gains in relaxivity were measured for the low molecular weight Gd^{3+} chelates by spin locking and the values decrease as B_0 increases as has been observed previously herein for the structurally similar clinical Gd^{3+} -based CAs. However, very large gains were observed for Mn^{2+} agents at all fields and increases as B_0 increases due to their unique magnetic properties. Moreover, the results demonstrate that relaxivity in the rotating frame scales proportionally with q. We demonstrated that in the rotating frame relaxivity lost on moving to higher B_0 field strengths was able to be “recovered” across all B_0 field strengths studied and for all hydration numbers (q) of Gd^{3+} and Mn^{2+} studied.

It has clearly been demonstrated that by combining the spin locking technique with such Mn^{2+} agents the potential exists to increase detection limits dramatically. This approach may prove to be most useful in ex vivo or in vivo animal model studies where the known stability and toxicity problems associated with these agents is a lesser concern. Such experiments would contribute to the field of Manganese Enhanced MRI (MEMRI), a growing area of research accelerated by recent safety concerns of clinical Gd^{3+} -based agents.¹⁰⁵⁻¹⁰⁶

CHAPTER 7. EXPERIMENTAL SECTION

7.1. Reagents and solvents

All reagents were purchased from commercially available sources unless otherwise noted. Type I water (18.2 MOhm·cm) was used for the preparation of all solutions of contrast media and phosphate buffered saline. Phosphate buffered saline (PBS) pH 7.4 (50 mM phosphate buffer with 15 mM NaCl) was prepared by combining 1 M aqueous sodium dihydrogenorthophosphate solution (7.6 mL), 1 M aqueous disodium hydrogenorthophosphate heptahydrate solution (42.4 mL) and 5 M aqueous sodium chloride solution (30.0 mL) and diluting to 2 L with water.

7.2. Instrumentation

Relaxation time constants were determined at low field using Bruker Minispec desktop relaxometers operating at fixed fields of 20 MHz (0.47 T) and 60 MHz (1.41 T) using a 2 mm broad-band probe with the temperature controlled using the installed Julabo F25-ED variable-temperature controller. High field relaxation time constants were determined using Bruker Avance IIa and III NMR spectrometers operating at 400.13 MHz (9.4 T) and 599.92 MHz (14.1 T), respectively. Both high field spectrometers were installed with 5 mm broad-band probes and the temperature was controlled using the installed variable-temperature controller model 2416 with BCU-05 chiller.

7.3. *Pulse sequences*

7.3.1. Inversion recovery pulse sequence

The factory installed inversion recovery pulse sequence was used throughout, this comprises: 180° inversion pulse – τ variable pulse delay – 90° excitation pulse – acquisition of FID.

7.3.2. Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence

The factory installed CPMG pulse sequence was used throughout, this comprises: 90° excitation pulse – τ variable pulse delay – 180° (n) refocusing pulses – acquisition of FID.

7.3.3. Spin locking pulse sequence

The factory installed spin locking pulse sequence was used throughout, this comprises: 90° excitation pulse – τ variable spin locking pulse duration – acquisition of FID.

7.4. *Fitting*

All rate constant data acquired at 0.47 and 1.41 T were analyzed using the factory installed fitting routine. All rate constant data acquired at 9.4 and 14.1 T were fitted off-line using a least squares fitting routine in Excel to Equations 1.12 (T_1 data), 1.13 (T_2 data) and 1.24 ($T_{1\rho}$).

7.5. Contrast media stock solution preparations

7.5.1 Clinical Gd^{3+} -based contrast agents

Seven of the nine clinically available Gd^{3+} -based contrast agents were studied. Three were macrocyclic chelates: gadoterate meglumine (Dotarem, 500 mM), gadoteridol (ProHance, 500 mM), gadobutrol (Gadavist, 1000 mM). Four were linear chelates: of which two were low molecular weight: gadopentetate dimeglumine (Magnevist, 500 mM) and gadodiamide (Omniscan, 500 mM); and two incorporated bulky substituents: gadobenate dimeglumine (MultiHance, 500 mM) and gadofosveset trisodium (Ablavar, 250 mM). All were obtained and studied in their clinical formulations and used as stock solutions. Gadoversetamide (Optimark) and gadoxetate disodium (Eovist/Primovist) were not studied given the structural similarities between these agents and gadodiamide (Omniscan) and gadobenate (MultiHance), respectively and the likelihood of identical or similar results for these two pairs. All contrast media were purchased from commercial sources with the exception of gadoterate which was a gift from Guerbet s.a.

7.5.2 $GdCl_3$

Approximately 5 mL of concentrated HCl (12.1 M) was added to a small quantity of Gd_2O_3 to dissolve. The solvent was evaporated by heating at 60 – 80 °C with stirring for several hours. Several subsequent small aliquots (1 – 2 mL) of HCl (12.1 M) were added and solvent evaporated in the same manner. After the final evaporation of solvent a

white crystalline product of GdCl_3 was afforded and used 'as is'. A stock solution of GdCl_3 (109.5 mM) was prepared by dissolving GdCl_3 (577.0 mg) in water (20 mL).

7.5.3. MnCl_2

A stock solution of MnCl_2 (~120 mM) was prepared by dissolving MnCl_2 (0.72 mmol, 0.091 g) in water (6 mL). The actual MnCl_2 concentration of this solution was determined by relaxometry (20 MHz and 25 °C). For this, the laboratory frame longitudinal relaxation rate constant for the stock solution and a series of dilute aqueous solutions were determined. Linear regression analysis of the experimental data using the least squares method and the known relaxivity for this agent under similar conditions ($7.44 \text{ mM}^{-1} \text{ s}^{-1}$)¹⁰³ using the solver function in Excel afforded the actual concentration of the stock solution (131.3 mM).

7.5.4. GdTTHA^{3-}

A stock solution of GdTTHA^{3-} (~50 mM) was prepared by dissolving GdCl_3 (0.5161 mmol, 0.1918 g) and H_6TTHA (0.5485 mmol, 0.2712 g) in a small volume of water (~3 mL), adjusting the pH to ~5 with dilute solutions of NaOH/HCl and diluting to ~20 mL with water prior to freeze drying the solution and re-dissolving the GdTTHA^{3-} in PBS pH 7.4 (10 mL). The actual GdTTHA^{3-} concentration of this solution was determined by relaxometry (20 MHz and 25 °C). For this, the laboratory frame longitudinal relaxation rate constant for a series of dilute solutions of GdTTHA^{3-} in PBS pH 7.4 were determined. Linear regression analysis of the experimental data using the least squares

method and the known relaxivity for this agent under identical conditions ($1.7 \text{ mM}^{-1} \text{ s}^{-1}$)¹⁰⁷ using the solver function in Excel afforded the actual concentration of the stock solution (31.31 mM).

7.5.5. *MnEDTA*

An aqueous stock solution of MnEDTA (56.8 mM) was prepared by mixing MnCl₂ stock solution (3.0 mL, 0.39 mmol) and 100 mM Na₂EDTA (3.938 mL, 0.39 mmol).

7.6. *Working solution preparations and experimental parameters*

7.6.1. *Chapter 2. Effect of pulse sequence parameters on longitudinal (T_1) and rotating ($T_{1\rho}$) frame time constants*

For the purposes of determining the effect pulse sequence parameters have on laboratory and rotating frame relaxation time constants (T_1 and $T_{1\rho}$ respectively) a solution (25 mM) of Dotarem was prepared from the formulated product. Experiments were performed at 25 and 37 °C using a low fixed field Bruker Minispec desktop relaxometer operating at 60 MHz (1.41 T). The factory installed inversion recovery and spin locking pulse sequences were employed. Except where changed for the purpose of the experiment the following pulse sequence parameters were used; inversion recovery pulse sequence; recycle delay = 0.1 s; number of data points = 16; number of averages = 4 and the inversion pulse delay times ranged from 0.2 – 100 ms. Spin locking pulse sequence; recycle delay = 4 s; number of data points = 16; number of averages = 4; spin locking

pulse durations ranged from 2 to 40 ms and the Rabi frequency (ω_1) = 20 kHz.

Relaxation time constants were obtained as single measurement determinations.

7.6.2. Chapter 3. Effect of spin lock field strength (γB_1) on the rotating frame longitudinal relaxation rate constant ($R_{1\rho}$)

For the purposes of B_1 power experiments the rotating frame longitudinal relaxation rate constants ($R_{1\rho}$) were determined for 100 mM solutions of ProHance and Magnevist in PBS (0.47 and 1.41 T) and a 5 mM solution of Dotarem in PBS (14.1 T) prepared from the respective formulated products. The factory installed spin locking pulse sequence was employed with the following pulse sequence parameters; recycle delay = 4 s; number of data points = 16; number of averages = 4; spin locking pulse durations ranged from 2 – 20 ms (0.47 and 1.41 T) and 25 to 800 ms (14.1 T). The Rabi frequency (ω_1) was varied from 1.2 kHz to 55.4 kHz (0.47 and 1.41 T) and 209.6 Hz to 17237 Hz (14.1 T). Relaxation time constants were determined by averaging the values obtained from six measurements for each value of ω_1 .

7.6.3. Chapter 4. A comparison of laboratory (r_1) and rotating ($r_{1\rho}$) frame longitudinal relaxivities for $q = 1$ clinical Gd^{3+} -based CAs

NMRD profiles were generated from laboratory and rotating frame relaxivity determinations of each clinically approved agent (Dotarem, ProHance, Gadavist, Magnevist, Omniscan, MultiHance and Ablavar) in PBS at the four magnetic field strengths studied (0.47, 1.41, 9.4 and 14.1 T). Relaxivities were determined by linear

regression analysis of the longitudinal relaxation rate constant as a function of contrast agent concentration in Excel.

Rotating frame longitudinal relaxation rate constants ($R_{1\rho}$) were determined on five solutions of each contrast agent in PBS varying in concentration from 10 to 25 mM (0.47 and 1.41 T) and 5 to 25 mM (9.4 and 14.1 T) with the exception of Dotarem at 600.13 MHz which was measured on five solutions varying in concentration from 1 to 5 mM solutions. The factory installed spin locking pulse sequence was employed with the following pulse sequence parameters; recycle delay $\geq 10 \times T_1$; number of data points = 16; number of averages = 4; spin locking pulse durations ranged from 2 to 40 ms (0.47 and 1.41 T) and 2.4 – 1600 ms (9.4 and 14.1 T) and the Rabi frequency (ω_1) = 35 kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 kHz (9.4 and 14.1 T respectively).

For purposes of generating laboratory frame NMRD profiles longitudinal relaxation rate constants (R_1) were determined using five solutions varying in concentration from 1 to 5 mM solutions of each contrast agent in PBS. The factory installed inversion recovery pulse sequence was used with the following parameters: Recycle delay $\geq 10 \times T_1$; number of data points = 16; number of averages = 4; inversion pulse delay times ranged from 2 ms to 2500 ms (0.47 and 1.41 T) and 10 ms to 5000 ms (9.4 and 14.1 T). Relaxation time constants were determined by averaging the values obtained from six measurements for each concentration.

7.6.4. Chapter 5. Effect of rotational correlation time (τ_R) on rotating frame longitudinal relaxivity ($r_{1\rho}$)

NMRD profiles were generated from laboratory frame relaxivity determinations of nanoassembled capsules (NACs) prepared at charge ratios (R) of 0.3, 0.5 and 1 in water at the four magnetic field strengths studied (0.47, 1.41, 9.4 and 14.1 T, R = 0.3 only performed at 0.47 T). Rotating frame relaxivity determination for the same samples could only be determined at 9.4 and 14.1 T (R = 0.3 only performed at 14.1 T) due to instrument limitations which limits the maximum spin lock pulse duration to 40 ms, insufficient time to observe complete relaxation with the sample concentration available. NMRD profiles were also generated from the laboratory and rotating frame relaxivity determinations of the free GdDOTP⁵⁻ chelate in water at the four magnetic field strengths studied (0.47, 1.41, 9.4 and 14.1 T). Relaxivities were determined by linear regression analysis of the longitudinal relaxation rate constant as a function of Gd³⁺ concentration in Excel. The aqueous suspension of NACs was mixed thoroughly in the NMR sample tube prior to each experiment and allowed to equilibrate to the set sample temperature for at least 5 minutes. This was repeated for each repetition to minimize errors in the measurement due to settling of the NACs in the tube.

Rotating frame longitudinal relaxation rate constants ($R_{1\rho}$) for NACs were determined on four solutions in water. The concentrations varied between 0.028 – 0.98 mM (9.4 and 14.1 T).

For the free chelate five solutions were used varying in concentration from 10 – 25 mM (0.47 and 1.41 T) and 1 – 5 (9.4 and 14.1 T). The factory installed spin locking pulse sequence was employed with the following pulse sequence parameters; recycle delay $\geq 10 \times T_1$; number of data points = 16; number of averages = 4; spin locking pulse durations for GdDOTP⁵⁻ ranged from 2 – 40 ms with a Rabi frequency (ω_1) = 35 kHz (0.47 and 1.41 T) and 5 – 1500 ms with a Rabi frequency (ω_1) = 6924.2 and 17237.0 kHz (9.4 and 14.1 T respectively). For NACs the spin locking pulse durations ranged from 4 – 400 ms with a Rabi frequency (ω_1) = 6924.2 and 17237.0 kHz (9.4 and 14.1 T respectively). Relaxation time constants were determined by averaging the values obtained from three measurements for each concentration.

Laboratory frame longitudinal relaxation rate constants (R_1) for NACs were determined on four solutions in water. The concentrations varied between 0.028 – 0.73 mM (0.47 and 1.41 T) and 0.22 – 0.98 (9.4 and 14.1 T) whereas for the free chelate five solutions were used varying in concentration from 1 – 5 mM at all four fields studied (0.47, 1.41 9.4 and 14.1 T). The factory installed inversion recovery pulse sequence was used with the following parameters: recycle delay $\geq 10 \times T_1$; number of data points = 16; number of averages = 4; inversion pulse delay times for GdDOTP⁵⁻ ranged from 1 – 4000 ms (0.47 and 1.41 T) and 10 – 5000 ms (9.4 and 14.1 T). For NACs the inversion pulse delay times ranged from 12.5 – 4000 ms (0.47 and 1.41 T) and 10 – 10000 ms (9.4 and 14.1 T). Relaxation time constants were determined by averaging the values obtained from three measurements for each concentration.

7.6.5. Chapter 6. Effect of hydration state (q) on rotating frame longitudinal relaxivity ($r_{1\rho}$)

NMRD profiles were generated from laboratory and rotating frame relaxivity determinations of each chelate investigated (MnEDTA, MnCl₂, GdTTHA³⁻, GdDTPA and GdCl₃) in PBS pH 7.4 at the four magnetic field strengths studied (0.47, 1.41, 9.4 and 14.1 T). Relaxivities were determined by linear regression analysis of the longitudinal relaxation rate constants as a function of contrast agent concentration in Excel.

Rotating and laboratory frame data for GdDTPA (Magnevist) were obtained from previous experiments for which experimental details have been described *vide supra* (7.6.3).

Rotating frame longitudinal relaxation rate constants ($R_{1\rho}$) were determined on five solutions of MnEDTA, MnCl₂ and GdCl₃ varying in concentration from 5 – 25 mM (0.47 and 1.41 T) and 1 – 5 mM (9.4 and 14.1 T) with the exception of GdCl₃ at 14.1 T which was measured from four solutions. GdTTHA³⁻ $R_{1\rho}$ values were obtained from a single point determination with solution concentrations of 80.53 mM (0.47 and 1.41 T) and 4.026 mM (9.4 and 14.1 T). The factory installed spin locking pulse sequence was employed with the following pulse sequence parameters; recycle delay $\geq 10 \times T_1$; number of data points = 16; number of averages = 4. Spin locking pulse durations for MnEDTA, MnCl₂ and GdCl₃ ranged from 0.5 to 40 ms (0.47 and 1.41 T) and 1 – 400 ms (9.4 and 14.1 T) and the Rabi frequency (ω_1) = 35 kHz (0.47 and 1.41 T) and 6924.2 and 17237.0

kHz (9.4 and 14.1 T respectively). For GdTTTHA^{3-} the spin locking pulse durations ranged from 0.5 to 40 ms (0.47 and 1.41 T) and 5 – 1500 ms (9.4 and 14.1 T) and the Rabi frequency (ω_1) = 35 kHz (0.47 and 1.41 T) and 6924.2 and 17237.0 kHz (9.4 and 14.1 T respectively). Relaxation time constants were determined by averaging the values obtained from six measurements (three for GdTTTHA^{3-}) for each concentration.

Laboratory frame longitudinal relaxation rate constants (R_1) were determined on five solutions of MnEDTA, MnCl_2 and GdCl_3 varying in concentration from 1 – 5 mM (0.47, 1.41 T, 9.4 and 14.1 T) with the exception of GdCl_3 14.1 T which was measured from three solutions. GdTTTHA^{3-} R_1 values were obtained from a single point determination with solution concentrations of 80.53 mM (0.47 and 1.41 T) and 4.026 mM (9.4 and 14.1 T). The factory installed inversion recovery pulse sequence was used with the following parameters: recycle delay $\geq 10 \times T_1$; number of data points = 16; number of averages = 4. Inversion pulse delay times for MnEDTA, MnCl_2 and GdCl_3 ranged from 1 – 5000 ms (0.47 and 1.41 T) and 6 – 6600 ms (9.4 and 14.1 T). For GdTTTHA^{3-} the inversion pulse delay times ranged from 1 – 5000 ms (0.47 and 1.41 T) and 10 – 3000 ms (9.4 and 14.1 T). Relaxation time constants were determined by averaging the values obtained from six measurements (three for GdTTTHA^{3-}) for each concentration.

COMPLETE LIST OF REFERENCES

- (1) Rabi, I. I.; Zacharias, J. R.; Millman, S.; Kusch, P., A New Method of Measuring Nuclear Magnetic Moment. *Phys Rev* **1938**, 53 (4), 318-327.
- (2) Purcell, E. M.; Torrey, H. C.; Pound, R. V., Resonance absorption by nuclear magnetic moments in a solid. *Phys Rev* **1946**, 69, 37-38.
- (3) Bloch, F.; Hansen, H. H.; Packard, M., Nuclear Induction. *Physical Review* **1946**, 69, 127.
- (4) Lauterbur, P. C., Image Formation by Induced Local Interactions: Examples of Employing Nuclear Magnetic Resonance. *Nature* **1973**, 242 (5394), 190-191.
- (5) Mansfield, P.; Maudsley, A. A., Medical imaging by NMR. *Br J Radiol* **1977**, 50, 188-194.
- (6) Damadian, R.; Goldsmith, M.; Minkoff, L., NMR in cancer: XVI. Fonar image of live human-body. *Physiol Chem Phys* **1977**, 9 (108), 97-100.
- (7) Blamire, A. M., The technology of MRI – the next 10 years? . *Br J Radiol* **2008**, 81, 601–617.
- (8) 2007 MRI Market Summary Report. IMV, Ltd.: 2007.
- (9) Kwong, R. Y.; Yucel, E. K., Cardiology patient pages. Computed tomography scan and magnetic resonance imaging. *Circulation* **2003**, 108, 104-106.
- (10) Tatlisumak, T., Is CT or MRI the method of choice for imaging patients with acute stroke? Why should men divide if fate has united? *Stroke* **2002**, 33, 2144-2145.
- (11) Gupta, R. T.; Kauffman, C. R.; Polascik, T. J.; Taneja, S. S.; Rosenkrantz, A. B., The state of prostate MRI in 2013. *Oncology-Ny* **2013**, 27, 262-270.
- (12) Li, X.; Priest, R. A.; Woodward, W. J.; Siddiqui, F.; Beer, T. M.; Garzotto, M. G.; Rooney, W. D.; Jr, C. S. S., Cell membrane water exchange effects in prostate DCE-MRI. *Journal of Magnetic Resonance* **2012**, 218, 77-85.
- (13) Li, X.; Priest, R. A.; Woodward, W. J.; Tagge, I. J.; Siddiqui, F.; Huang, W.; Rooney, W. D.; Beer, T. M.; Garzotto, M. G.; Jr, C. S. S., Feasibility of shutter-speed

DCE-MRI for improved prostate cancer detection. *Magnetic Resonance in Medicine* **2013**, *69*, 171-178.

(14) Rooney, W. D.; Johnson, G.; Li, X.; Cohen, E. R.; Kim, S.-G.; Ugurbil, K.; Springer Jr, C. S., Magnetic Field and Tissue Dependencies of Human Brain Longitudinal $^1\text{H}_2\text{O}$ Relaxation in Vivo. *Magnetic Resonance in Medicine* **2007**, *57*, 308–318.

(15) Tieleman, A.; Vandemaele, P.; Seurinck, R.; Deblaere, K.; Achten, E., Comparison between functional magnetic resonance imaging at 1.5 and 3 tesla - effect of increased field strength on 4 paradigms used during presurgical work-up. *Invest Radiol* **2007**, *42*, 130-138.

(16) Levitt, M. H., *Spin Dynamics: Basics of Nuclear Magnetic Resonance*. Second ed.; John Wiley & Sons Ltd: United Kingdom, 2008.

(17) Vold, R. L.; Waugh, J. S.; Klein, M. P.; Phelps, D. E., Measurement of spin relaxation in complex systems. *J Chem Phys* **1968**, *48*, 3831-3832.

(18) Meiboom, S.; Gill, D., Modified spin-echo method for measuring nuclear relaxation times. *Rev Sci Instr* **1958**, *29* (8), 688-691.

(19) Carr, H. Y.; Purcell, E. M., Effects of diffusion on free precession in nuclear magnetic resonance experiments. *Phys Rev* **1954**, *94* (3), 630-638.

(20) Fletcher, L. M.; Barsotti, J. B.; Hornak, J. P., A Multispectral Analysis of Brain Tissues. *Magn. Reson. Med.* **1993**, *29*, 623-630.

(21) Hammer, M. MRI Physics: Tissue Contrast in MRI. <http://www.xrayphysics.com/> (accessed 05/15/2015).

(22) Aime, S.; Botta, M.; Fasano, M.; Terreno, E., Lanthanide(III) chelates for NMR biomedical applications. *Chemical Society Reviews* **1998**, *27*, 19-29.

(23) Woods, M.; Zhang, S.; Kovacs, Z.; Sherry, D., Advances in the design of responsive and targeted lanthanide complexes as diagnostic and therapeutic agents. *Advances in Supramolecular Chemistry* **2003**, *9*, 1-38.

- (24) Woods, M.; Zhang, S.; Dean, S., Toward the design of MR agents for imaging β -cell function. *Current Medicinal Chemistry: Immunology, Endocrine & Metabolic Agents* **2004**, *4* (4), 349-369.
- (25) Woods, M.; Woessner, D. E.; Sherry, D., Paramagnetic lanthanide complexes as PARACEST agents for medical imaging. *Chem Soc Rev* **2006**, *35* (6), 500-511.
- (26) Sherry, D.; Zhang, S.; Woods, M., Water exchange is the key parameter in the design of next-generation MRI agents. *Medicinal Inorganic Chemistry* **2005**, *903* (151-165).
- (27) Kalman, F. K.; Woods, M.; Caravan, P.; Jurek, P.; Spiller, M.; Tircso, G.; Kiraly, R.; Brucher, E.; Sherry, D., Potentiometric and Relaxometric Properties of a Gadolinium-Based MRI Contrast Agent for Sensing Tissue pH. *Inorg. Chem.* **2007**, *46*, 5260-5270.
- (28) Caravan, P.; Ellison, J.; McMurray, T. J.; Lauffer, R. B., Gadolinium(III) Chelates as MRI Contrast Agents: Structure, Dynamics, and Applications. *Chem Rev* **1999**, *99*, 2293-2352.
- (29) Burtea, C.; Laurent, S.; Elst, L. V.; Muller, R. N., Contrast Agents: Magnetic Resonance. In *Handbook of Experimental Pharmacology*, W, S.; M, S., Eds. Springer-Verlag: Berlin, 2008; Vol. 185, pp 135-165.
- (30) Lauffer, R. B., Paramagnetic Metal Complexes as Water Proton Relaxation Agents for NMR Imaging: Theory and Design. *Chem Rev* **1987**, *87*, 901-927.
- (31) Pascolo, L.; Cupelli, F.; Anelli, P. L.; Lorusso, V.; Visigalli, M.; Uggeri, F.; Tiribelli, C., Molecular Mechanisms for the Hepatic Uptake of Magnetic Resonance Imaging Contrast Agents. *Biochem Biophys Res Commun* **1999**, *257*, 746-752.
- (32) Aime, S.; Caravan, P., Biodistribution of gadolinium-based contrast agents, including gadolinium deposition. *J Magn Reson Imaging* **2009**, *30* (6), 1259 - 1267.
- (33) Rohrer, M.; Bauer, H.; Mintorovitch, J.; Requardt, M.; Weinmann, H. J., Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. *Invest. Radiol* **2005**, *40*, 715-724.

- (34) Erno, B.; Dean, S., Stability and toxicity of contrast agents. The chemistry of contrast agents in medical magnetic resonance imaging. Merbach, A. E.; Toth, E., Eds. John Wiley and Sons Ltd: New York, 2001; Vol. 243, pp 243-278.
- (35) Raymond, K. N.; Pierre, V., Next Generation, High Relaxivity Gadolinium MRI Agents. *Bioconjugate Chem* **2005**, *16*, 3-8.
- (36) Tweedle, M. F.; Wedeking, P.; Kumar, K., Biodistribution of radiolabeled, formulated gadopentetate, gadoteridol, gadoterate, and gadodiamide in mice and rats. . *Invest Radiol* **1995**, *30*, 372-380.
- (37) Wedeking, P.; Kumar, K.; Tweedle, M. F., Dose-dependent biodistribution of [^{153}Gd]Gd(acetate)_n in mice. . *Nucl Med Biol*. **1993**, *20*, 679-691.
- (38) Wedeking, P.; Kumar, K.; Tweedle, M. F., Dissociation of gadolinium chelates in mice: relationship to chemical characteristics. . *Magn Reson Imaging* **1992**, *10*, 641-648.
- (39) Gibby, W. A.; Gibby, K. A.; Gibby, W. A., Comparison of Gd DTPA-BMA (Omniscan) versus Gd HPDO3A (ProHance) retention in human bone tissue by inductively coupled plasma atomic emission spectroscopy. . *Invest Radiol* **2004**, *39*, 138-142.
- (40) White, G. W.; Gibby, W. A.; Tweedle, M. F., Comparison of Gd(DTPA-BMA) (Omniscan) versus Gd(HP-DO3A) (ProHance) relative to gadolinium retention in human bone tissue by inductively coupled plasma mass spectroscopy. *Invest Radiol* **2006**, *41*, 272-278.
- (41) Wedeking, P.; Tweedle, M., Comparison of the biodistribution of ^{153}Gd -labeled Gd(DTPA)²⁻, Gd(DOTA)⁻, and Gd(acetate)_n in mice. *Int J Rad Appl Instrum B* **1988**, *15*, 395-402.
- (42) Solomon, I., Relaxation processes in a system of two spins. *Phys Rev* **1955**, *99*, 559-565.
- (43) Solomon, I.; Bloembergen, N., Nuclear magnetic interaction in the HF molecules. *J Chem Phys* **1956**, *25*, 261-266.
- (44) Bloembergen, N., Proton relaxation times in paramagnetic solutions. *J Chem Phys* **1957**, *27*, 572-573.

- (45) Bloembergen, N.; Morgan, L. O., Proton relaxation times in paramagnetic solutions. Effects of electron spin relaxation. *J Chem Phys* **1961**, *34*, 842-850.
- (46) Freed, J. H., Dynamic effects of pair correlation functions on spin relaxation by translational diffusion in liquids. II. Finite jumps and independent T_1 processes. *J Chem Phys* **1978**, *68*, 4034-4037.
- (47) Anderson, A. G.; Redfield, A. G., Nuclear spin-lattice relaxation in metals. *Physical Review* **1959**, *116*, 583-591.
- (48) Rooney, W. D.; Johnson, G.; Li, X.; Cohen, E. R.; Kim, S.-G.; Ugurbil, K.; Springer, C. S., Jr., Magnetic field and tissue dependencies of human brain longitudinal $^1\text{H}_2\text{O}$ relaxation in vivo. *Magn. Reson. Med.* **2007**, *57* (2), 308-318.
- (49) Lauffer, R. B., Paramagnetic metal complexes as water proton relaxation agents for NMR imaging: theory and design. *Chem. Rev.* **1987**, *87* (5), 901-27.
- (50) Powell, D. H.; Dhubhghaill, O. M. N.; Pubanz, D.; Helm, L.; Lebedev, Y. S.; Schlaepfer, W.; Merbach, A. E., High-pressure NMR kinetics. Part 74. Structural and Dynamic Parameters Obtained from ^{17}O NMR, EPR, and NMRD Studies of Monomeric and Dimeric Gd^{3+} Complexes of Interest in Magnetic Resonance Imaging: An Integrated and Theoretically Self-Consistent Approach. *J Am Chem Soc* **1996**, *118* (39), 9333-9346.
- (51) Caravan, P., Strategies for increasing the sensitivity of gadolinium based MRI contrast agents. *Chemical Society Reviews* **2006**, *35*, 512-523.
- (52) Cacheris, W. P.; Quay, S. C.; Rocklage, S. M., The Relationship between Thermodynamics and the Toxicity of Gadolinium Complexes. *Magn. Reson. Imaging* **1990**, *8*, 467-481.
- (53) Dickins, R. S.; Aime, S.; Batsanov, A. S.; Beeby, A.; Botta, M.; Bruce, J. I.; Howard, J. A. K.; Love, C. S.; Parker, D.; Peacock, R. D.; Puschmann, H., *J. Am. Chem. Soc.* **2002**, *124*, 12697-12705.
- (54) Datta, A.; Raymond, K. N., Gd-Hydroxypyridinone (HOPO)-Based High-Relaxivity Magnetic Resonance Imaging (MRI) Contrast Agents. *Accounts of Chemical Research* **2009**, *42*, 938-947.

- (55) Aime, S.; Calabi, L.; Cavallotti, C.; Gianolio, E.; Giovenzana, G. B.; Losi, P.; Maiocchi, A.; Palmisano, G.; Sisti, M., [Gd-AAZTA]⁻: A New Structural Entry for an Improved Generation of MRI Contrast Agents. *Inorganic Chemistry* **2004**, *43*, 7588-7590.
- (56) Tóth, E. v.; Helm, L.; Merbach, A. E., Wiley: New York, 2001; p 45.
- (57) Terreno, E.; Castelli, D. D.; Viale, A.; Aime, S., Challenges for molecular magnetic resonance imaging. *Chem Rev* **2010**, *110*, 3019-3042.
- (58) Werner, E. J.; Datta, A.; Jocher, C. J.; Raymond, K. N., High-relaxivity MRI contrast agents: where coordination chemistry meets medical imaging. *Angewandte Chemie International Edition* **2008**, *47*, 8568-8580.
- (59) Benmelouka, M.; Borel, A.; Moriggi, L.; Helm, L.; Merbach, A. E., Design of Gd(III)-Based Magnetic Resonance Imaging Contrast Agents: Static and Transient Zero-Field Splitting Contributions to the Electronic Relaxation and Their Impact on Relaxivity. *The Journal of Physical Chemistry B* **2007**, *111*, 832-840.
- (60) Senn, F.; Helm, L.; Borel, A.; Daul, C. A., Electronic fine structure calculation of [Gd(DOTA)(H₂O)]⁻ using LF-DFT: The zero field splitting. *Comptes Rendus Chimie* **2012**, *15*, 250-254.
- (61) Powell, D. H.; Ni Dhubhghaill, O. M.; Pubanz, D.; Helm, L.; Lebedev, Y. S.; Schlaepfer, W.; Merbach, A. E., High-pressure NMR kinetics. Part 74. Structural and Dynamic Parameters Obtained from ¹⁷O NMR, EPR, and NMRD Studies of Monomeric and Dimeric Gd³⁺ Complexes of Interest in Magnetic Resonance Imaging: An Integrated and Theoretically Self-Consistent Approach. *J. Am. Chem. Soc.* **1996**, *118* (39), 9333-9346.
- (62) Redfield, A. G., Nuclear magnetic resonance saturation and rotary saturation in solids. *Phys Rev* **1955**, *98*, 1787-1809.
- (63) Sepponen, R. E.; Pohjonen, J. A.; Sipponen, J. T.; Tanttu, J. I., A method for T_{1ρ} imaging. *J Comput Assist Tomogr* **1985**, *9* (6), 1007-1011.

- (64) Halavaara, J. T.; Sepponen, R. E.; Lamminen, A. E.; Vehmas, T.; Bondestam, S., Spin Lock and Magnetization Transfer MR Imaging of Focal Liver Lesions. *Magn. Reson. Imag.* **1998**, *16* (4), 359-364.
- (65) Grohn, O. H. J.; Makela, H. I.; Lukkarinen, J. A.; DelaBarre, L.; Lin, J.; Garwood, M.; Kauppinen, R. A., On- and Off-Resonance $T_{1\rho}$ MRI in Acute Cerebral Ischemia of the Rat. *Magn. Reson. Med.* **2003**, *49*, 172-176.
- (66) Regatte, R. R.; Akella, S. V. S.; Wheaton, A. J.; Borthakur, A.; Kneeland, J. B.; Reddy, R., $T_{1\rho}$ -Relaxation Mapping of Human Femoral-Tibial Cartilage *In Vivo*. *J. Magn. Reson. Imag.* **2003**, *18*, 336-341.
- (67) Borthakur, A.; Wheaton, A. J.; Gougoutas, A. J.; Akella, S. V. S.; Regatte, R. R.; Charagundla, S. R.; Reddy, R., *In Vivo* Measurement of $T_{1\rho}$ Dispersion in the Human Brain at 1.5 Tesla. *J. Magn. Reson. Imag.* **2004**, *19*, 403-409.
- (68) Borthakur, A.; Sochor, M.; Davatzikos, C.; Trojanowski, J. Q.; Clark, C. M., $T_{1\rho}$ MRI of Alzheimer's disease. *NeuroImage* **2008**, *41*, 1199-1205.
- (69) Haris, M.; Singh, A.; Cai, K.; Davatzikos, C.; Trojanowski, J. Q.; Melhem, E. R.; Clark, C. M.; Borthakur, A., $T_{1\rho}$ ($T_{1\rho}$) MR imaging in Alzheimer' disease and Parkinson's disease with and without dementia. *J Neurol* **2011**, *258*, 380-385.
- (70) Chopra, S.; McClung, R. E. D.; Jordan, R. B., Rotating-Frame Relaxation Rates of Solvent Molecules in Solutions of Paramagnetic Ions Undergoing Solvent Exchange. *J Mag Res* **1984**, *59*, 361-372.
- (71) Kumar, K.; Jin, T.; Wang, X.; Desreux, J. F.; Tweedle, M. F., Effect of Ligand Basicity on the Formation and Dissociation Equilibria and Kinetics of Gd^{3+} Complexes of Macrocyclic Polyamino Carboxylates. *Inorg. Chem.* **1994**, *33*, 3823-3829.
- (72) GmbH, B. O., The minispec: mq series users manual. 2.2 ed.; Germany, 2003.
- (73) Celine, H.; Sophie, L.; Luce, V. E., How to perform accurate and reliable measurements of longitudinal and transverse relaxation times of MRI contrast media in aqueous solutions. *Contrast Media Mol Imaging* **2009**, *4*, 312-321.

- (74) Avedano, S.; Botta, M.; Haigh, J.; Longo, D.; Woods, M., Coupling fast water exchange to slow molecular tumbling in Gd^{3+} chelates: why faster is not always better. *Inorganic Chemistry* **2013**, 52 (15), 8436-8450.
- (75) Alford Jamu, K.; Rutt Brian, K.; Scholl Timothy, J.; Handler William, B.; Chronik Blaine, A., Delta relaxation enhanced MR: improving activation-specificity of molecular probes through R_1 dispersion imaging. *Magn Reson Med* **2009**, 61 (4), 796-802.
- (76) Alford, J. K.; Scholl, T. J.; Handler, W. B.; Chronik, B. A., Design and construction of a prototype high-power B_0 insert coil for field-cycled imaging in superconducting MRI systems. *Concepts Magn. Reson., Part B* **2009**, 35B (1), 1-10.
- (77) Choi, C.-H.; Hutchison, J. M. S.; Lurie, D. J., Design and construction of an actively frequency-switchable RF coil for field-dependent Magnetisation Transfer Contrast MRI with fast field-cycling. *J. Magn. Reson.* **2010**, 207 (1), 134-139.
- (78) Hoelscher Uvo, C.; Lothar, S.; Fidler, F.; Blaimer, M.; Jakob, P., Quantification and localization of contrast agents using delta relaxation enhanced magnetic resonance at 1.5 T. *MAGMA* **2012**, 25 (3), 223-31.
- (79) Lurie, D. J.; Aime, S.; Baroni, S.; Booth, N. A.; Broche, L. M.; Choi, C.-H.; Davies, G. R.; Ismail, S.; O hOgain, D.; Pine, K. J., Fast field-cycling magnetic resonance imaging. *Comp. Rend. Phys.* **2010**, 11 (2), 136-148.
- (80) Lurie, D. J.; Davies, G. R.; Pine, K. J. Field-offset coil for use with an open mri scanner. 2013-GB51921, 20130718., 2014.
- (81) Santyr, G. E.; Henkelman, R. M.; Bronskill, M. J., Spin locking for magnetic resonance imaging with application to human breast. *Magn Reson Med* **1989**, 12, 25-37.
- (82) Richardson, O. C.; Scott, M. L. J.; Tanner, S. F.; Waterton, J. C.; Buckley, D. L., Overcoming the low relaxivity of gadofosveset at high field with spin locking. *Magn Reson Med* **2012**, 68 (4), 1234-8.
- (83) Tanttu, J. I.; Sepponen, R. E.; Lipton, M. J.; Kuusela, T., Synergistic enhancement of MRI with Gd-DTPA and magnetization transfer. *J Comput Assist Tomogr* **1992**, 16, 19-24.

- (84) Aronen, H. J.; Peltonen, T. K.; Tanttu, J. I.; Sipila, L. M.; Ruhala, M. T.; Jaaskelainen, J.; Sepponen, R., Spin-Lock Imaging in Contrast-Enhanced Magnetic Resonance Imaging of Human Gliomas. *Acad Radiol* **1996**, *3*, S170-S172.
- (85) Aronen, H. J.; Ramadan, U. A.; Peltonen, T. K.; Markkola, A. T.; Tanttu, J. I.; Jaaskelainen, J.; Hakkinen, A.-M.; Sepponen, R. E., 3D spin-lock imaging of human gliomas. *Magn Reson Imag.* **1999**, *17*, 1001-1010.
- (86) Gerald, C. F. G. C.; Sherry, A. D.; Brown, R. D., III; Koenig, S. H., Magnetic field dependence of solvent proton relaxation rates induced by gadolinium(3+) and manganese(2+) complexes of various polyaza macrocyclic ligands: implications for NMR imaging. *Magn. Reson. Med.* **1986**, *3* (2), 242-50.
- (87) Laurent, S.; Henoumont, C.; Vander Elst, L.; Muller, R. N., Synthesis and Physicochemical Characterisation of Gd-DTPA Derivatives as Contrast Agents for MRI. *Eur. J. Inorg. Chem.* **2012**, *2012* (12), 1889-1915.
- (88) Wilson, G. J.; Woods, M.; Jr, C. S. S.; Bastawrou, S.; Bhargava, P.; Maki, J. H., Human whole-blood $^1\text{H}_2\text{O}$ longitudinal relaxation with normal and high-relaxivity contrast reagents: Influence of trans-cell-membrane water exchange. *Magn Reson Med* **2014**, 1746-1754.
- (89) Caravan, P.; Cloutier, N. J.; Greenfield, M. T.; McDermid, S. A.; Dunham, S. U.; Bulte, J. W. M.; Jr, J. C. A.; Looby, R. J.; Supkowski, R. M.; Jr, W. D. H.; McMurry, T. J.; Lauffer, R. B., The Interaction of MS-325 with Human Serum Albumin and Its Effect on Proton Relaxation Rates. *Journal of the American Chemical Society* **2002**, *124* (12), 3152-3162.
- (90) Bottomley, P. A.; Foster, T. H.; Argersinger, R. E.; Pfeifer, L. M., A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1–100 MHz: Dependence on tissue type, NMR frequency, temperature, species, excision, and age. *Med Phys* **1984**, *11*.
- (91) Bottomley, P. A.; Hardy, C. J.; Argersinger, R. E.; Allen-Moore, G., A review of ^1H nuclear magnetic resonance relaxation in pathology: Are T_1 and T_2 diagnostic? *Med Phys* **1987**, *14* (1), 1-37.

- (92) Hocq, A.; Luhmer, M.; Saussez, S.; Louryan, S.; Gillis, P.; Gossuin, Y., Effect of magnetic field and iron content on NMR proton relaxation of liver, spleen and brain tissues. *Contrast Media Mol. Imaging* **2015**, *10*, 144-152.
- (93) Plush, S. E.; Woods, M.; Zhou, Y.-F.; Kadali, S. B.; Wong, M. S.; Sherry, D., Nanoassembled Capsules as Delivery Vehicles for Large Payloads of High Relaxivity Gd^{3+} Agents. *J. AM. CHEM. SOC.* **2009**, *131*, 15918-15923.
- (94) Aime, S.; Botta, M.; Crich, S. G.; Giovenzana, G. B.; Pagliarin, R.; Piccinini, M.; Sisti, M.; Terreno, E., Towards MRI contrast agents of improved efficacy. NMR relaxometric investigations of the binding interaction to HSA of a novel heptadentate macrocyclic triphosphonate Gd(III)-complex. *J. Biol. Inorg. Chem.* **1997**, *2* (4), 470-479.
- (95) Chan, K. W.-Y.; Wong, W.-T., Small molecular gadolinium(III) complexes as MRI contrast agents for diagnostic imaging. *Coord. Chem. Rev.* **2007**, *251* (17-20), 2428-2451.
- (96) Lauterburg, P. C.; Dias, M. H. M.; Rubin, A. M., *Frontiers of Biological Energetics*. Academic Press, New York, 1978.
- (97) Aoki, I.; Tanaka, C.; Takegami, T.; Ebisu, T.; Umeda, M.; Fukunaga, M.; Fukuda, K.; Silva, A. C.; Koretsky, A. P.; Naruse, S., Dynamic activity-induced manganese-dependent contrast magnetic resonance imaging (DAIM MRI). *Magn. Reson. Med.* **2002**, *48*, 927-933.
- (98) Crossgrove, J.; Zheng, W., Manganese toxicity upon overexposure. *NMR Biomed.* **2004**, *17*, 544-553.
- (99) Pautler, R. G., In vivo, trans-synaptic tract-tracing utilizing manganese-enhanced magnetic resonance imaging (MEMRI). *NMR Biomed.* **2004**, *17*, 595-601.
- (100) Aschner, M.; Guilarte, T. R.; Schneider, J. S.; Zheng, W., Manganese: Recent advances in understanding its transport and neurotoxicity. *Toxicol. Appl. Pharmacol.* **2007**, *221*, 131-147.
- (101) Gale, E. M.; Zhu, J.; Caravan, P., Direct Measurement of the Mn(II) Hydration State in Metal Complexes and Metalloproteins Through ^{17}O NMR Linewidths. *J Am Chem Soc.* **2013**, *135* (49), 18600-18608.
- (102) Ailion, D. C., NMR and ultraslow motions. *Adv. Mag. Res.* **1971**, *5*, 177-227.

- (103) Koenig, S. H.; Brown, R. D., Relaxation of Solvent Protons by Paramagnetic Ions and Its Dependence on Magnetic Field and Chemical Environment: Implications for NMR Imaging. *Magnetic Resonance in Medicine* **1984**, *1*, 478-495.
- (104) Koenig, S. H.; Brown, R. D.; Studebaker, J. In *Quant. Biol.*, Cold Spring Harbor Symp., 1971; p 551.
- (105) Idée, J.-M.; Port, M.; Medina, C.; Lancelot, E.; Fayoux, E.; Ballet, S.; Corot, C., Possible involvement of gadolinium chelates in the pathophysiology of nephrogenic systemic fibrosis: A critical review. *Toxicology* **2008**, *248*, 77-88.
- (106) Sieber, M. A.; Steger-Hartmann, T.; Lengsfeld, P.; Pietsch, H., Gadolinium-based contrast agents and NSF: evidence from animal experience. *J. Magn. Reson. Imag.* **2009**, *30* (6), 1268-1276.
- (107) Chen, J. W.; Belford, R. L.; Clarkson, R. B., Second-Sphere and Outer-Sphere Proton Relaxation of Paramagnetic Complexes: From EPR to NMRD. *J. Phys. Chem. A.* **1998**, *102*, 2117-2130.

APPENDIX: T_1 AND $T_{1\rho}$ TIME CURVES AT 1.41 T (60 MHz) AND 37 °C
(APPENDIX TO CHAPTER 2).

Figure A1.1: Effect of deliberate variations to the relaxation delay (RD) time on T_1 time curves (inset shows deviation (squares) when relaxation delay is $< 10 \times T_1$). Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25$ mM. $n = 1$.

Figure A1.2: Effect of deliberate variations to the relaxation delay (RD) time on $T_{1\rho}$ time curves.

Sample: PBS pH 7.4 solution of Dotarem, $[Gd^{3+}] = 25$ mM. $n = 1$.

Figure A1.3: Effect of deliberate variations to the first pulse delay time (τ) on T_1 (a – c) and $T_{1\rho}$ (d – g) time curves. Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25 \text{ mM}$, $n = 1$.

Figure A1.4: Effect of deliberate variations to the last pulse delay time (τ) on T_1 (a – c) and $T_{1\rho}$ (d – e) time curves. Sample: PBS pH 7.4 solution of Dotarem, $[\text{Gd}^{3+}] = 25$ mM. $n = 1$.

Figure A1.5: Effect of deliberate variations to the number of data points on T_1 (a – d) and $T_{1\rho}$ (e – h) time curves. Sample: PBS pH 7.4 solution of Dotarem, $[Gd^{3+}] = 25$ mM. $n = 1$.